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ABSTRACT
Perley, Jeffrey P. PhD, Purdue University, May 2016. Advancing Multiple Model-
Based Control of Complex Biological Systems: Applications in T Cell Biology. Major
Professor: Ann E. Rundell.
Activated CD4+ T cells are important regulators of the adaptive immune response
against invading pathogens and cancerous host cells. The process of activation is me-
diated by the T cell receptor and a vast network of intracellular signal transduction
pathways, which recognize and interpret antigenic signals to determine the cell’s re-
sponse. The critical role of these early signaling events in normal cell function and
the pathogenesis of disease ultimately make them attractive therapeutic targets for
numerous autoimmune diseases and cancers.
Scientists increasingly rely on predictive mathematical models and control-theoretic
tools to design effective strategies to manipulate cellular processes for the advance-
ment of knowledge or therapeutic gain. However, the application of modern control
theory to intracellular signal transduction is complicated by a unique set of intrinsic
properties and technical limitations. These include complexities in the signaling net-
work such as crosstalk, feedback and nonlinearity, and a dearth of rapid quantitative
measurement techniques and specific and orthogonal modulators, the major conse-
quences of which are uncertainty in the model representation and the prevention of
real-time measurement feedback. Integrating such uncertainties and limitations into
a control-theoretic approach under practical constraints represents an open challenge
in controller design.
The work presented in this dissertation addresses these challenges through the
development of a computational methodology to aid in the design of experimen-
tal strategies to predictably manipulate intracellular signaling during the process of
xviii
CD4+ T cell activation. This work achieves two main objectives: (1) the development
of a generalized control-theoretic tool to effectively control uncertain nonlinear sys-
tems in the absence of real-time measurement feedback, and (2) the development and
calibration of a predictive mathematical model (or collection of models) of CD4+ T
cell activation to help derive experimental inputs to robustly force the system dy-
namics along prescribed trajectories. The crux of this strategy is the use of multiple
data-supported models to inform the controller design. These models may represent
alternative hypotheses for signaling mechanisms and give rise to distinct network
topologies or kinetic rate scenarios and yet remain consistent with available data.
Here, a novel adaptive weighting algorithm predicts variations in the models’ predic-
tive accuracy over the admissible input space to produce a more reliable compromise
solution from multiple competing objectives, a result corroborated by several exper-
imental studies. This dissertation provides a practical means to effectively utilize
the collective predictive capacity of multiple prediction models to predictably and
robustly direct CD4+ T cells to exhibit regulatory, helper and anergic T cell-like sig-
naling profiles through pharmacological manipulations in the absence of measurement
feedback. The framework and procedures developed herein are expected to widely
applicable to a more general class of continuous dynamical systems for which real-
time feedback is not readily available. Furthermore, the ability to predictably and
precisely control biological systems could greatly advance how we study and inter-




Activated CD4+ T cells are critical players in the adaptive immune response against
both internal and external threats, but are also implicated in numerous forms of
autoimmunity and cancer. In many cases, the source of disease lies in the cellular
mechanisms that control the recognition and interpretation of extracellular signals,
the precise manipulation of which may enable effective targeted therapies. Techniques
to control such systems increasingly rely on predictive mathematical models to help
determine appropriate control actions (i.e. drugs or reagents intended to force or
perturb the system). Such models serve to encapsulate our current understanding
of intracellular signaling systems and have the potential to provide a basis for the
rational design of experiments, clinical interventions; however, these models are of-
ten rough approximations of reality because the biological mechanisms are not well
understood, not all events are represented to constrain complexity, and efforts to ex-
perimentally resolve model uncertainties are impeded by resource costs and a dearth
of feasible inputs and measurements. Furthermore, quantitative measurement assays
tend to be too slow for real-time feedback, further increasing the risk of compounding
errors due to plant-model mismatch (i.e. deviation of the model-predicted behavior
from the actual system response).
This dissertation presents a comprehensive quantitative approach, founded on the
principles of Systems Biology, Information and Control theory, to facilitate the de-
sign of experimental strategies to predictably manipulate intracellular signaling in
CD4+ T cells. The crux of this work is the effective use of information encoded
in multiple data-supported models to ensure robust control of the intracellular sig-
naling processes despite the inherent limitations imposed by such a system. The
integrated model-based approach is expected to advance the study of intracellular
signaling systems, altering the design from comprehensive and ad hoc experimental
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strategies to deliberate and effective ones. Furthermore, the ability to control the
signaling processes involvled in CD4+ T cell activation and differentiation may help
identify critical molecular targets for drug design, yield alternative strategies for drug
intervention scheduling, and facilitate the development of personalized therapies for
autoimmunity, cancer and other immune-related pathologies.
The remainder of this chapter provides important background information and
motivation for this work. First, the role of CD4+ T cells during the immune re-
sponse, their relevant phenotypes, and the intracellular signaling processes involved
in their activation are discussed. Next, an introduction to the computational tools
needed for this work is provided and the challenges associated with their application
to intracellular signaling systems are detailed. Finally, organizational details for the
remainder of the dissertation are provided in the concluding remarks.
1.1 CD4+ T Cells and Their Functions
In response to an infection, a variety of cells of the innate and adaptive im-
mune systems become activated and collaborate in the effort to control and eliminate
invading pathogens. CD4+ T cells play critical roles during the adaptive immune
response [1]. They help B cells to produce antibody and to undergo class switch-
ing and affinity maturation; they recruit and activate CD8+ T cells, macrophages,
neutrophils, eosinophils, basophils and other effector cells. They also directly act on
many tissue cells, including epithelial cells and mucosal cells, during the process of
pathogen clearance. The diverse functions of CD4+ T cells are determined by their
cytokine secretion patterns and their tissue locations.
T cells originate in the thymus and undergo a process of selection in which cells
able to bind complexes of self peptide and major histocompatibility complex (MHC)
with some threshold affinity are rescued from apoptosis (positive selection), whereas
cells with high affinity for self peptide-MHC complexes are eliminated (negative selec-
tion). When naive CD4+ T cells recognize foreign antigenderived peptides presented
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in the context of MHC class II on dendritic cells in the periphery, these cells undergo
a process that includes massive proliferation and differentiation into distinct helper
T cell subsets. Each expresses a distinct set of regulatory transcription factors, as
well as hallmark cytokines. The cytokine environment created by activated CD4+ T
cells, dendritic cells and/or by other cell types during the course of differentiation is
one of the key determinants for T cell fate.
At least two major groups of T cell subsets have been studied in great detail. The
helper T (Th) cell subsets (e.g. Th1, Th2 and Th17) generally promote inflamma-
tion by sensing foreign antigens and secreting cytokines to recruit and activate other
specialized immune cells such as B cells, cytotoxic T cells and macrophages [1–3].
Th1 cells produce interleukin-2 (IL-2), TNF-α, and IFN-γ, and are associated with
cell-mediated immunity against intracellular pathogens. In contrast, Th2 cytokines,
such as IL-4, -5 and -10, are involved in the control of extracellular infections and
circulating pathogens by enhancing antibody-mediated immunity. Both Th1 and Th2
cells require IL-2 to undergo proliferation, but are antagonistic towards one another
where each capable of blocking the generation and effector functions of the other [4].
The appropriate balance of Th cell immunity is therefore paramount for the mainte-
nance of health. Inversely, an inappropriate response of either subset can have drastic
consequences. Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis,
transplant rejection and type 1 diabetes are thought to result partially from an aug-
mentation of Th1 cells, primarily the increased production of their unique profile of
inflammatory cytokines [5]. Th2 cells on the other hand are associated with asthma,
allergies and increased susceptibility to the human immunodeficiency virus (HIV) [6].
The second major group of T cell subsets are the regulatory T (Treg) cells. Regu-
latory T (Treg) cells serve to moderate excessive immune reactions and maintain self-
tolerance by suppressing or downregulating the induction and proliferation of effector
T cells [3, 7, 8]. The most highly-studied form of Tregs are those that are naturally
generated in the thymus (nTregs) and stably express CD4, CD25, and foxhead box P3
(FOXP3) (CD4+CD25+FOXP3+ ) [7]. It is widely accepted that FOXP3+ Tregs act
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as gate-keeper for almost any type of immune reaction. On one hand, they can
suppress unwanted immune responses such as autoimmunity, allergy or transplant
rejection [9]. This feature enables the use of allogeneic bone marrow transplantation
for treating hematologic malignancies, in large part by suppressing the expansion
of alloreactive T cells in the proinflammatory environment that is the hallmark of
graft-versus-host disease. On the other hand, Tregs can also prevent protective im-
mune responses against invading pathogens or tumors, thus exerting “unproductive”
immunosuppression leading to unwanted reactions or even promoting disease pro-
gression (e.g., in cancer) [10, 11]. In fact, numerous studies have shown that cancer
patients have increased Treg counts within peripheral blood, lymphoid tissues and
the tumor microenvironment. The elevated Treg numbers help the tumors evade a
productive immune response and is frequently associated with a poor prognosis [12].
When properly regulated, the immune system effectively balances the tasks of rec-
ognizing and eliminating foreign antigens while maintaining tolerance to self-antigens.
However, a significant disruption of the homeostatic balance among the T cell subsets
can lead to a large number of inflammatory autoimmune disorders and cancers.
1.2 T Cell Receptor Signal Transduction Pathway and its Role in CD4+ T
Cell Differentiation
A critical first event in the determination of CD4+ T cell fate is activation by
way of the T cell receptor (TCR) and CD28 signaling pathways (depicted in Fig-
ure 1.1). This process begins at the engagement of the TCR to the first signal—
cognate peptide-bound major histocompatibility complexes (pMHC) on the surface
of antigen-presenting cells (APCs) [13–15]—which in turn triggers a number of early
phosphorylation and dephosphorylation events. Prior to TCR engagement, the CD45
phosphatase primes sarcoma (Src) family of kinases (SFK) members [16,17] by remov-
ing inhibitory phosphate groups (Y505 on LCK) [18, 19]. Following ligation, primed
SFKs are activated by receptor-mediated autophosphorylation (Y394 on LCK) [19],
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which in turn doubly phosphorylate the immunoreceptor tyrosine-based activation
motifs (ITAMs) on the TCR-associated CD3 ζ-chain. These provide docking sites
for the Src homology 2 (SH2) domains of the zeta-chain-associated protein kinase 70
(ZAP-70), a Syk family kinase, allowing ZAP-70 to be activated by SFK-mediated
phosphorylation of its Y319 and Y493 residues [20–22]. ZAP–70-activated phospho-
lipase C-γ1 (PLCγ1) then hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2)
to second messengers inositol 1,4,5-trisphosphate (IP3) [23–25], which migrates to
the cytoplasm to release intracellular calcium (Ca2+) from the endoplasmic retic-
ulum [23, 26, 27] and activate nuclear factor of activated T-cells (NFAT) [28], and
diacylglycerol (DAG), which operates within the cell membrane to activate rat sar-
coma (Ras) and protein kinase Cθ (PKCθ) [29]. Ras triggers the extracellular signal-
regulated kinase (ERK) cascade that results in the activation of activator protein-1
(AP-1) [30], whereas PKCθ activates both AP-1 and the nuclear factor κB (NFκB)
pathway [31–34]. Upon entering the nucleus, the NFAT, AP-1 and NFκB transcrip-
tion factors interact to support cooperative regulation of IL-2 [35,36], which is critical
to the development of Th cell development [1–3].
The second signal driving T-cell activation and fate determination is provided by
CD28-mediated costimulation [37]. CD28 signaling is mediated through PKCθ and
AKT, which recruit and regulate several signaling molecules, including NFκB [33,38]
and mammalian target for rapamycin (mTOR) [39], the catalytic subunit in two
structurally-distinct complexes. The serine/threonine protein kinase mTOR complex
1 (mTORC1) controls the expression of FOXP3, which is widely considered the master
transcriptional regulator in the development of Tregs [3,7,39,40]. The second mTOR
complex (mTORC2) promotes PKC, AKT and NFκB signaling and is critical to Th1
and Th2 commitment [41].
The relative strengths of the TCR and CD28 signals are known to differentially
affect activation and lineage commitment in CD4+ T cells. TCR ligation ultimately
leads to anergy or a state of hyporesponsiveness in the absence of a second signal [42].




































































































Fig. 1.1.: Intracellular signaling pathway in CD4+ T-cell activation. TCR-mediated
signal transduction is initiated when the receptor binds to a peptide-MHC complex
presented by an antigen-presenting cell. Engagement of the TCR leads to the recruit-
ment of LCK and FYN, which phosphorylate the ITAMs of the TCR. This provides
docking sites for the SH2 domains of ZAP-70, allowing ZAP-70 to be phosphorylated
and activated by LCK. Once activated, ZAP-70 phosphorylates the adaptor proteins
SLP-76 and LAT. This, coupled with CD28 costimulation, results in calcium mobi-
lization, activation of the MAPKs and PI3Ks, nuclear localization of NFAT, AP-1
and NFκB, and the transcription of IL-2 and FOXP3, each respectively critical to
the development of CD4+ Th and Treg cells. Activation and inhibition reactions are
denoted by black arrows and red diamonds, respectively.
2 production, T cell proliferation and the prevention of anergy. Strong TCR and
CD28 signals suppress FOXP3 and force IL-2 to become the dominant species, indi-
cating that the cell is fully active. However, a weak CD28 signal shifts the balance
of dominance toward FOXP3, leaving IL-2 at a much reduced level. Indeed, weak
to moderate CD28 costimulation have been linked to FOXP3 induction and the de-
velopment of the regulatory phenotype in CD4+ T cells [43]. Thus, because of their
significance in the larger context of the immune response, targeted manipulation of
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IL-2 and FOXP3 via their upstream signaling networks could provide a strategy for
regulating the balance of CD4+ Th and Treg cells for therapeutic gain.
1.3 Existing Control-Theoretic Tools and Their Limitations
1.3.1 Model Predictive Control (MPC)
Model predictive control (MPC) is a strategy that uses a mathematical encoding
of the underlying system dynamics to predict the future behavior of the system and
optimize performance. Recent reviews of process control methods have concluded that
MPC has been the most successful approach to date for controlling chemical processes
[44–46], which share many properties with biochemical processes, such as intracellular
signaling. MPC is generally implemented as an iterative optimization algorithm that
uses a mathematical model to generate control actions to boost performance in the
controlled plant.
MPC algorithms typically involve a two-step procedure (Fig. 1.2). First, the
controller predicts the plant behavior over the finite prediction horizon by evaluating
the mathematical equations encoding the system dynamics. From the current state,
the controller then computes the optimal control action sequence for the plant to
reach the set point, or target trajectory. That is, a numerical optimization algorithm
is used to survey the possible state trajectories stemming from the current state and
select the control sequence associated with the one that best fits the objective. Once
the optimal control sequence is determined, the first control step in the sequence is
simulated, and the MPC procedure is repeated at the next time step. This allows
the controller to resample the actual plant state and update the reference model to
compensate for deviation of the model from the plant dynamics. A variation can
also include a component for minimizing the use of control inputs or deviation from
previous control inputs. This is an important feature, especially when dealing with
cellular systems because reagents could potentially be in short supply, difficult or
time-consuming to produce, or too expensive to waste on unnecessary control actions.
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Fig. 1.2.: Summary of the MPC process: (1) Predict future behavior of the system
over the finite prediction horizon Hp, (2) compute future control inputs u(ti) , ... ,
u(tti+Hu−1) over the input horizon Hu by minimizing the cost function under con-
straints, and (3) apply the first control input u(ti) to the plant and repeat over the
new prediction window.
MPC derives several distinct advantages over other control strategies by having
at its core a predictive mathematical model that characterizes the dynamics of the
process. Realistic and practical constraints such as physical bounds or operational re-
strictions on the control inputs and system states can be enforced in the form of equal-
ity and inequality constraints [47, 48]. MPC is capable of handling highly nonlinear
dynamics and is robust to model uncertainties and measurement noise [49]. Further-
more, MPC can easily accommodate discrete-time feedback control (i.e. closed-loop
control) when dealing with occasional bench-top or clinical measurements [50] or,
most importantly, for situations in which frequent sampling of the system is impos-
sible or impractical (i.e. open-loop control), making it ideal for nonlinear cellular
processes such as signal transduction [51].
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1.3.2 Current Biological Applications of Control Theory
While pharmaceutical and biomass production [52–54] and automated glucose
monitoring for diabetes management [48, 55, 56] remain some of the most highly-
developed applications of control theory in biology and medicine, great strides have
been made recently to adapt control-theoretic tools to a broader array of biomedical
applications. Within the past decade, research has started to evaluate engineered
control strategies for single and multi-cellular processes within experiments. Noble
and Rundell [57] used closed-loop control with experiments to direct HL60 cell differ-
entiation through periodic boluses of a differentiation-inducing agent determined by
MPC. Uhlendorf et al. [58] also achieved long-term control of gene expression on the
single-cell and population level by manipulating the osmotic stress in a microfluidic
environment through MPC. In opto-genetics, Milias-Argeitis et al. [59] introduced a
light-responsive Phy/PIF module to alter the expression of a yellow florescent pro-
tein (YFP) through the Gal1 promoter in Saccharomyces cerevisiae and Toettcher
et al. [60, 61] used light to modulate the localization of PIF-tagged proteins to the
cell membrane. Both of these studies achieve long-term regulation of cell activities
through transcriptional control determined via model-based control.
1.3.3 Challenges in Controlling Intracellular Signaling Dynamics
Signal transduction involves complex networks of highly-connected molecular play-
ers that relay information and coordinate responses to environmental cues [62]. The
innate robustness exhibited by such networks to intracellular and extracellular per-
turbations involve considerable feedback [63], crosstalk [64] and are highly nonlinear
in nature [65]. The application of control theory to intracellular signaling systems is
an emerging area of research; however, there exist a number of unique challenges for
controlling such systems. First, realizable control actions are often limited due to the
lack of highly-specific manipulation techniques. Second, reagents and equipment for
state-of-the-art measurement assays (e.g. Western blotting, ELISA, flow cytometry,
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fluorescence microscopy) can be expensive, time-consuming, have low target sensitiv-
ity and specificity, and produce qualitative or semi-quantitative data. This prevents
the use of real-time feedback and introduces modeling uncertainty. Third, heterogene-
ity within cellular systems is especially problematic as cell populations given identical
treatment will exhibit unique responses. Even genetically homogeneous cells cultured
in identical environments can exhibit striking phenotypic heterogeneity due to the
stochastic activation of the regulatory control processes that govern cell function [66].
Small batch-to-batch variations in culture conditions will exacerbate these effects.
In the absence of real-time feedback, a high-quality prediction model is critical
for successful implementation of MPC to intracellular signaling. However, effectively
characterizing such systems with mathematical models while accounting for diverse
sources of uncertainty is a fundamental challenge in the field of systems biology and
control [67]. A single pathway may have a number of mathematical representations
(e.g. ordinary differential equations (ODEs), partial differential equations (PDEs),
Boolean logic), structural topologies (i.e. participating species and interactions among
them) and reaction rate laws (e.g. law of mass action, Michaelis–Menten, multi-site
enzyme kinetics). These structurally-unique models represent qualitatively-distinct
hypotheses about how the interactions among participating species affect the biologi-
cal dynamics [68]. Furthermore, systems biology models are generally becoming more
mechanistic and complex, often requiring tens or hundreds of parameters. Binding,
unbinding and maximum reaction rates can sometimes be found for isolated experi-
ments in test tubes. However, directly measuring model parameters in cells can be
difficult or impossible, so very few of these have values that have been experimen-
tally determined. Thus, a single model structure may have data-consistent parameter
scenarios (i.e. model parameters resulting in model dynamics that are supported by
experimental data) that span several orders of magnitude may be highly correlated,
making the determination of appropriate parameter values (and initial conditions)
a significant challenge [69]. As a result, it is routine for cellular processes to have
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several distinct model structures and many different sets of parameter values for each
structure that are capable of replicating preexisting experimental data [68,69].
The absence of a uniquely-identifiable “correct” model is problematic in controller
design, as the predicted optimal design may change depending on the model used and
the strategy may ultimately fail if the mismatch between the model and the plant
is too significant (Fig. 1.3). Furthermore, selecting the single “best” model may
not necessarily yield the best results. This is the practical reality as all models are
approximations to some degree. A means of effectively integrating multiple approxi-
mations of a system could improve the robustness and reliability of control strategies
for intracellular signaling systems.
















































































Fig. 1.3.: Consequences of plant-model mismatch. (A) Optimal control inputs as
predicted by each model independently. (B) Implementation of the designed control
inputs in the uncertain system with the goal of forcing the system trajectory to
track the target trajectory (dashed black line). Matched (ideal ) cases are along the
diagonal. Off-diagonal plots show mismatched (realistic) cases.
Indeed, growing attention in systems biology has been given to control method-
ologies that employ multiple prediction models to improve robustness to uncertainty
and disturbance. These methods typically partition the parameter space into sub-
models (or parameter scenarios) in which no abrupt changes occur, and then compute
the optimal control inputs by blending and/or switching between sub-models. These
multi-scenario approaches have been successfully used to improve robustness to para-
metric uncertainty in closed-loop model-based control [70–73]. In 2012, Noble and
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Rundell [74] revised their original approach to improve the transient response of the
differentiating HL60 cells over 20 days by using a multi-scenario adaptive MPC. Con-
trol inputs were chosen such that the average tracking error and resource efficiency
were optimized, which resulted in superior controller performance over single-model
MPC. However, none of the existing methods are designed to be employed to control
the rapid dynamics of intracellular signaling. Thus, creating a means of effectively
integrating the information encoded in multiple predictive models and scenarios to
improve the robustness and reliability of control strategies for intracellular signaling
systems is the first objective of this work.
1.4 Existing T Cell Activation and Differentiation Models and Their Lim-
itations
Several mathematical models have been generated to understand and predict the
complex biological phenomena involved in T cell signaling pathways [75–83]. These
models serve to encapsulate our current understanding of the biological system, in-
dicate gaps in that understanding, and provide the basis for the rational design of
experiments and clinical intervention.
The models presented by Levchenko [75], Hoffmann [84] and O’Dea [85] attempt to
capture the dynamics of a small portion of the signaling network—the MAPK [75] and
NFκB [84,85] modules—at high resolution, considering every hypothesized molecular
interaction or complex formation. While effective at small scale, this resolution of
detail is prohibitive to simulate for the entire signaling network, predominantly due to
computational intractability, but also due to uncertainties in the existence or rates of
these events. Coombs [86] and Wylie [87] address the role of location as a regulatory
event, analyzing early T-cell signaling events within a spatial context. These models
were also limited in scope to offset the added computational expense of such an
analysis.
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Several models were developed to broadly capture TCR-mediate signaling on the
cellular level. These models reflect the current understanding of the intracellular sig-
naling events leading to T-cell activation, describing the primary events that occur
upon TCR engagement in terms of protein binding, phosphate group transfers and ki-
nase and phosphatase activation. Altan-Bonnet [76], Zheng [88] and Lipniacki [80] all
investigated the potential biochemical mechanisms linking the bistability and digital-
like response of ERK phosphorylation to the antigenic sensitivity of the TCR complex
using systems of ODEs. All three studies recognized the critical importance of the
competition between positive and negative feedback loops mediated respectively by
ERK and SHP-1, but provided varying mechanisms by which the loops are achieved.
The model by Klamt [78] and the expansion by Saez-Rodriguez [79] sought to cap-
ture the input/output relationship among the TCR and companion receptors and a
number of activation-critical transcription factors such as NFAT, NFκB and AP-1
using discrete-time logical expressions. While these models are able to capture many
dominant behaviors, they do not support a detailed analysis of the interactions in a
continuous state and parameter space and the ability to predict responses to analog
knockdown or mutation scenarios.
Treg differentiation was the subject of models by Miskov-Zivanov [83] and Carbo
[82], but with contrasting approaches. Miskov-Zivanov presented a logical model fo-
cusing on the competition between IL-2 and FOXP3 in the development of Tregs and
found that the duration of TCR stimulation can modulate phenotype commitment
[83]. Carbo on the other hand, focused on the role of the cytokine milieu and corre-
sponding cytokine receptors in modulating a small set of downstream transcription
factors that control T cell phenotype commitment.
Because these models all vary in terms of scope and mechanistic detail to some
degree, they understandably vary in terms of network topology, functional represen-
tations, and kinetic rates. While each of these models has its advantages and role,
none of them filled the role needed in this dissertation. Thus, a new mathemati-
cal model was developed to facilitate this investigation. The development of this
14
model, which focuses on the intracellular signaling mechanisms involved in CD4+ T
cell activation—events such as receptor ligation and trafficking, signal propagation
and amplification, and gene transcription—and their roles in Th and Treg cell differ-
entiation, is the second objective of this dissertation.
1.5 Concluding Remarks
CD4+ T cell activation plays an important role in the adaptive cell-mediated im-
mune response and its aberrant regulation leads to inflammatory diseases and cancer.
The ability to predictably manipulate T cell behavior is thus critical for successfully
translating benchtop experiments into clinical therapies to reduce patient morbidity
and mortality. The aim of this work is to develop a strategy to predictably manip-
ulate T cell behavior via intracellular signaling pathways that could help generate
effective clinical therapies to treat T cell-related pathologies.
This work presents a progressive development of model-based control strategies,
addressing increasingly realistic models and scenarios requiring more robust con-
trollers, and culminating into an integrated approach to the predictive modeling and
manipulation of intracellular signaling dynamics in CD4+ T cells. The presented
methodology specifically addresses the integration of multiple prediction models and
scenarios into a control-theoretic framework to improve the effectiveness and robust-
ness of open-loop control actions.
The dissertation is organized into seven chapters, most presenting published jour-
nal and conference papers. Each chapter is prefaced with a description of how the
work fits into the entire dissertation. In Chapter 2, a sparse grids-based MPC strat-
egy for generating qualitatively similar dynamics in models of incommensurate scales
is presented. A strategy for intelligently and adaptively weighting multiple models to
generate a more robust open-loop solution is introduced in Chapter 3. This strategy
is extended in Chapter 4 with multiobjective optimization and a new model weighting
strategy for improved open-loop target tracking and uncertainty robustness. Chapter
15
5 discusses quantitative modeling and analysis of early CD4+ T-cell signaling that
initiate phenotype commitment, which forms the basis for the study presented in
the following chapter. In Chapter 6, all previous work is integrated into a cohesive
and practical approach to model building, experiment design, and reliable control
of CD4+ T-cell activation and differentiation. Chapter 7 presents conclusions and
proposals for future work.
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2. MULTIPLE MODEL CONTROL TO GENERATE
QUALITATIVELY SIMILAR DYNAMICS FOR
UNCERTAIN INTRACELLULAR SIGNALING SYSTEMS
2.1 Preface
The study described in this chapter explored the use of multiple predictions mod-
els within an open-loop MPC framework and introduced the considerations for the
successful control of signal transduction in T cells. Two main considerations were
identified. The first involved the discrepancies among the prediction models in terms
of topology and scale. Prediction models with varying network topologies required a
transformation of the state space in order to achieve outputs that are commensurate
with one another. This included adjustments in temporal and quantity scales, and
(non)linear transformations of the state and output spaces such as state combina-
tions and feature normalization. The second consideration involved the selection of
the compromise control solution. In this chapter, the compromise control action was
defined to be the optimal solution of the uniformly-weighted cost manifold aggregate.
The control optimization procedure was aided by the use of sparse grid interpola-
tion to save computational expense from repeated integrations of multiple ordinary
differential equation models. The material presented in this chapter was originally
submitted to the Proceedings of the 2011 Conference on Decision and Control.
2.2 Abstract
Control strategies for intracellular signaling are generally informed by mathemat-
ical representations of complex molecular interactions and events. However, the char-
acterization of such systems is non-unique, enabling the existence of multiple data-
24
consistent models and parameter sets. This uncertainty corrupts the input decision
process, making a control strategy based on a single model unreliable. Alternatively, a
control strategy informed by multiple models exhibiting qualitatively similar dynam-
ics may help alleviate this problem. Herein, we present a computationally-efficient
strategy for robust control of uncertain nonlinear systems using multiple models with
similar qualitative behaviors. The approach utilizes a sparse grid-based interpola-
tion technique for rapid and efficient screening of the control space and robust input
identification for multiple models. The proposed framework is first demonstrated on
a set of test models to illustrate the methodology before being applied to an uncer-
tain intracellular signaling network used in cell growth stimulation. The results show
the strategy’s ability to drive the predicted qualitative dynamical behaviors of mul-
tiple models of the plant to a specified reference profile. While demonstrated using
a biological system, this approach may be applied to the control of any uncertain
system.
2.3 Introduction
In this era of tissue and cellular engineering, there is a need for systematic con-
trol theoretic-based strategies to design experiments that manipulate the dynamics
of signaling pathways to achieve a desired cell response. Effective controller design
typically depends upon the existence of a mathematical model that adequately char-
acterizes the system behavior. However, models encoding the molecular interactions
and events involved in intracellular signaling pathways are generally gross simplifica-
tions of an exceedingly complex biochemical system to a computationally tractable
level. The models are an abstraction of the biological reality and are developed
through assumptions and the selective inclusion and exclusion of system components
and processes. Although a necessary and generally successful approach, the accumu-
lation of imprecise assumptions can misrepresent the biological reality and further
contribute to the uncertainty. This intrinsic uncertainty most directly stems from an
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unfortunate data-rich, data-poor paradox in which remarkable amounts of qualitative
data are readily available, but little are sufficiently quantitative for modern control
techniques [1]. As direct measurements of molecular concentrations and kinetic rates
can be difficult or impossible, model structures are generally inferred from sparse and
noisy data. As a result, the characterization of intracellular signaling networks is
non-unique, enabling the existence of multiple models and parameter sets that are
equally capable of reproducing available data.
This intrinsic ambiguity in the intracellular signaling system and its mathemat-
ical representation is propagated to the decision process for determining the control
strategy as each feasible characterization of the uncertain system potentially trans-
lates to a different set of control actions. A control strategy informed by multiple
models of the uncertain system that exhibit qualitatively similar dynamical features
may help alleviate this problem. Several proposed methodologies are equipped to
employ multiple models, but most are designed for linear or simple nonlinear mod-
els [2–4]. A more relevant approach taken by Donahue [5] evaluates the quantitative
performance of multiple models independently and selects a compromise control ac-
tion using an intuitive decision scheme. However, the method is computationally
expensive and prohibitive when considering numerous models. Consequently, the ex-
isting techniques for robust control design using multiple models are insufficient for
the purposes of controlling intracellular signaling and require new methodologies.
This paper presents a computationally efficient systematic strategy for robust
input design for uncertain nonlinear systems using the qualitatively similar dynam-
ical behaviors evoked using multiple models of the plant. The control methodology
described in Section 2.4 extends recent work using sparse grid-based interpolation
as a computational cost-cutting tool for characterizing biological models and global
optimization for control applications in systems biology [5]. The computationally in-
tensive model evaluations are limited by strategically simulating the model at specific
locations in the input space and building a network of support nodes to construct
an error-controlled multivariate interpolant. The polynomial interpolant is used as a
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surrogate for the model output to estimate responses in input regions not explicitly
evaluated, thereby supporting the computational efficiency required when consider-
ing multiple models during the design process. In Section 2.5, we demonstrate the
proposed strategy using a set of toy models for visualization of the approach and an
exemplar uncertain biological system, the mitogen-activated protein kinase (MAPK)
signaling cascade. Conclusions and future work are presented in Section 2.6.
2.4 Methods
2.4.1 General Representation of Biological Models
Mathematical characterizations of biological systems are often formulated as sys-
tems of nonlinear ordinary differential equations (ODEs) of the form
ẋ = f(θ, x, u, t), x(0) = x0,
y = g(x)
(2.1)
with constant model parameters θ ∈ Rp, and time-dependent state variables, x(t) ∈
Rn, with initial conditions x0, and multiple input signals, u(t) ∈ RNu . The model
outputs, denoted y(t) ∈ Rm, are a function of a subset of states that are available
for observation, which may be few due to the limitations of current experimental
capabilities.
2.4.2 Input Space Characterization using Sparse Grids
The process of characterizing the plant response to proposed control actions gen-
erally requires great computational expense in the form of model evaluations. This
expense can be attenuated using a multi-output sparse grid-based interpolation tech-
nique, which utilizes an error-controlled interpolant of the model outputs to character-
ize the entire input space [6]. That is, a multidimensional interpolating polynomial is
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generated using strategically placed support nodes to approximate the model output
in response to any feasible control action.
As in [6] and elsewhere, the general univariate interpolation formula Qi to estimate







where i ∈ N, and µij ∈ [−1, 1] are support nodes in the normalized input space and αij
are the basis functions, respectively. The tensor products of the sequence of univariate
formulas generate the multivariate formula for multi-input systems of dimension Nu,
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The multivariate interpolant of the input space at a defined time point can then
be constructed by summing a select subset of these product combinations using the
Smolyak algorithm. To track the dynamic plant response, sparse grids are created at
various time points in the simulated experiment and a univariate interpolant across
the time domain is generated. The placement of these nodes follows the placement






, i = 0, . . . , 2d; Ts = {ti}, (2.4)
where d is the largest polynomial dimension, scaled over the appropriate time frame
and Ts is the set of sampled time points spanning from some Tmin to Tmax. Inter-
mediate values for the jth output of the plant, j ∈ [1, 2, . . . ,m], in response to the
input signal u, are estimated by evaluating the interpolating polynomial constructed






where Li(t) is the Lagrange polynomial that is one at ti and zero at tj, j 6= i and
yj(u, ti) is the interpolating polynomial (in the input variable u) at time ti obtained
by Equation 2.3. The procedures of sparse grid construction and multivariate inter-
polation are implemented using the Sparse Grid Toolbox for Matlab, version 5.1.1 [7].
Specifically, the Chebyshev method is used for grid construction with the tolerances
for estimated relative and absolute grid errors (as calculated by the sparse grid tool-
box) set to 1% and 10−3, respectively, to ensure sufficient interpolation accuracy.
2.4.3 Normalization of Output Trajectories
As a first step toward characterizing plant output dynamics by qualitative features,
model output trajectories generated in response to prescribed control signals must be
processed to elucidate the characteristic behavior of the modeled system. This is done
by scaling and positioning the trajectories so that they span the functional magnitude





where ỹj is the predicted j
th output of the given model in response to input u for
time t ∈ [Tmin, Tmax] (omitted for readability). This operation preserves the dynamic
response of the model to prescribed controls while removing dependencies on scale
and response magnitude. As a result, qualitative comparisons among features can
be easily made with less regard to their exact quantitative nature when considering
multiple models of a process.
2.4.4 Control Problem Formulation
The objective of this control problem is to design the input signal using multiple
plant models that will cause an uncertain nonlinear system to reach and maintain a
target qualitative profile. The input design problem is constrained by approximating
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a continuous input signal u(t) ∈ RNu by a piecewise constant signal ũ(t) ∈ RNu×NTu ,
where Nu is the number of inputs and NTu is the number of allowed input administra-
tions. It is assumed that the input sequence can switch values only at pre-specified
time points distributed in the time frame of interest.
From an initial state, the multi-model-based controller calculates an appropriate
input sequence by solving a nonlinear, multi-input, constrained optimization problem.
The optimization objective is to minimize the deviations of the normalized output
trajectories from a reference trajectory as well as their derivatives for multiple models,
Nm, in addition to the magnitude of the piecewise constant control inputs. For
the objective function, the integral of the differences in the trajectories and their













where ŷ(k)(ũ, ti) represents the normalized interpolated output vector of the k
th model
in response to the piecewise constant input, ũ, sampled at time ti, ŝ(ti) is the value of
the reference trajectory, their derivatives are denoted as ˙̂y(k)(ũ, ti) and ˙̂s(ti), respec-
tively. (The derivatives of the output and reference trajectories are estimated from
the Lagrange interpolating polynomial used to characterize the time course.) The
constant weights, qk,i, pk,i and ri, in the objective function are adjustable by the user
to incorporate uncertainties and preferences. The piecewise constant approximation
to the input is defined by ũ(ti), where ti ∈ [Tmin, Tmax], i ∈ [1, 2, . . . , NTu ].
Herein, the optimal control solution (u∗) to the objective in Equation 2.7 is de-
termined using Matlab’s constrained optimization solver fmincon on the characteri-
zation of the output dynamics with sparse grid interpolation. This sparse grid-based
optimization strategy utilizes the interpolated dynamics as a surrogate for the plant
models to quantify their behavior in across the high dimensions (ũ(t) ∈ RNu×NTu ) of
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the piecewise constant input space. As the computational expense for evaluating large
systems of ODEs is generally much greater than for polynomials, the interpolation
strategy significantly reduces the computational requirements for input identification.
For large-scale optimization problems where fmincon may fail to converge to a
reasonable solution for the piecewise constant input sequence because of dimension-
ality or multiple minima, a sparse grid-based strategy similar to that employed by
Noble et al. [8] is utilized. First, a screening grid is built on the cost function to
characterize the cost manifold over the entire feasible input space. Focused grids are
placed upon this course grid in regions of acceptably low cost to increase the accuracy
of the interpolating polynomial without “wasting” model evaluations. Centers and
ranges for these grids are determined using a Latin hypercube sampling-based search
for local minima, and estimates of their respective Hessians. Considering all focused
grids, the point with the lowest identified cost is then chosen as the starting point for
a constrained search of the cost function on the interpolated dynamics using fmincon.
2.5 Results
2.5.1 Illustrative Example of Qualitative Feature Classification
To illustrate the method, we use two simple toy models:
Model 1:
ẋ




(2) = x2(u2 − x(2))/u1, x(2)(0) = 0.1,
y(2) = x(2)(t);
(2.8)
where the input variables u1 and u2 are subject to the bounds uj ∈ [10−2, 101],
j = {1, 2}. As a desired reference trajectory, we use s(t) = arctan(t) over the interval
t ∈ [0, 10]. In this example, we assume that inputs are constant and applied only at
the start of the experiment, t1 = 0. This assumption allows the objective function
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to be visualized in two dimensions. Fig. 2.1A and 2.1B depict the objective func-
tion cost manifolds considering each of the models separately over the input space.
The surfaces are color coded by cost function value (blue = good fit; red = poor
fit). It can clearly be seen that the input spaces possess distinct regions in which
qualitative dissimilarity between model and reference trajectories is low (dark blue).
The identification of the optimal compromise input, which best satisfies the objective
(Equation 2.7) considering both models, is illustrated in Fig. 2.1C using fmincon
with the interpolant of the model output dynamics to approximate and minimize the
cost manifold. For illustration purposes only since the dimension of the input space
is small, Fig. 2.1D shows the alternative optimization approach with focused sparse
grids that results in finding a similar solution to that generated by fmincon alone.
The application of the optimal compromise input to the plant models resulted in a
robust qualitative fit to the desired target profile (see Fig. 2.1E).
2.5.2 MAPK Activation Models
The proposed multiple-model qualitative controller design was applied to the in-
tracellular mitogen-activated protein kinase (MAPK) pathway. This pathway is a
highly conserved feature of receptor-mediated signal transduction and is known to
be involved in the immune response and the development of cancer. The cascade is
initiated by the introduction of activated RAS, which is a cytosolic G-protein and
RAF kinase. RAS phosphorylates RAF once to form RAFp. This activated form
of RAF induces two serine phosphorylations on MEK to form MEKp and MEKpp.
The doubly phosphorylated form of the dual-specificity kinase MEK phosphorylates
MAPK on threonine and tyrosine residues to form MAPKp and MAPKpp. A graph-
ical representation of this system is shown in Fig. 2.2A.
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Fig. 2.1.: Method demonstration using toy models in Equation 2.8. (A-B) Cost
manifolds of y(1)(t) and y(2)(t) independently with regard to the reference profile,
s(t). (C) Compromise cost manifold with fmincon-identified input (magenta star).
(D) Compromise cost manifold with sparse grid method-identified input (magenta
star). (E) Application of identified control inputs to plant model.
For this pathway, two mathematical models following the nonlinear ODE form of
Equation 2.1 are considered:
No Scaffold:
ẋ
(1) = f (1)(θ(1), x(1), u, t), x(1)(0) = x
(1)
0 ,
y(1) = [MAPKppfree](1) + [MAPKppbound](1);
Scaffold:
ẋ
2) = f (2)(θ(2), x(2), u, t), x(2)(0) = x
(2)
0 ,






























































Fig. 2.2.: Schematic of MAPK signaling. (A) Core set of biochemical reactions show-
ing the sequential phosphorylation of the MAPK kinases and their dephosphorylation
by the corresponding phosphatases. RAS* denotes constant, nonzero activation, and
1,2 indicate potential targets of control input reagents. (B) Various kinase-scaffold
combinations postulated by [10]. Both MEK and MAPK, indicated by shaded circles,
are able to bind to the scaffold in their inactive forms. The signaling elements are
released from the scaffold upon phosphorylation (p). (C) Simulations of both mod-
els for total MAPKpp concentration (M) in response to RAS* over the course of 30
minutes.
The first, a modified version of the model presented in [9], represents the core set
of phosphorylation events and the dephosphorylation events by corresponding phos-
phatases of the MAPK signaling cascade depicted in Fig. 2.2. The model consists
of 22 state variables and 30 kinetic parameters in order to characterize 30 biochem-
ical reactions. Rate equations were derived from the Michaelis-Menten description
of enzymatic reactions, in which enzymes are presumed to bind reversibly to their
substrates and dissociate upon forming the product.
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The second model, formulated by Levchenko et al. [10], extends the first MAPK
model with the inclusion of generalized scaffold proteins (see Fig. 2.2B), which serve
as moderators of signal transduction. These proteins bind several members of a
signaling cascade and are thought to promote kinase activity by eliminating interac-
tions with other competing molecular species. Different kinase-scaffold complexes are
formed through the binding and releasing of various kinases by the scaffold protein.
The model consists of 86 state variables and 300 kinetic parameters in order to char-
acterize 300 biochemical reactions. For a complete description of the model equations
and assumptions, the reader is referred to [10].
Because the second model simulates the implications of scaffolding proteins in
the MAPK signaling cascade, it is referred to herein as the “Scaffold” model. The
first model, which represents the core reactions of the MAPK cascade, is referred to
herein as the “No Scaffold” model. For both models, initial concentrations of the
signaling participants and model parameters are set as published [9, 10]. The model
outputs are interpreted as the total concentration of doubly phosphorylated MAPK
(MAPKpp). The MAPK pathway is simulated in response to continuous activation
of RAS (a prolonged activation can be stimulated in vitro with phorbol 12-myristate
13-acetate (PMA)). Simulations of both models under these conditions are shown in
Fig. 2.2C.
2.5.3 Input Reagents for Practical Control
The MAPK signaling cascade has several known commercially available reagents
that act at several different points in the pathway to facilitate or impede progress
through the pathway. The reagent U0126 is a MEK 1/2 inhibitor that inhibits active
and inactive MEK 1/2 and thus blocks the phosphorylation of MAPK, effectively
blocking downstream signaling [11]. The reagent sanguinarine, a MAPK phosphatase
(MAPKPH) inhibitor, hinders the dephosphorylation of phosphorylated MAPK al-
lowing prolonged activation of MAPK [12].
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For the purpose of representing the reagent actions within the MAPK ODE mod-
els, the models were modified slightly to incorporate their action. To simulate these
reagents as control inputs, the controller was parameterized by six administered
dosages, ũ(·) ∈ R2×6, of the two reagents at uniformly-distributed update times,
τi, over the course of 30 minutes. Their action within the model was represented by
altering the associated rate parameter, kp, to estimate of its effective value in the















Sanguinarine: j = 1, p = {8, 10}, τr,j = 180, τd,j = 3600;
U0126: j = 2, p = {3, 5, 5a}, τr,j = 180, τd,j = 3600.
(2.10)
The action of the reagent on the signaling pathway rate parameter is incorporated
through µj(t) that accounts for the response time, τr,j, and duration of action, τd,j,
of the jth reagent with 1+(·) as the Heaviside function to simulate administration.
Parameter ωj is a reagent-specific conversion factor from concentration to effectiveness
on the rate parameters. For this simulation study, this conversion factor was assumed
to be one for both reagents. The control inputs were subject to the constraints
ũj(i) ∈ [0, 0.5], ∀i, j.
2.5.4 Determination of Reagent Dosing for Qualitative Control
Herein, we applied the multi-model methodology for robust control using nor-
malized trajectories from two published models of MAPK activation. Our aim was
to predictably manipulate the activation of MAPK in silico by controlling its phos-
phorylation through periodic additions of MAKPH inhibitor sanguinarine and MEK
inhibitor U0126.
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Using the initial conditions and kinetic parameter values for both models as de-
scribed in [9,10], the controller used sparse grids to strategically probe the input space
to characterize the possible dynamics of each plant model. The resulting multidimen-
sional interpolating polynomials were used as surrogates for further evaluations of the
plant models in order to solve the optimization problem posed in Equation 2.7. As for
reference trajectories, three different profiles were used to elucidate the behavior of the
control algorithm: (1) peak activity is delayed in the experiment (s1(t) = 1−e−t/500),

































































Fig. 2.3.: Control strategy for delayed peak MAPK activation. (A) Predicted con-
centrations of MAPKpp from both models. (B) The derived control strategy for
s1(t).
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The results from the first experiment and the set of proposed control actions are
provided in Fig. 2.3. The upper plot shows the qualitative time-course responses of
MAPKpp as directed by the multi-model-based controller. The lower plot shows the
derived control strategy indicating how much of each reagent to apply at each time
point. To achieve the desired goal, which was to drive the output to peak at the end
of the time course, the controller proposed supplementing the reaction with small
amounts of sanguinarine during the middle of the time course. This action serves to
further accelerate the phosphorylation of MAPK until the activity is nearly saturated
at the end of the experiment. It was estimated that this action would best mimic the
desired response while minimizing the amount of reagent that needed to be added.
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Fig. 2.4.: Control strategy for transient MAPK activation. (A) Predicted concentra-






















































Fig. 2.5.: Control strategy for early termination of MAPK activation. (A) Predicted
concentrations of MAPKpp from both models. (B) The derived control strategy for
s3(t).
Fig. 2.4 and 2.5 depict the results of the second and third experiments, respec-
tively, and the sequences of control actions designed to produce them. To achieve
transient MAPK activation, the controller proposed counteracting the constant ac-
tivation signal by adding small amounts of U0126 to the reaction during the middle
of the time course. This sequence would allow the concentration of MAPKpp to rise
early in response to the activation signal, and then be suppressed during the latter
portion of the experiment. The objective of early termination of MAPK activity is
achieved through a more complex control strategy. This strategy, shown in Fig. 2.5,
calls for the early addition of sanguinarine to facilitate the phosphorylation of MAPK,
followed by sizable doses of U0126 to suppress the kinase activity of MEK, thereby
significantly lowering the concentration of MAPKpp.
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From these results we see that the control strategy informed by multiple mod-
els effectively controls the qualitative behavior of this highly complex and uncertain
nonlinear system. It should be noted that it was not possible to achieve this con-
trol objective without first normalizing the output of each models’ trajectories and
providing a normalized target reference signal since the quantitative values of the
model outputs differed substantially (see Fig. 2.2). The quantitative difference in the
un-normalized model outputs impeded the controller design since it was not possible
to select a single reference signal that had the desired qualitative features that could
be achieved by both models with the same control inputs.
The underlying sparse grid methodology provided a tool for efficient character-
ization of the dynamics and cost manifolds of the plant models and facilitated the
analysis of normalized dynamical responses. Additionally, the formulation of Equa-
tion 2.7 created a cohesive strategy for utilizing all the available knowledge embedded
in the multitude of published mathematical models. The computational efficiency of
the sparse grid-based approach is evident when comparing the number of simulated
model evaluations. For the non-sparse grid approach (i.e. fmincon only), the total
numbers of calls for both models considering s1, s2 and s3 were 529004, 285996, and
249637, respectively, whereas for the sparse grid-based approach utilized only 383673
calls, which is nearly a three-fold savings overall. By constructing an interpolant
of the model dynamics, this approach allows any combination of weighting schemes
and reference profiles to be considered without any further evaluations of the models.
This can lead to significant time savings for complex mathematical models.
2.6 Conclusion and Future Work
Structural and parametric uncertainty is an unfortunate consequence of model de-
velopment based on generally limited, noise-corrupted, semi-quantitative data. Char-
acterizations of uncertain systems are non-unique, and with those come an inherently
more challenging control problem. The analysis of the exemplar MAPK signaling
40
cascade highlights this very clearly—an initial search in the BioModels Database [13]
for published and annotated models of MAPK signaling elicited more than 50 models
from its records. Since each of these multiple models is supported by different sub-
sets of the available data and rarely does one model fit all available data, a sound
control strategy should employ these models to derive actions that are robust to the
inaccuracies of each model independently. Furthermore, the use of multiple mod-
els necessitates the analysis of qualitative features sets because the referencing of
fixed targets is not feasible when plant models’ outputs differ in their quantitative
calibration.
This work presents a framework for robust control of uncertain nonlinear sys-
tems using normalized features of multiple plant models’ trajectories to generate
predictable dynamical responses. The underlying sparse grid methodology provides
a tool for efficient characterization of the dynamics and cost manifolds of the plant
models and facilitated the analysis of qualitative feature sets. Additionally, the formu-
lation of the control objective creates a cohesive strategy for utilizing all the available
knowledge embedded in the multitude of published mathematical models.
The in silico controller implementation showed excellent performance in tracking
a qualitative reference profile and minimizing input requirements despite the uncer-
tainty from multiple model characterizations. These results will be evaluated in in
vitro experiments to verify the efficacy of the control strategy. Future work will
also emphasize improving cost manifold identification for better characterization of
acceptable controller input spaces.
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3. SYSTEMATICALLY MANIPULATING T-CELL
SIGNALING DYNAMICS VIA MULTIPLE MODEL
INFORMED OPEN-LOOP CONTROLLER DESIGN
3.1 Preface
This chapter describes technical improvements to the methodology presented in
the previous chapter for the effective use of multiple prediction models within an
open-loop MPC framework. The improvements followed the revelation that models
that are equally consistent with existing data may not be all equal—that is, they
may have considerable variation in novel scenarios. In open-loop, a high quality
prediction model bank is paramount for successful control. To account for model
variability, an adaptive model weighting strategy was introduce. This process was
designed to account for the fact that models differ in their ability to accurately reflect
the system dynamics under different experimental conditions. The material presented
in this chapter was originally published in the Proceedings of the 2012 Conference on
Decision and Control [1]:
Perley, J.P.; Mikolajczak, J.; Dinh, V.C.; Harrison, M.L.; Buzzard, G.T.; Rundell,
A.E., “Systematically manipulating T-cell signaling dynamics via multiple model in-
formed open-loop controller design,” Decision and Control (CDC), 2012 IEEE 51st
Annual Conference on, vol., no., pp.380–385, 10–13 Dec. 2012. doi: 10.1109/CDC.
2012.6426023
3.2 Abstract
A multiple-model approach to open-loop control of T-cell signaling pathways is
presented. Mathematical models of the T-cell signaling pathway are used to inform
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the controller design. The proposed framework employs a model predictive control
strategy to reduce the computational complexity of the open loop control problem.
Predictions from each model are weighted using adaptive Akaike weights that are
iteratively computed for each controller update step based upon the most relevant
training data subsets. This process accounts for the fact that models differ in their
ability to accurately reflect the system dynamics under different experimental condi-
tions. The algorithm is evaluated in silico and simulations demonstrate how the model
weighting strategy more effectively manages the inaccuracies of any single model. Fur-
thermore, the multiple-model control strategy is evaluated in vitro to direct T-cell
signaling. The controller-derived input sequence successfully drives the relative con-
centration of phosphorylated Erk along the desired trajectory when implemented in
the laboratory.
3.3 Introduction
T lymphocytes (T cells) are an integral part of the human body’s natural defense
against the threats of invading pathogens and cancerous cells. Engagement of T cell
receptors (TCRs) immediately initiates intracellular signal transduction pathways
resulting in the activation of transcription factors that ultimately direct the cell’s
action. During this process, manipulations to the early signaling events within the
transduction pathways can alter the cell’s response through changes to the active
transcription factor profile. Traditional biochemical assays can monitor only a limited
number of signaling molecules and do not support real-time observations. As a result,
open-loop control provides a suitable tool for designing systematic manipulations to
obtain desired signaling responses.
Successful open-loop controller design requires an accurate mathematical model
of the underlying process. Unfortunately, most mathematical models are crude ab-
stractions of biological reality and pose unique challenges in control applications [2].
Multiple models currently exist that describe aspects of the TCR-activated signal-
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ing pathways that differ in dominant species, network structure, parameter values,
and functional representation [3–6]. As with most signaling pathways, the limited
amount of pre-existing quantitative data and qualitative observations is unable to
unambiguously discriminate between the models.
Multiple models, or scenarios, have been previously used to improve robustness in
closed-loop model-based control to parametric uncertainty [7, 8]. Rao et al. [9] com-
puted control actions by weighting step-response models using relative Bayesian prob-
abilities to control hemodynamic variables in hypertensive subjects. Kuure-Kinsey et
al. [10] extended the concepts in [9] for disturbance rejection in a van de Vusse reactor,
using an average linear prediction model generated by multiple Bayesian probability-
weighted linear models. The recursive weighting system effectively eliminated the
“hard switch” between controllers. Noble et al. [11] predictably manipulated cell
differentiation experimentally with a model predictive controller based on multiple
data-consistent parameter characterizations. All of these approaches use feedback
that is not available for control of signaling pathways. Furthermore, the limited sig-
naling data do not support Bayesian methods. Consequently, existing techniques for
multiple-model control are insufficient for controlling T-cell signaling.
In this paper we present a practical framework for designing open-loop control
informed by multiple models for directing intracellular signaling dynamics in T cells.
To address model uncertainty, we consider weighted predictions made by multiple
nonlinear ordinary differential models of T-cell signaling to design controller actions
(manipulations). Prediction model weights are based upon Akaikes Information Cri-
terion (AIC), an information-theoretic method previously used for model selection
that considers complexity and fitness to existing experimental data [12,13]. To facil-
itate the open-loop controller design, we employ the model predictive control frame-
work. Thus we propose an adaptive Akaike-based multiple-model predictive control
for open-loop control of T-cell signaling. This strategy is evaluated using simulated
and in vitro experiments on a well-established cell line (Jurkat) typically used for
studying T-cell signaling pathways.
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3.4 Methods
The control strategy presented herein employs multiple prediction models to form
a compromise control sequence that ameliorates the effects of the inaccuracies of any
single model. As illustrated in Fig. 3.1, the first stage is to select an appropriate
set of prediction models to populate the model bank. Using initial model weights
estimated from training data, the multiple-model controller surveys the input space
and proposes a control action for the next control update step. Since models differ in
accuracy for different scenarios or data sets, model weights are re-estimated using the
portion of the training data that most closely corresponds to the proposed control
action. Adaptation continues until model weights (and associated control action)
no longer change or a maximum iteration is reached. The process repeats for each
control update step and continues until the entire open-loop control sequence has
been specified and is ready to be applied to the simulated or experimental plant.
3.4.1 Model Representation
The multiple-model control strategy is based on the use of a set of mathematical
models, M = {M (1), . . . ,M (nM )}, of the general form given by Equation 3.1:
M (i) =
ẋ





where the superscript i denotes the model number. The state variables, manipulated
variables (control inputs), process parameters and process outputs are x ∈ Rn, u ∈ Rd,
θ ∈ Rp and y ∈ Rm respectively, and f : Rn × Rd → Rn and g : Rn → Rm are twice
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Fig. 3.1.: Block diagram of multiple model control strategy. (A) Overview of open-
loop configuration for implementation of multiple model-based control of T-cell sig-
naling in the laboratory. (B) Detailed flowchart of adaptive Akaike-weighted multiple-
model control algorithm.
3.4.2 Prediction Model Bank
The targeted signaling pathway is the TCR-activated extracellular signal-regulated
kinase (Erk, or MAPK) pathway as shown in Fig. 3.2. The engagement of the TCR
causes recruitment of protein tyrosine kinase Zap70 and Src-family kinases Lck and
Fyn, which initiates signal propagation to the Erk-MAPK cascade. Two ordinary
differential equation (ODE) models of the TCR-mediated signaling cascade are used
for the basis of the model bank [3,4] with four additional hybrid models created from
these two by replacing the ubiquitous MAPK cascade portion (Fig. 3.2B) of the sig-




























































































































Fig. 3.2.: TCR-mediated signaling pathway. (A) General representation of critical
components and reactions that are characterized by the prediction models. (B) Ex-
panded view of reaction in the Erk-MAPK cascade. Arrowheads denote activation of
target molecule or reaction direction and diamond heads denote inhibition. Molecules
in green and red are activators and inhibitors, respectively, and denote possible con-
trol reagents. (C) Illustration depicting how modules are combined to form prediction
models in the model bank.
(Z0) contains primarily first- and second-order mass action kinetics with 24 ODEs and
53 reaction parameters. The Lipniacki et al. [4] model (L0) differs in that it explicitly
incorporates SHP-mediated negative feedback and Erk-mediated positive feedback to
characterize the kinetic proofreading inherent to the TCR signaling pathway. The
model consists of 37 ODEs and 97 parameters derived from mass action kinetics.
To illustrate the controller method with a sufficiently rich set of ODE-based models
without additional complications derived from fuzzy logic or Boolean models, we
formulated four hybrid models by modifying the Erk-MAPK cascade equations in
Z0 and L0 with two alternative MAPK models presented by Levchenko et al. [14]
that employ Michaelis-Menten-derived rate equations with and without the presence
of scaffold proteins. The Levchenko model without the scaffold contains 22 ODEs
with 30 kinetic parameters while the version with scaffold proteins contains 86 ODEs
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with 300 parameters. Fig. 3.2C illustrates how these additional models were formed.
We denote these additional models by: Z0+Scaffold (ZS), Z0+No Scaffold (ZNS),
L0+Scaffold (LS) and L0+No Scaffold (LNS).
The output of each model is considered to be the total concentration of phos-
phorylated Erk. The prediction models were modified to contain control inputs that
simulate the action of two commercially available reagents that regulate T-cell signal-
ing: sanguinarine and U0126 (shown in Fig. 3.2 in red). Sanguinarine is an inhibitor
of Erk phosphatase and can lead to increased phosphorylation of Erk [15]. U0126 on
the other hand is a small molecule inhibitor of Mek with high selectivity [16] which
effectively inhibits activation of Erk. For each prediction model, optimal parameter
vectors were determined by minimizing the residual sum of squares between model
outputs and training data. To account for the differences in scale between the models,
the outputs were normalized to ensure that the peak uncontrolled response scaled to
unity.
3.4.3 Akaike Model Weight Calculation
Using inferences made by multiple competing prediction models with varying lev-
els of accuracy and complexity necessitates the use of a weighting system to rank
our confidence in each model. Akaike’s Information Criterion (AIC) provides a prac-
tical measure of the tradeoff between model fitness and complexity by estimating
the theoretical Kullback-Leibler (KL) “distance”, or loss of information, between an
approximating model and full reality [12]. Denoting the parameter estimates ˆtheta,
given model M (i) and a set of data y, the relative KL information is approximated
by the biased log-likelihood function defined by Equation 3.2:
AIC(i) = −2 log(L(θ̂(i)|y)) + 2K, (3.2)
where L is the log-likelihood function and K, denoting the number of model pa-
rameters, is the bias estimate (the factor 2 was introduced for historical reasons).
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Assuming normally distributed errors with constant variance, then the AIC can be
estimated as Equation 3.3:
AIC(i) = N log(ε(i)
>
Λ(i)ε(i)/N) + 2K, (3.3)
where N is the number of data and ε(i) = [y
(i)
1 − ỹ1, . . . , y
(i)
N − ỹN ] is the vector of
residuals between experimental data ỹ and their corresponding outputs y(i) from the
ith model. The residual weighting matrix, Λ(i), is traditionally the identity although
herein we will use it to selectively weight models and subsets of the data as further
explained in Section 3.4.5.
If N/K < 40, an additional bias term is introduced to accommodate small samples
to yield the corrected-AIC (AICc) given by Equation 3.4
AICc(i) = AIC(i) +
2K(K + 1)
N −K − 1
. (3.4)
It is important to note that the AICc values are only meaningful relative to one
another. This stems from the AIC being a relative rather than absolute estimate
of KL distance. As a result, only the quantity ∆(i) = AICc(i) − AICcmin will be
considered for each model. It follows that the relative likelihoods of the models are





The weight ω(i) is considered to be the strength of evidence in support of the ith
model being the KL best model given the data and the set of models [12].
3.4.4 Akaike-Weighted Multiple-Model Predictive Control
The multiple-model control strategy is built around the conventional MPC frame-
work in order to reduce the computational complexity of the open-loop control prob-
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lem. At each update index, the controller surveys the possible trajectories stemming
from the current state over a finite prediction horizon (Hp) and control horizon (Hu)
and selects the control sequence so that the predicted output tracks a desired trajec-
tory. The initial value of the control sequence is set and used to update the states of
the prediction models so the procedure can repeat for the remaining control update
steps.
The control objective function penalizes the error between the predicted output
for model i and the desired trajectory and a measure of the control effort over the
prediction horizon starting at time tk ∈ Ts, as given by 3.6:
J (i)(U) = [Y (i) − S]>Q[Y (i) − S] + U>RU, (3.6)
where the vectors Y (i) = [y
(i)
1 (tk|k), . . . , y
(i)
m (tk+Hp|k)]
> and S = [s1(tk|k), . . . , sm(tk+Hp|k)]
>
are the predicted and target outputs overHp, respectively, U = [u1(tk|k), . . . , ud(tk+Hu−1|k)]
>
are the discrete controller inputs over Hu, and Q and R are diagonal weighting ma-
trices associated with the error and control effort, respectively.
The optimal control sequence is determined by solving the optimization problem




s.t. Umin ≤ U ≤ Umax,
(3.7)
where ω and J are vectors of Akaike weights and objective function values associated
with the nM prediction models. Thus the control objective minimizes a weighted
aggregate of the predictions from multiple models that mitigates the inaccuracies of
any single model. Herein, the solution to Equation 3.7 is computed by MATLAB’s
constrained nonlinear optimization solver (fmincon).
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3.4.5 Akaike Model Weight Adaptation
As illustrated in Fig. 3.1, model weights, computed using Equations 3.3–3.5, are
updated from their original values based on the proposed control action at each step.
Primarily due to the effects of model-plant mismatch, it is quite common for a model’s
fitness quality to change between data sets generated under different experimental
conditions (i.e. different levels or combinations of the control inputs). Therefore,
we adaptively update the Akaike weights to consider only the training data collected
under conditions that most closely resemble the proposed control action.
For a given number of training data sets, let uk,j be the input used to generate the
observations ỹk,j for the j
th experiment involving the kth control variable. Further-
more, let u∗k be the proposed control action for the k
th control variable at the current
update step. For the following calculations, the magnitudes of uk,j and u
∗
k should be
normalized by their corresponding upper bounds to prevent giving disproportionate
weight to larger values. The relative distance between the points on the input space
and the predicted control action in the kth dimension is δk,j = |uk,j −u∗k|. Now, let us
only consider the points in each dimension that neighbor u∗k since they most directly
correspond to the current proposed control action. Let Rk refer to these points, that
is, the set of indices of two points in the kth dimension forming the smallest interval
containing u∗k. This leads to the relative weight of each point in Rk with respect to





for r in Rk, where Lk is the distance between the two points in Rk. Now, the residuals
between the observations ỹk,r, where r ∈ Rk, and the corresponding outputs predicted








where d is the dimension of the input space. The term βk,r is used to weight the
residuals computed from data generated under experimental conditions most similar
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to the proposed control action. We use the weights in Equation 3.9 as the entries in a
diagonal matrix, Λ, to be used as the residual weighting matrix in Equation 3.3. The
corresponding residual is the vector of differences, y
(i)
Rk
− ỹRk , over the corresponding
set of Rk and i. Using updated definitions for Λ and ε
(i) to include only the subset of
relevant data, new Akaike weights are computed using Equations 3.3–3.5. In essence,
this adaptive weighting strategy gives priority to the models best supported by the
data relevant to the experiment at hand in the calculation of the Akaike weights for
the next iteration.
3.4.6 Experimental Methods
Erk phosphorylation (pErk) data were collected from Jurkat T leukemia cell line
(Jurkat clone E6.1; ATCC). Cells were grown in RPMI 1640 (Sigma) supplemented
with 7.5% heat-inactivated fetal bovine serum (BioWest), 1mM sodium pyruvate
(Gibco), 12.5 mM HEPES pH 7.4 (Sigma), 12 µM sodium bicarbonate (Sigma) 50
µM 2-Mercaptoethanol (Sigma), 50 µg/ml streptomycin and 50 units/ml penicillin
in an incubator at 37◦C in humidified air containing 5% carbon dioxide. Cells were
harvested in log-phase growth and 2× 107 cells per treatment. Cells were stimulated
using anti-human CD3 (10 µg/ml, clone: UCHT-1, eBioscience) as the stimulatory
signal at 37◦C in a water bath. Cells were treated with the Mek1/2 inhibitor U0126
(Calbiochem) or the MKP inhibitor sanguinarine (Sigma), depending on the protocol,
dissolved in DMSO at the indicated time points with the indicated concentrations.
Experimental control samples where treated with the same amount of DMSO. Sam-
ples of 2×106 cells were taken at the indicated time points and lysed in 1% NP40 lysis
buffer (1% NP40, 25 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1mM NaV, 10
mM NaF, 10 µg/ml each of aprotinin and leupeptin) for 15 min on ice. Lysates were
centrifuged for 5 min at 18000 g at 4◦C. The supernatant was added to the same vol-
ume of 2X protein solubilizing mixture (PSM, 25% (w/v) sucrose, 2.5% (w/v) sodium
dodecyl sulfate, 25 mM Tris, 2.5 mM EDTA, 0.05% bromophenol blue) and boiled for
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five minutes. Proteins were separated via SDS-PAGE, blotted for phospho-Erk1/2
(Cell Signaling), phospho-ZAP-70 (pY319, Cell Signaling) and GAPDH (Ambion).
IRDye 800 and 680 secondary anti-mouse and anti-rabbit antibodies (Li-Cor) were
used for signal detection using an Odyssey infrared scanner. Images of the blots were
analyzed using ImageJ to produce quantitative data for model comparison. Model
predictions were scaled to compensate for the fact that the data showed relative
quantities only rather than absolute concentrations.
3.5 Results and Discussion
The performance of the open-loop multiple-model control strategy for system-
atically manipulating T-cell signaling dynamics is evaluated using two approaches:
simulated experiments and laboratory experiments. For simulated experiments, the
controller is trained with data generated from in silico experiments to demonstrate
the effectiveness of the multiple-model controller and adaptive weighting strategy.
For laboratory experiments, the open-loop control sequence is administered to a pop-
ulation of Jurkat T cells to evaluate its ability to direct TCR-mediated signaling in
vitro. For this case, training data were also collected from in vitro experiments. In
both cases, the training experiments were designed to rapidly screen the effects of the
control reagents on a T cell population (in silico: n = 3; in vitro: n = 1). In all there
were 10 experiments: four different doses of sanguinarine (5, 10, 20 and 50 µM), five
different doses of U0126 (0.5, 1, 2, 5 and 10 µM), and an experimental control (i.e.
no inputs). Control inputs were added at 5 minutes after stimulation by anti-CD3
and samples of pErk were taken at 0, 2, 5, 10, 12, 15, 20 and 30 minutes.
For both the simulated and laboratory experiments, the desired trajectory (target
profile) for the model output is defined by the equation s1(t) = (1− e−t)(1 + et−10)−1.
It has been reported that constitutive activation of the Erk pathway is present in
high frequency (¿50%) in patients suffering from acute myeloid leukemia (AML) and
is associated with a marked reduction in survival duration [17, 18]. This suggests it
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may be therapeutic to rapidly force pErk to baseline levels shortly after reaching its
peak activity as defined by s1. Manipulated variables u1 and u2 are defined to be con-
centrations of sanguinarine and U0126, respectively. The five possible input update
steps (dosing times) Ts begin at 3 minutes post-stimulation with anti-CD3 and are
spaced 5 minutes apart to accommodate both the rapid dynamics of TCR signaling
and the experimental constraints on input update and observation rates. The ex-
periment is terminated at 30 minutes when no inputs are applied but measurements
are taken. The horizons Hu and Hp are set to 1 and 2, respectively, and weighting
matrices Q and R are each chosen to be identity. Input constraints on sanguinarine
and U0126 are set to [0, 50] µM and [0, 10] µM, respectively. The rationale for the
upper limits come from experimental results that indicate saturation effects at levels
above the specified concentrations.
3.5.1 Simulated Controller Performance
Plant Response
Z 0





























































































































































Fig. 3.3.: Illustrative results of in silico controller implementation. Row labels de-
note the prediction models used to generate training data (with 10% Gaussian noise
added). (A, D) Akaike weight adaptation for all models. (B, E) Control sequence
computed by the controller considering all six prediction models fitted to simulated
data. (C, F) Normalized pErk concentration of the plant with multiple model in-
formed open loop control. Note that a negative value means that the output is below
its initial concentration.
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In the simulated case, the multiple-model controller is evaluated six different times,
each time assuming a different model as the “true” but unknown plant. Noisy data are
generated from the “true” plant model using the conditions described in the previous
section and adding 10% Gaussian noise. For each simulated data set in triplicate, all
six prediction models are re-fitted to the data and new model weights are computed
using Equations 3.3–3.5. For illustrative purposes, only two simulated experiments
are shown: (1) Z0 as the “true” plant and (2) LNS as “true” plant. It is evident
from Fig. 3.3A,D that the accuracy of the prediction models partially depends on
the training data. In the case where the Z0 plant is assumed, the Akaike weights
strongly favor the predictions from the Z0 model. This suggests that its predictive
capability is unmatched by rival models given the available data. However, when the
LNS plant is assumed, the weights tended to oscillate between LNS and L0, most
likely due to the number of shared characteristics between the two structures. This
also suggests that the predictive capacity of both models changed as a function of
the control input updates. As it is unclear which is more favorable, both models
are used to inform the controller. In both cases the adaptive weighting strategy is
able to filter out unlikely models given the training data. As shown in Fig. 3.3B,E
the controller chose a ramp-up in U0126 doses between 8 and 13 minutes for the
scenario when Z0 was the “true” but unknown plant, while a single bolus-type dose
was chosen for the LNS plant scenario. Nevertheless, the plant output tracked the
target response reasonably well even though the two predicted control actions were
different (Fig. 3.3C,F). This is in stark contrast to the performances of single-model
controllers with similar MPC set-ups (Fig. 3.4). When the plant and prediction
model are mismatched, a likely scenario in practice, there is moderate to extreme
deterioration in the tracking performance (e.g. when ZNS informs the controller).
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Fig. 3.4.: In silico single-model controller performance. Predicted pErk dynamics for
assumed plants (A) Z0 and (B) LNS. Legend denotes prediction model used to inform
the controller and resulting plant output.
3.5.2 Experimental Controller Performance
Training data were collected according to Sections 3.4.6 and 3.5. The addition of
low to moderate doses of sanguinarine had negligible effects on pErk concentrations.
Only the highest dose tested caused a sustained elevation of pErk. On the other hand,
U0126 produced immediate reductions in pErk concentrations even at low doses. The
representation of the controller input functions in the prediction models were modified
to exhibit these trends.
Starting with the training data, the multiple-model open-loop control strategy
with adaptive Akaike weights is implemented to evaluate its ability to direct TCR-
mediated signaling in vitro. Comparing Fig. 3.5A with Fig. 3.3A reveals an interest-
ing contrast between the cases of model training with experimental data as opposed
to simulated data. Initially, ZNS vastly outweighs its rivals, resulting in a control
strategy based primarily on it alone. As the open-loop control sequence is being
built, however, there is a dramatic shift in confidence towards Z0, indicating it is a
better fit to the relevant data collected under conditions at each of the subsequent
controller update steps. Had a single prediction model or a fixed weighting strategy
been used, one could not be as confident in the resulting controller given the data.
This demonstrates that the models’ predictive capabilities can be variable over the
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input space especially when training data is limited and noisy. Furthermore, this sup-
ports the usefulness of the adaptive Akaike weights in the open-loop multiple-model
control problem. When implemented in the laboratory, the proposed control sequence
(shown in Fig. 3.5B) was able to effectively drive the relative levels of pErk along the
target trajectory (n=3, shown in Fig. 3.5C).


















































































Fig. 3.5.: Results of in vitro controller implementation. (A) Akaike weight adaptation
for all prediction models. (B) Control sequence computed by the controller consider-
ing all six prediction models fitted to in vitro training data. (C) Normalized in vitro
pErk concentrations collected from the experimental control (i.e. no inputs) shown in
blue and the multiple-model open-loop control-based experiment shown in red (n=3
for both sets). Asterisks (*) denote statistically significant differences between groups
(pleq0.05) as calculated by one-way ANOVA with Tukey multiple comparisons test.
Data shows mean ± standard error.
3.6 Conclusion and Future Work
This work presents a practical framework for open-loop control of uncertain non-
linear systems using multiple models to generate predictable dynamical responses.
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The model weighting strategy employs adaptive Akaike weights that give priority to
the models most supported by the data relevant to the control input at that up-
date step. This open loop controller design pairs multiple model predictive control
with adaptive Akaike model weights to create a cohesive strategy for systematically
utilizing the most relevant knowledge embedded within limited training data in a
computationally tractable manner.
In silico controller implementation showed excellent performance in tracking a
target response profile despite the uncertainty from multiple model characterizations.
These results were corroborated with in vitro experiments. However, the precision
gained by using multiple prediction models came at the expense of computational effi-
ciency. The computation time is approximately proportional to the number of models
and iterations of the weight adaptation algorithm, with variability due to the com-
plexity of the additional models and the modified objective space topography. The
proposed approach also does not incorporate new data in real time. Unfortunately,
the maximum feedback frequency afforded by current experimental protocols is in-
sufficient to control the rapid dynamics of Erk signaling. Open-loop control provides
the only reasonable systematic means of manipulating Erk dynamics. That said, one
could easily modify the proposed approach to accommodate observational feedback
should it be available.
Future work will emphasize cost manifold identification for accurate and efficient
solution to the multiple-model predictive control problem. Incorporating parametric
uncertainties will be streamlined to better inform the design of compromise solutions.
Next steps will also address multi-output control to systematically manipulate the
dynamics of more than one signaling species within a signaling pathway to allow for
more sophisticated control strategies.
The TCR Erk-MAPK signaling pathway studied herein is known to be associated
with allergies, asthma, auto-immune disorders, and acute myeloid leukemia among
others [17,18]. The ability to predictably alter the T-cell signal transduction dynam-
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ics, and thereby indirectly modify the transcription factor activation profile and gene
regulatory networks, may ultimately have therapeutic applications.
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4. MULTIPLE MODEL-INFORMED OPEN-LOOP
CONTROL OF UNCERTAIN INTRACELLULAR
SIGNALING DYNAMICS
4.1 Preface
The study described in this chapter introduced the concept of model weight maps
and the use of multiobjective optimization to facilitate model weight adaptation. The
purpose of the weight maps were to indicate the probability of each model in the pre-
diction model bank for any admissible input in the controller design space. This was
achieved by computing the relative likelihood of each model given existing experi-
mental data. Likelihoods in unsampled regions of the design space were estimated
through interpolation/extrapolation of the experimental data. The control optimiza-
tion problem was recast into a multiobjective framework to facilitate model weight
adaptation. This allowed the controller to have the most updated estimates of the
model weights when calculating the optimal compromise control action. The material
presented in this chapter was originally published in the PLoS Computational Biology
journal [1]:
Perley JP, Mikolajczak J, Harrison ML, Buzzard GT, Rundell AE (2014) Multiple
Model-Informed Open-Loop Control of Uncertain Intracellular Signaling Dynamics.
PLoS Comput Biol 10(4): e1003546. doi:10.1371/journal.pcbi.1003546
4.2 Abstract
Computational approaches to tune the activation of intracellular signal transduc-
tion pathways both predictably and selectively will enable researchers to explore and
interrogate cell biology with unprecedented precision. Techniques to control complex
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nonlinear systems typically involve the application of control theory to a descriptive
mathematical model. For cellular processes, however, measurement assays tend to be
too time consuming for real-time feedback control and models offer rough approxima-
tions of the biological reality, thus limiting their utility when considered in isolation.
We overcome these problems by combining nonlinear model predictive control with a
novel adaptive weighting algorithm that blends predictions from multiple models to
derive a compromise open-loop control sequence. The proposed strategy uses weight
maps to inform the controller of the tendency for models to differ in their ability to
accurately reproduce the system dynamics under different experimental perturbations
(i.e. control inputs). These maps, which characterize the changing model likelihoods
over the admissible control input space, are constructed using preexisting experimen-
tal data and used to produce a model-based open-loop control framework. In effect,
the proposed method designs a sequence of control inputs that force the signaling
dynamics along a predefined temporal response without measurement feedback while
mitigating the effects of model uncertainty. We demonstrate this technique on the
well-known Erk/MAPK signaling pathway in T cells. In silico assessment demon-
strates that this approach successfully reduces target tracking error by 52% or bet-
ter when compared with single model-based controllers and non-adaptive multiple
model-based controllers. In vitro implementation of the proposed approach in Jurkat
cells confirms a 63% reduction in tracking error when compared with the best of the
single-model controllers. This study provides an experimentally-corroborated con-
trol methodology that utilizes the knowledge encoded within multiple mathematical
models of intracellular signaling to design control inputs that effectively direct cell
behavior in open-loop.
4.3 Author Summary
Most cell behavior arises as a response to external forces. Signals from the extra-
cellular environment are passed to the cell’s nucleus through a complex network of
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interacting proteins. Perturbing these pathways can change the strength or outcome
of the signals, which could be used to treat or prevent a pathological response. While
manipulating these networks can be achieved using a variety of methods, the ability
to do so predictably over time would provide an unprecedented level of control over
cell behavior and could lead to new therapeutic design and research tools in medicine
and systems biology. Hence, we propose a practical computational framework to aid
in the design of experimental perturbations to force cell signaling dynamics to follow a
predefined response. Our approach represents a novel merger of model-based control
and information theory to blend the predictions from multiple mathematical models
into a meaningful compromise solution. We verify through simulation and experi-
mentation that this solution produces excellent agreement between the cell readouts
and several predefined trajectories, even in the presence of significant modeling un-
certainty and without measurement feedback. By combining elements of information
and control theory, our approach will help advance the best practices in model-based
control applications for medicine.
4.4 Introduction
The ability to predictably manipulate intracellular signaling pathways would pro-
vide an unprecedented level of control of cellular processes and could potentially
generate new approaches for therapeutic design and research tools in medicine and
systems biology. Intracellular signaling networks are complex assemblies of inter-
connected molecular components that relay information and coordinate responses to
environmental cues. For example, T lymphocytes are critical regulators of the im-
mune response against the threats of invading pathogens and cancerous host cells.
Their response to external stimuli is coordinated through several mediators includ-
ing extracellular signal-regulated kinases (Erk), which are particularly noteworthy as
they have been implicated in a number of autoimmune diseases and cancers [2–5].
Phenotypic change due to extracellular perturbation is a robust property of normal
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cell behavior and involves considerable feedback and crosstalk and is highly nonlin-
ear. To help resolve the uncertainty and understand the complexity inherent within
these signaling pathways, many researchers have developed mathematical models of
signaling processes [6–11]. These models can be used to inform control strategies that
try to predictably manipulate the intracellular signaling response, but also give rise
to a new set of challenges in systems biology and control engineering.
To date, the majority of model-based control of cellular processes and systems
has focused on biomass production in bioreactors [12, 13] or were largely theoretical.
Within the past decade, research has started to evaluate engineered control strate-
gies for single and multiple cell signaling processes within experiments. Noble and
Rundell [14] used closed-loop (i.e. in silico feedback) control to direct HL60 cell dif-
ferentiation through periodic boluses of a differentiation-inducing agent determined
by nonlinear model predictive control (MPC). In 2012, they revised the initial ap-
proach to improve the transient response of the differentiating cells over 20 days by
using a multi-scenario adaptive model predictive control [15]. Uhlendorf et al. [16]
applied open-loop (i.e. non-feedback) and closed-loop control to provide long-term
regulation of gene expression on the single-cell and population level by manipulating
the osmotic stress on cells in a microfluidic environment. The open-loop approach
failed to regulate mean fluorescence to the desired set points in the laboratory. On
the other hand, attempts using measurement feedback proved to be more successful
at coping with modeling inaccuracies and inherent intracellular fluctuations. Opto-
genetics and synthetic biology provide effective methods for control theory to interface
with cellular processes at the genetic and signal transduction level. Milias-Argeitis
et al. [17] attempted to control the activation of a light-responsive Phy/PIF module
that altered the expression of a yellow florescent protein (YFP) activated through
the Gal1 promoter in Saccharomyces. As in [16], the closed-loop approach proved
more successful in driving YFP intensity to the desired set points in the laboratory.
Toettcher et al. [18,19] also used light as the control input to modulate the localization
of PIF-tagged proteins to the cell membrane. This has the ability to alter intracellular
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signaling through coordination of the localization. Both of these studies achieve long-
term regulation of cell activities through transcriptional control. Another closed-loop
control study was proposed in Menolascina et al. [20] using pulse width modulation
to specify the duration of pulses of galactose administered via microfluidics. Their ex-
perimental results confirm the predictive capabilities of their model for the synthetic
gene network in S. Cerevisiae.
All of the aforementioned studies rely upon computer-based feedback control: a
computer in the loop uses system measurements to inform control decisions. While
closed-loop control is widely understood to be more robust to disturbance and un-
certainty, in many cases the rapid dynamics, scale and complexity of intracellular
signaling events and absence of real-time measurement assays prohibit its use. In
these cases, any control strategy must design the control inputs in advance without
measurements to inform future steps and rely solely upon prior information gleaned
from existing experimental data. However, this may introduce unwanted degradation
in control performance due to discrepancies between the actual system and the pre-
diction model (i.e. plant-model mismatch). Methods to systematically and optimally
combine this prior information with the predictive capacity of multiple mathematical
models are needed.
Because mathematical models are abstractions of biological reality, they may dif-
fer in dominant species, network structure, parameter values, and functional repre-
sentation. For most signaling pathways, limited preexisting quantitative data and
qualitative observations are insufficient to discriminate unambiguously between the
mathematical models. When applying control theory techniques, the experimental
perturbations (i.e. control inputs) predicted to elicit a desired behavior from a sys-
tem may be different for each model. Selecting the “best” of these models is an
important challenge to control theorists for systems biology applications [21]. Apgar
et al. [22] applied control theory to discriminate among mechanism-based chemical
kinetic models of epidermal growth factor receptor signaling. The method designs
dynamic stimuli to delineate the system’s response to subtle differences in the net-
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work topology. The model associated with the best controller is deemed the best
representative of the original system. However, in using this model alone, we would
implicitly assume that the model is also the most accurate in alternate operating
regions, which may or may not be the case. Without performing the experiments
there is no way to know a priori which model is best; furthermore, the best model
may change depending upon the experiment planned. How to optimally combine
information from these network models to design control inputs that, when applied
to the cell, force the signaling dynamics along a desired path is the subject of much
debate.
Growing attention in systems biology has been given to control methodologies
considering multiple prediction models. Multiple models, or scenarios, have been
previously used to improve robustness to parametric uncertainty in closed-loop model-
based control [15,23–26]. The approach proposed by Rao et al. [25] computed control
inputs by weighting multiple step-response models using a Bayesian algorithm to con-
trol hemodynamic variables in hypertensive subjects. These concepts were extended
for disturbance rejection in a van de Vusse reactor using Bayesian methods to pro-
duce a weighted-average linear prediction model [26]. The recursive weighting system
was effective at eliminating the “hard switch” between controllers. Noble et al. [15]
employed adaptive nonlinear MPC based on multiple data-consistent parameter char-
acterizations to manipulate cell differentiation experimentally. Control inputs were
chosen such that the average tracking error and resource efficiency were optimized,
which resulted in superior controller performance over single-model MPC. However,
this approach assumes all parameter scenarios are equally likely and does not consider
that their accuracy in predicting actual system dynamics often varies between dis-
tinct regions of the state and control input spaces. Furthermore, the aforementioned
approaches consider essentially single model structures with little to no variation in
the mathematical equation structures. While methods considering model uncertainty
explicitly are numerous, it is generally in the form of disturbances and process noise
with very little consideration given to qualitatively distinct biological hypotheses.
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This is a critical flaw as these hypotheses could translate into qualitatively distinct
equation structures and input/output and state/output relationships. Finally, all
of these approaches employ real-time feedback that is not available for most intra-
cellular signaling pathways because the dynamics are often too rapid for standard
measurement assays.
In this paper, we present a practical open-loop control framework with a novel
method for employing existing experimental data to confidently combine multiple
model predictions to form effective control inputs. That is, an automated control
input selection process is developed for the open-loop case; this process is advised by
information regarding model accuracy in regions of the input space where potential
control inputs are likely to be present. Akaike weights, based on an information-
theoretic metric penalizing model complexity and lack-of-fitness used for model dis-
crimination [27, 28], are employed for this purpose. In the results, we successfully
demonstrate the algorithm with several simulated test cases and corroborate a subset
of these with in vitro experiments in Jurkat T lymphocytes. Conclusions and future
work are presented in the discussion and detailed and illustrated descriptions of the
algorithm and experimental protocols are provided in the materials and methods.
4.5 Results
4.5.1 Controlled System: T Cell Activation
The signaling pathway considered herein is the T cell receptor (TCR)-activated
extracellular signal-regulated kinase (Erk, or MAPK) pathway (generalized in Fig-
ure 4.1). Activated Erk is an important condition in lymphocyte development and
activation processes because it is a highly conserved and ubiquitous mechanism for
transferring extracellular signals from membrane-bound receptors to the nuclear do-
main for gene regulation. The stimulation of TCRs by antigenic peptides (e.g. αCD3,
shown in green in Figure 4.1) initiates a number of molecular reactions involved in
signal transduction through Erk. During ligand binding, the TCR recruits and is
70
phosphorylated by the tyrosine kinase Lck. A second tyrosine kinase, ZAP70, binds
the tyrosine phosphorylated TCR subunits and is phosphorylated and activated by
Lck. The receptor-kinase complex recruits and phosphorylates the adapter proteins
LAT and Grb2 and phosphorylates and activates PLCγ leading to the formation
of GTP-bound Ras. Activated Ras initiates the canonical Raf/Mek/Erk signaling

































Fig. 4.1.: Generalized illustration of the TCR-mediated signaling pathway through the
Erk-MAPK cascade. Arrow- and diamond-heads denote activation and inhibition of
substrate molecules, respectively. TCR stimulation is achieved through αCD3 (green)
binding. Subsequent Erk activation (black) controlled using small molecule inhibitors
sanguinarine (blue) and U0126 (red).
4.5.2 Prediction Model Bank
Three mathematical models of the TCR-mediated signaling cascade are used for
the basis of the prediction model bank [6–8]. The model proposed by Zheng [6] (herein
referred to as Model Z ) contains primarily first- and second-order mass action kinetics
with 24 ODEs and 53 reaction parameters. The second model (herein referred to
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as Model L) is the deterministic version of the model proposed by Lipniacki et al.
[7], which explicitly incorporates SHP-mediated negative feedback and Erk-mediated
positive feedback. Model L consists of 32 reaction parameters and 37 ODEs derived
from mass action kinetics. The original version of the third model, presented by Klamt
et al. [8], uses Boolean logic to describe the main steps involved in the activation of
CD4+ helper T cells. CellNetAnalyzer, a Matlab software package [8] for structural
and functional analysis of signaling networks, and the Odefy toolbox [29] were used to
convert the logical model to a continuous homologue (herein referred to as Model K )
with 40 states and 147 reaction parameters. Values for these reaction parameters were
taken from Table 1 in [30]. All prediction models were modified to contain control
inputs that simulate the actions of sanguinarine and U0126. In addition, model
outputs (i.e. total concentration of phosphorylated Erk) are normalized so that the
peak uncontrolled response scaled to unity in order to account for the differences in
scale (see Section A.1.2 for further details). All programming and simulation was
performed in Matlab R2011b (7.13.0) and code is available in Dataset S1???.
Herein, the computational burden of repeatedly evaluating large nonlinear ODE
models is mitigated by using sparse grid interpolation. Sparse grids have been used
as computational cost-cutting tools for control applications in systems biology [15,31]
by serving as surrogates for slow-evaluating models and objective functions to allow
rapid screening of the design space.
4.5.3 Open-Loop Multiple-Model Control with Adaptive Weights
In traditional model predictive control (MPC), also referred to as receding horizon
control, the controller surveys the possible trajectories stemming from the current
state and selects the control input sequence so that the predicted model outputs track
the desired trajectories over a finite prediction horizon. The first control input of the
selected sequence is used to update the prediction model state and the procedure is
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Fig. 4.2.: A framework for multiple-model open-loop control of uncertain intracel-
lular signaling in the laboratory. First, the model bank is populated with a set of
relevant models that predict the system response to possible control inputs. During
the initial stage, training data are used to generate weights maps. These maps inform
the controller of the tendency for models to differ in their ability to accurately repro-
duce the system dynamics under different control inputs. During each time interval
of the controller stage, the performance metrics for the models are optimized simul-
taneously using a multiobjective technique within a MPC framework to generate a
candidate solution set. The tasks involved in the adaptive model weighting strategy
are contained within the gray box: control inputs are selected from the solution set
by prioritizing them according to the weight maps, then model weights are automati-
cally recalibrated using the portion of training data that most closely corresponds to
the proposed control input. Optimization and input selection cycles repeat for subse-
quent time intervals as the prediction horizon slides along until the entire open-loop
control sequence is specified and ready to be applied to the in vitro system.
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based on a single model, the controller is at risk of degraded performance because of
mismatch between the predicted and actual system behaviors. The proposed control
strategy, illustrated in Figure 4.2, employs multiple prediction models to mitigate the
effects of model uncertainty.
In our approach, first, the model bank is populated with a set of relevant models,
each of which predicts the system response to possible control inputs (in control
theory terms this is referred to as the plant response). During the initial stage,
training data and the corrected-Akaike Information Criterion (AICc) are used to
generate weight maps for the prediction models. These weight maps give the relative
probability that a given model is consistent with training data at any given point in
the feasible input space. In essence, these maps inform the controller of the tendency
for models to differ in their ability to accurately reproduce the system dynamics
under different control inputs. We then use a model predictive control framework
in which the performance metrics for the models are optimized simultaneously using
a multiobjective technique. Optimal control inputs are selected from the resulting
Pareto solution set by prioritizing the solutions according to the pre-computed weight
maps. Model weights are automatically recalibrated using the portion of training data
that most closely corresponds to the proposed control input. Optimization and input
selection cycles repeat for subsequent time intervals as the prediction horizon slides
along until the entire open-loop control sequence is specified and ready to be applied
(see Section 4.8 for further details).
4.5.4 Description of In Silico and In Vitro Case Studies
As discussed previously, the purpose of this manuscript is to present a computa-
tional strategy to aid in the design of experimental input regimens to elicit predictable
dynamical behaviors from biological processes. Herein, we demonstrate our approach
using the well-known TCR signaling pathway both through simulation and labora-
tory experiments. First, we explored two in silico case studies, each considering a
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pair of control reagents acting on different regions of the T cell signaling pathway, to
demonstrate the functionality of the proposed control strategy. In both case studies,
we performed a series of experiments in which one model was selected from the afore-
mentioned set of three models to serve as the simulated system. This model was also
used to design the optimal control input regimen as a controller based on this model
would match the actual system exactly and represent the best possible scenario. The
remaining two models were then used to form the basis of the control strategies we
wished to compare: single-model control (mismatched model), multiple-model con-
trol with fixed equal weights, and our proposed multiple-model control with adaptive
Akaike weights. For the in vitro case study, a subset of the control input regimens
derived from the simulated case studies were tested on populations of Jurkat T cells
for experimental corroboration.
In each of our case studies of the TCR signaling pathway, we desired the system
readout (i.e. total concentration of phosphorylated Erk) to follow a series of prede-
fined time course trajectories. These target trajectories were characterized by the
equation si(t) = (1 − e−t)((1 − pss,i)(1 + et−toff,i))−1 + pss,i), where t = 0 refers to
the time at which the initial stimulation dose of αCD3 is administered. The term
pss represents the desired steady-state fraction of maximal activation that is to be
achieved by the end of the 30-minute experiment. The term toff represents the time
in minutes, following an initial interval of maximal activation, at which the controller
should begin driving the output to the desired steady-state fraction. The ten parame-
ter pairs chosen for this study are (toff , pss) = (8,0), (15,0), (22,0), (8,0.25), (15,0.25),
(22,0.25), (8,0.5), (15,0.5), (22,0.5), (30,1). The five possible input dosing times be-
gan at 3 min post-αCD3-stimulation and were spaced 5 min apart to accommodate
both the rapid dynamics of TCR signaling and the limitations of experimental input
dosing and measurement rates.
The control inputs used to perturb the TCR signaling pathway were chosen based
on both the need to demonstrate the efficacy of our methodology and for experi-
mental corroboration. For our simulated and experimental case studies, we chose
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two commercially-available reagents known to control the dynamics of phosphory-
lated Erk: sanguinarine and U0126. Sanguinarine (Figure 4.1) is a small-molecule
inhibitor of Erk dual-specificity phosphatase-1 (MKP-1) and leads to elevated Erk
phosphorylation [32]. U0126 (Figure 4.1) on the other hand is a Mek inhibitor with
high selectivity, which effectively inhibits activation of Erk [33]. To further evalu-
ate controller performance using a variety of objectives, our second simulated case
study replaces these reagents with two hypothetical reagents that modulate the func-
tion of phosphorylated ZAP70. The two reagents, aZAP and iZAP (Figure 4.1),
act to promote and inhibit the function of pZAP70, respectively. Sanguinarine and
U0126 concentrations were constrained to the intervals [0, 50] µM and [0, 10] µM,
respectively, the upper limits of which were estimated from experimental results that
indicate saturation effects at levels above the specified concentrations (see Figure 4.8
in Section 4.8.2). aZAP and iZAP were normalized to the interval [0,1] as they are hy-
pothetical. For details on our in silico implementation of all control reagents, readers
are referred to Section A.1.1 and to the Matlab code provided in Dataset S1???.
4.5.5 In Silico Experiments
The control strategy was first tested by considering combinations of two models
at a time to control an unknown system, which is simulated by the remaining third
model. In the following discussion, we will use S to denote single-model control
with a subscript to denote the model (Z, L, or K) and M to denote multiple-model
control with the subscript indicating either equal weights (eq) or adaptive weights
(aw). For illustrative purposes, the case in which Model K was the simulated system
and the target profile corresponded to full termination at 22 min (i.e. (toff , pss) =
(22, 0)) is described and illustrated in detail (results for all experiments are provided
in Sections A.3 and A.4). Figure 4.3 shows the control input dosing regimens for
(A) the matched single-model controller SK , (B-C) the two mismatched single-model
controllers SZ and SL, (D-E) the multiple-model controller with fixed equal weights
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Fig. 4.3.: Simulations indicate adaptive weighting strategy significantly improves over-
all target tracking performance. (A-E) Control input dosing regimens for the matched
(SK) and mismatched (SZ and SL) single-model controllers and the multiple-model
controllers with fixed equal weights (Meq) and with adaptive Akaike weights (Maw).
(F) Akaike weights for Maw. (G) Target trajectory (solid black) and simulated system
(Model K) responses controlled by SK (dashed red), SZ (dotted blue), SL (dotted
green), Meq (dashed cyan) and Maw (solid magenta). (H) The squared error values
for all five controllers.
(Meq) and with adaptive Akaike weights (Maw), (F) the Akaike weights for Maw, (G)
the simulated system responses, and (H) the squared error values for all five control
strategies.
The ideal scenario was defined to be one in which the model used to derive the
control inputs is the same as the model used to simulate the actual system response,
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although it is generally not feasible in the laboratory and thus considered only for the
purpose of theoretical comparison. For this ideal scenario, the control input regimen
necessary to track the target profile included negligible input quantities to maintain
initial Erk activation, quickly followed by a large bolus of U0126 at 23 min to promote
Erk dephosphorylation near the end of the experiment (Figure 4.3A). As shown in
Figure 4.3, the single-model controllers specified qualitatively different control inputs
profiles, each causing qualitatively different simulated system responses. To achieve
the sustained pErk activation phase of the target profile, SZ required a ramp-up
in the sanguinarine doses (Figure 4.3B), which consequently caused the simulated
system to systematically overshoot the target (Figure 4.3G, blue). On the other hand,
SL predicted that negligible quantities of either reagent are necessary (Figure 4.3C),
which caused the simulated system to track the target moderately well, undershooting
the target only slightly (Figure 4.3G, green). For the rapid dephosphorylation phase,
SZ specified a large dose of U0126 at 23 min while SL specified relatively small
doses over the final two intervals. In contrast to the activation phase, the small
doses specified by SL were insufficient to track the desired rapid transient behavior;
the large dose specified by SZ produced significantly better tracking. Considering the
experiment as a whole, however, neither controller adequately controlled the simulated
system over the entire time interval.
The multiple-model controller with equal weights (Meq) considered the predictions
from both models equally in specifying the control inputs (Figure 4.3D), but tracked
only marginally better than either of the mismatched controllers SZ or SL (Figure
4.3G, cyan). On the other hand, the adaptive weighting strategy allowed the multiple-
model controller to inherit the best characteristics of both single-model controllers
(Figure 4.3E). According to Figure 4.3F, the weights tended toward Model L as it was
the better representative of the simulated system initially, then shifted toward Model
Z as it more accurately described the rapid dephosphorylation dynamics possessed
by the simulated system. As a result, Maw tracked the target significantly better
with at least a 74% reduction in the squared error (see Figure 4.3H) than any of the
78
mismatched single-model and fixed equal weight controllers as indicated in dynamics
shown in Figure 4.3G.
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Fig. 4.4.: Summary of target tracking performances for the simulated case studies. (A)
Summary of experiments involving realistic control reagents sanguinarine and U0126.
(B) Summary of experiments involving hypothetical reagents aZAP and iZAP. Target
tracking performance is measured by the squared error between target profiles and
controlled plants. Data shown are mean ± standard error between matched (Sm, n =
30) and mismatched (Smis, n = 60) single-model controllers, Meq (n = 30) and Maw
(n = 30). Group letters denote statistically significant differences between groups
(p ≤ 0.05) as calculated by one-way ANOVA with Tukey multiple comparisons test
(SigmaStat v3.5, Systat Software, Inc).
Controller performances for the simulated case studies involving the real commercially-
available control reagents sanguinarine and U0126 and the hypothetical control reagents
aZAP and iZAP are summarized in Figures 4.4A and 4.4B, respectively. Both plots
show the target tracking error between the predicted system dynamics and the tar-
get trajectories for all target and system model combinations. Matched single-model
scenarios (Sm) are cases when the model used to design the control inputs is identical
to that which is used to simulate the system response while the mismatched single-
model scenarios (Smis) use different models in both roles, the latter case tending to
be the better representation of biological reality. As shown in both plots of Figure
4.4, Smis had relatively large error values and tracked quite poorly. Meq were able to
partially mitigate these effects by averaging out some of the inconsistencies, but still
performed no better than Smis. The proposed controller strategy (Maw) performed
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significantly better than Smis and Meq by preferentially selecting predictions from the
models that were known to match the desire behavior at any point in time. This effect
was more pronounced in scenarios where the dynamics differ among the prediction
models because the controller was better able to filter out the inadequate models,
thus improving tracking performance relative to the other controllers. Notably, the
only scenarios not outperformed by Maw were those in which a matched prediction
model was used; however, these cases would be unrealistic in practice.
4.5.6 In Vitro Experiments using Jurkat T Lymphocytes
We conducted a set of experiments where control input regimens were computed
considering all three prediction models and implemented in vitro in Jurkat T cells
according to the experimental protocol described in Section 4.8.1. Since the equal
weighted multiple-model controller design did not improve performance when com-
pared with the single-model controllers for the simulated experiments, we did not
include those in the more expensive in vitro study. The model weight maps were
trained using preexisting experimental data (see Figure 4.8 in Section 4.8.2). Figure
4.5 shows for a representative experiment (A-D) the computed control input dosing
regimens for SZ , SL, SK and Maw, and (E) the Akaike weights for Maw and (F)
quantitative Western blot data. The specified target in the illustrated case required
that Erk undergo rapid and sustained phosphorylation for 22 min and then rapidly
return to steady state at basal levels. The quantitative Western blot data for this
exemplar experiment are shown in Figure 4.6C. Without any external manipulation,
pErk returned to its basal level slower and sooner than desired (Figure 4.6C, cyan
triangle). Of the three single-model controllers, only SZ (Figure 4.5A) correctly pre-
dicted that an initial ramp-up in sanguinarine was required to sustain pErk levels as
desired. Based on the a priori information contained in the model weight maps, Maw
was preferential towards the predictions made by Model Z because it most accurately
reflects the cell behavior (Figures 4.5D and 4.5E). However, Model Z was unable to
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replicate the rapid transient behavior of pErk in Jurkat cells in response to U0126 as
accurately as the other models. In this case, Maw deferred to the predictions made
by Model K. Because of this ability to adapt the weights based on the current con-
ditions, Maw was able to control pErk much more tightly over the entire experiment
than any of the models considered in isolation (Figure 4.6C, magenta dot).




























































































































Fig. 4.5.: In vitro experiments demonstrate superior target tracking performance by
Maw; corroborates observed in silico trends. (A-D) Control input dosing regimens
for single-model controllers (SZ , SL and SK) and the multiple-model controller with
adaptive Akaike weights (Maw). (E) Akaike weights for Maw.
Overall controller performances, defined as the squared error between the target
output profiles and the corresponding observed plant dynamics, for the aforemen-
tioned experiment as well as the two other performed corroborating experiments are
summarized in Figure 4.6D (descriptions of all experiments are provided in Section
A.5). Unsurprisingly, the largest deviations from the target trajectory were the un-
controlled responses. The single-model controllers improved tracking performance,
but varied quite widely due primarily to the degree of how accurately the mathemati-
cal model predicted the signaling response (extent of plant-model mismatch). On the
other hand, the intracellular signaling dynamics were much more tightly controlled
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Fig. 4.6.: Overall in vitro target tracking performances between target profiles and
measured Erk phosphorylation. Experiments with target trajectories (solid black)
defined by the (toff , pss) pairs of (A) (8,0), (B) (15,0) and (C) (22,0). Data are
measurements of plant dynamics that were uncontrolled (UC, cyan O, n = 12) and
controlled by SZ (blue , n = 9), SL (green ×, n = 9), SK (red ◦, n = 9) and
Maw (magenta •, n = 9). Data shown are mean ± standard error. (D) Controller
performances as measured by squared error between target trajectories and controlled
plant dynamics. Group letters denote statistically significant differences between
groups (p ≤ 0.05) as calculated by one-way ANOVA with Tukey multiple comparisons
test (SigmaStat v3.5, Systat Software, Inc).
by our multiple-model controller with adaptive Akaike weights, corroborating our
in silico findings. The adaptive weighting strategy reduced the squared error by at
least 63% over the best performing single-model controller. This indicates that our
proposed control strategy is able to successfully filter out the prediction models in
situations where they are known to be inaccurate and include them otherwise.
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4.6 Discussion
Recent studies have advanced and evaluated engineered control strategies to di-
rect cellular processes in a desired manner. A few notable works that used feedback
control approaches paired in silico control with experimental corroboration include
controlling cell differentiation via nonlinear MPC [14,15] and long-term feedback con-
trol of gene expression in yeast [16, 17]. This study augments this literature base by
providing a novel and experimentally-corroborated methodology to enable the suc-
cessful design and implementation of open-loop control strategies. Feedback control
has many advantages over open-loop control since it uses measurements during the
event to adjust the control inputs based upon the system response. This closed-
loop approach helps to overcome inaccuracies of the supporting mathematical model.
However, feedback control is not always possible due to experimental limitations.
Open-loop control pre-specifies the control inputs: like a recipe. The feasibility of
our open-loop control approach to overcome the inaccuracies of a single mathemati-
cal model has been demonstrated by experimental signal tracking by an intracellular
signaling pathway.
While the concept of multiple-model-based control is not new, it is employed nearly
exclusively in the closed-loop framework [15,23–26], where system data are collected
to inform future controller inputs. For the TCR-mediated Erk activation pathway
and similar systems, the biological reality and practical experimental constraints ne-
cessitated the use of multiple mathematical models in an open-loop framework to
achieve sufficient control. Because of these constraints, we formulated a new tech-
nique for control input selection that did not require real-time feedback data. Our
novel technique uses what limited quantitative data are already available to generate
a series of weight maps that indicate the likelihood of each model for any feasible
control input scenario. When selecting the appropriate control input, these maps
serve as a sort of filter that emphasizes data most relevant to the given scenario and
excludes data that would only confound the selection process. Thus our approach
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effectively utilized multiple models with an adaptive weighting scheme to plan the
control inputs.
Selecting such control inputs from multiple models with competing predictions
generally does not have a unique solution because the criterion by which a solution is
chosen depends entirely upon the decision maker. In this multiobjective optimization
framework, each objective can be defined as controller performance based on one
model. Attempting to satisfy multiple conflicting objectives will lead to a family of
solutions (i.e. Pareto solutions) for which any improvement in one objective comes
at the cost of at least one other objective. While the Pareto front topography is
method-independent, choosing a particular solution along the front depends entirely
upon the preferences of the decision maker. Typically a scalarization technique is
used to compact the multidimensional problem into a single objective. Zarei et al.
formulated a fuzzy rule set comprised of linear membership functions to aggregate
the objectives based on the authors preferences to control HIV dynamics in a CD4+
T cell population [34]. Another group employed a trade-off method in which the
chosen Pareto point is closest in some sense to the decision maker’s aspiration level,
or desired value of each objective [35]. A trade-off operator changes the aspiration
level based on which criterion the decision maker wants to improve if the suggested
point is not satisfactory. Promethee uses a pair-wise outranking relation among all
Pareto points so that a satisfactory solution is identified as soon as the points are
found [36]. The relation is typically fixed once established and cannot update itself
automatically. Bemporad et al. proposed choosing control inputs based on a time-
varying, state-dependent decision criterion that is informed by real-time observational
feedback [37]. Unfortunately, most available methods share a common challenge in
that they are not fully automated, require observational feedback or are application-
specific. Because our goal is to control uncertain intracellular signaling dynamics, we
define our preference between objectives to be the relative likelihoods of the models
as quantified by the Akaike weights. This allows us to automatically determine an
optimal “blend” of the various models based on existing data and predicted input
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conditions to maximize prediction confidence while controlling for target tracking
error.
4.6.1 Remarks on General Use and Limitations
We have presented a method that was shown to improve target-tracking perfor-
mance in a biochemical system with relatively high modeling uncertainty and mea-
surement noise. Naturally, we employed our own knowledge of the system as well as
that taken from literature to ease the implementation of the control method in the
laboratory setting. Even so, the proposed framework is general enough to be em-
ployed in a wide variety of engineering applications. The method is suitable for any
physical system with possible dynamics that can be characterized by a set of math-
ematical models. The models should include feasible control inputs that are capable
of manipulating the output dynamics and can be structurally unique. Furthermore,
the ensemble of models should adequately recapitulate the relevant behaviors of the
system. The method does not require real-time observability in its current open-loop
configuration, although observations should not be ignored when available. While
we have tested and corroborated the method only with nonlinear ODE models, we
believe the modeling format is an application-related issue and not restricted by the
method.
Although our proposed framework is widely applicable, its efficacy for a given
system depends on a variety of modeling and experimental constraints (i.e. problem-
specific information used to inform the controller), and computational constraints
(i.e. control problem dimensionality).
From a modeling and experimental perspective, efficacy depends on how well the
system is characterized by the prediction model bank, the accuracy of the model
weight maps and the availability of quantitative measurement tools or assays and
control reagents or actuators. First, the prediction model bank should be formulated
in such a manner that all desired system behaviors are within the reachable dynamics
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of the ensemble of models. Any characteristic behaviors or operating points not
included in the model bank would not be able to be recapitulated, regardless of
the adaptive model weighting scheme. However, these behaviors or operating points
may be captured by including models with alternate parameter values or equation
structures. In the case studied in this manuscript, each model had a different equation
structure, but represented alternate plausible mechanisms that are at least partially
supported by data.
Second, the accuracy of the model weight maps depends on the quantity and
quality of preliminary data. Without any prior information, the models are considered
equally when selecting control inputs. As experiments are performed, the gathered
data can be used to train the weight maps to the actual model-system relationship.
Models can then be selected according to its capacity to accurately predict the effects
of the inputs on the system. An implicit assumption here is that if a model is good
at predicting the effect of some input at some time, it will be good at predicting the
effect of another input at another time. While this assumption may not always be
true, the known dynamics, developed and refined based on considerable experimental
work, provide extensive constraints on what the possible unknown dynamics could
be.
Finally, while our method does not require data in real time because of the open-
loop formulation, accurate quantitative assays and specific control reagents are highly
beneficial in the development of accurate models and model weight maps help decrease
the effects of plant-model mismatch, a common failure mode in open-loop control.
Even so, with the proposed adaptive weighting procedure, each model need only be
partially data-consistent. We were able to demonstrate control using quantitative
Western blots to measure Erk phosphorylation dynamics in T cells, despite the fact
that Western blots are notoriously difficult to use and chemical reagents generally
have some off-target effects.
Computational tractability is another important area to consider. To get the most
benefit from the adaptive model weighting strategy, our control strategy involves a
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multiobjective optimization problem (of dimension nM × ny) at every time interval.
In practice, this is equivalent to solving a series of single-objective optimization prob-
lems (of dimension nu × Hu), the number of which depends on the desired Pareto
front resolution. In this manuscript, we greatly reduce the complexity of our control
problem by considering only three models, a single controlled output, and two dis-
cretized control inputs and a control horizon of one interval (at a time). However, it
would not be far-fetched to have a control problem with potentially dozens of models,
multiple inputs and outputs, and an extended control horizon. In such a case, it
would be critical to reduce the control problem down to a computationally tractable
size. This can be achieved a number of ways. For instance, dimensions corresponding
to different model outputs can be scalarized using weighted aggregation. Also, di-
mensions corresponding to models that are redundant or dominated (i.e. low Akaike
weights throughout the input space) should be removed.
4.6.2 Uncertainty in the Model Weight Maps
As previously mentioned, the purpose of the weight map strategy is to help esti-
mate an optimal blend of the considered models to create the best possible compro-
mise input solution given modeling uncertainty. The accuracy of these maps depends
heavily on the quantity and quality of the preliminary data used to train the maps.
Without any prior information, there would be no evidence supporting one model
over another and the resulting weight map topology would be flat. Inversely, if the
system dynamics are known with certainty, but requires more than one model to
recapitulate them all, then the resulting weight map topology would appear digital.
That is, only one model would dominate in any given experimental scenario and the
transition between which model dominates would be immediate.
In our presented experimental study, we considered a case in which a substantial
amount of time-course data (432 individual measurement points in total) was used
to train the model weight maps. Due to the relatively large number of data, the
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A B C C
Fig. 4.7.: Analysis of uncertainty in the model weight maps and resulting predicted
control strategies and performance. Model weights over the input space for (A-C) the
original case study (full dataset) and (D-F) the case study with the limited dataset.
Model rankings over the input space for (G-I) the original case study (full dataset)
and (J-L) the case study with the limited dataset. (M) Adaptive weights and (N)
corresponding control input regimen for the exemplar experiment characterized by
the target trajectory defined by the pair (toff = 8, pss = 0). (O) Controller perfor-
mances as measured by squared error between target trajectories and plant dynamics
controlled by single-model controllers that are matched (Sm, n = 30) and mismatched
(Smis, n = 60), and adaptively-weighted multiple-model controllers with the original
“digital” weight maps (Maw(o), n = 30) and smoother weight maps from the limited
dataset (Maw(ld), n = 30). Data shown are mean ± standard error. Group letters
denote statistically significant differences between groups (p ≤ 0.05) as calculated
by one-way ANOVA with Tukey multiple comparisons test (SigmaStat v3.5, Systat
Software, Inc).
88
AICc tends to show a strong sensitivity to any differences in model fitness values,
causing the weight map topography to appear somewhat digital in nature (Figure
4.7A-C). However, let us consider a case in which we have fewer data (144 individual
measurement points in total), or alternatively, more uncertainty in our models’ ability
to recapitulate the observed system behaviors. With fewer data, the AICc tends to
show a weaker sensitivity to differences in model fitness values, causing the weight
map topography to appear smoother (Figure 4.7D-F). Although the weight maps for
these two scenarios are clearly different quantitatively, the order in which the models
are prioritized (i.e. model rankings) are essentially identical (Figure 4.7G-L). To
illustrate the effects of these characteristics, let us consider one exemplar experiment
(Figure 4.7M). When utilizing the full dataset, the control strategy tends to heavily
favor one model over the others at any given time. However, when the limited dataset
is considered, the time course is covered by a non-trivial (i.e. non-digital) combination
of the models, each representing a portion of actual system behavior. Even so, the
orders in which the models are prioritized are very similar between the two cases. This
means that for any given region of the input space, the choice of model providing
the most reliable information is somewhat robust to the amount or quality of the
training data. As a result, the predicted control regimens (Figure 4.7N) and their
corresponding target tracking performance values (Figure 4.7O) also exhibit this same
qualitative robustness.
4.6.3 Importance of Erk Signaling in T Lymphocytes
T lymphocytes are an integral part of the human body’s natural defense against
the threats of invading pathogens and cancerous host cells. The function of these
specialized immune cells largely depends on their phenotypic response to external
stimulating signals. Propagating extracellular signals to their target substrates takes
the coordinated effort of very large networks of molecular species with complex in-
teractions ranging across vastly different spatial domains and temporal scales. While
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there are numerous mediators of signal transduction in lymphocytes, Erk is particu-
larly noteworthy as it is an evolutionarily-conserved and ubiquitous group of signaling
proteins critical to T cell development, proliferation and differentiation. Studies have
linked Erk-mediated regulation to the differentiation of helper T cells into certain
subtypes, particularly Th1 and Th2, and to allergies, asthma and serious immune
disorders if improperly subtyped [2,3]. Furthermore, it has been recognized that con-
trolling the Ras/Raf/Mek/Erk pathway maybe beneficial towards advancing effective
therapies for leukemia [38]. Constitutive activation of the Erk pathway is present in
a high frequency (>50%) in patients suffering from acute myeloid leukemia (AML)
and is associated with a marked reduction in survival duration [4, 5]. Conversely,
blocking Erk activation has been shown to cause cell death in leukemia cell lines [4].
Treatments based on methods that work to balance these opposing forces to restore
proper Erk-mediated regulation in T cells would be highly beneficial to patients suf-
fering from such pathologies. Historically this has been the subject of experimental
research [39,40]. This study has confirmed that when used in combination the existing
mathematical models of the Erk/MAPK pathway in T cells can support the engineer-
ing of control inputs to manipulate the activation and deactivation time course in a
desired manner.
4.7 Conclusions
We have developed a practical framework for controlling uncertain nonlinear sys-
tems using multiple models to generate predictable open-loop dynamical responses.
The embedded model weight maps enable the controller to estimate the likelihood
of each model in any feasible control scenario based on prior training data. The
adaptive weighting strategy allows the controller to purposefully select subsets of the
training data so that control decisions are made considering only the most relevant
information at each time interval. Our open-loop controller design pairs model pre-
dictive control with an adaptive model weighting system based in information theory
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to create a cohesive strategy for systematically utilizing the most relevant knowledge
embedded within limited training data in a computationally tractable manner. In
both simulated and laboratory experiments this multiple-model control strategy and
adaptive weighting scheme successfully reduced the open-loop target tracking error
by more than half relative to multiple-model control with fixed weights (simulation
only) and single-model control.
4.8 Materials and Methods
4.8.1 Experimental Protocol
Erk phosphorylation (pErk) data were collected from Jurkat T leukemia cell line
(Jurkat clone E6.1; ATCC). Cells were grown in RPMI 1640 (Sigma) supplemented
with 7.5% heat-inactivated fetal bovine serum (BioWest), 1mM sodium pyruvate
(Gibco), 12.5 mM HEPES pH 7.4 (Sigma), 12 µM sodium bicarbonate (Sigma) 50
µM 2-Mercaptoethanol (Sigma), 50 µg/mL streptomycin and 50 units/mL penicillin
in an incubator at 37◦C in humidified air containing 5% carbon dioxide. Cells were
harvested in log-phase growth at a density of 2× 107 cells per treatment. Cells were
stimulated using anti-human CD3 (10 µg/mL, clone: UCHT-1, eBioscience) as the
stimulatory signal at 37◦C in a water bath. Cells were treated with the Mek1/2 in-
hibitor U0126 (Calbiochem) or the MKP inhibitor sanguinarine (Sigma), depending
on the protocol, dissolved in DMSO at the indicated time points with the indicated
concentrations. Experimental control samples were treated with the same amount of
DMSO. Samples of 2× 106 cells were taken at the indicated time points and lysed in
1% NP40 lysis buffer (1% NP40, 25 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA,
1mM NaV, 10 mM NaF, 10 µg/mL each of aprotinin and leupeptin) for 15 min on ice.
Lysates were centrifuged for 5 min at 18000 g at 4◦C. The supernatant was added
to the same volume of 2X protein solubilizing mixture (PSM, 25% (w/v) sucrose,
2.5% (w/v) sodium dodecyl sulfate, 25 mM Tris, 2.5 mM EDTA, 0.05% bromophenol
blue) and boiled for five minutes. Proteins were separated via SDS-PAGE, blotted
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for phospho-Erk1/2 (Cell Signaling), phospho-ZAP-70 (pY319, Cell Signaling) and
GAPDH (Ambion). IRDye 800 and 680 secondary anti-mouse and anti-rabbit an-
tibodies (Li-Cor) were used for signal detection using an Odyssey infrared scanner.
Images of the blots were analyzed using ImageJ to produce quantitative data for
model comparison. Model predictions were scaled to compensate for the fact that the
data represent relative quantities only rather than absolute concentrations.
4.8.2 Training Experiments
Training experiments were designed to rapidly screen the responses of T cell pop-
ulations to potential control reagent combinations. Fourteen different experiments
were conducted: an experimental control (i.e. no control inputs), five individual
doses of sanguinarine (0.5, 2, 5, 20 and 50 µM) at the 15 minute mark, five individual
doses of U0126 (0.5, 1, 2, 5 and 10 µM) at the 6 minute mark, and three combined
doses of 0.5 and 1, 50 and 1, and 50 and 10 µM for sanguinarine and U0126, respec-
tively, at the 6 minute mark. These data were collected according to the experimental
protocols described in Section 4.8.1. The addition of low doses of sanguinarine had
negligible effects on pErk concentrations. Only the moderate to high doses tested
caused elevated to sustained phosphorylation of Erk (Figure 4.8A). On the other
hand, U0126 produced an immediate reduction in the Erk phosphorylation rate even
at low doses (Figure 4.8B) and tended to overpower the effects of sanguinarine when
added together (Figure 4.8C). The representation of the controller input functions in
the prediction models were modified to exhibit these trends.
Due to the prevalence of observation noise, experimental data were smoothed using
cubic smoothing splines to filter spurious oscillations from the time courses while
retaining primary trends. This was performed in Matlab using the csaps function
with the smoothing parameter p set to 0.6. The smoothing splines were sampled at
31 evenly spaced time points to increase the density of the time course data.
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Fig. 4.8.: Training data used to generate the model weight maps. Rows correspond
to doses of sanguinarine only, U0126 only, and combinations of the two reagents,
respectively. Symbols and error bars denote means ± standard errors of the raw
normalized data. Lines represent smoothed data. Arrows denote the time at which
the reagents were administered.
4.8.3 Model Bank Representation
The proposed control strategy is based on a set of two or more mathematical
models, M = M (1),M (2), ...,M (nM ), of a given system with the general form:
M (i) =








where the superscript i denotes the model number. The state variables, control inputs,
system parameters, measured outputs and controlled outputs are x ∈ Rnx , u ∈ Rnu ,
θ ∈ Rnθ , y ∈ Rny and z ∈ Rnz , respectively, and f : Rnx ×Rnu → Rnx , g : Rnx → Rny
and h : Rnx → Rnz are twice continuously differentiable functions for the system
dynamics, measured outputs and controlled outputs, respectively. Note that y(i) and
z(i) are functions of u, t and x
(i)
0 . For our purposes we will use the simplified notation
y(i)(u, t) and z(i)(u, t).
4.8.4 Approximating Model Dynamics with Sparse Grids
Sparse grids were implemented using the Sparse Grid Interpolation Toolbox for
MATLAB, version 5.1.1 [41], which is available at http://www.ians.uni-stuttgart.de/spinterp/.
Our approach for approximating model dynamics using interval-based sparse grid in-
terpolation is similar to that of Noble et al. [15]. The control inputs are assumed
to lie within the bounded nu-dimensional space containing all feasible control input
vectors, defined by
Ω ≡ I1 ⊗ I2 ⊗ ...⊗ Inu ⊂ Rnu (4.2)
where Ij = [ujmin , ujmax ], j = 1, ..., nu, and uj is the j
th value of the input vector.
For each model, nz output variables are selectively evaluated at points in the nu-
dimensional input space and nt-dimensional time domain to form a series of nz × nt
grids of dimension nu (see [15] for further details). On each grid, weighted Lagrange
basis functions are combined at the support nodes to construct an input-domain in-
terpolant with which the value of an output at a single time point can be estimated for
any point in the input space. In this interval-based approach, interpolation between
grids placed at various time points ensures a continuous trajectory over the predic-
tion horizon for any point in the input space. To prevent excessive computational
expense during grid construction, limits on absolute and relative error tolerances and
allowable interpolation depth were specified (0.01, 1%, and 6, respectively).
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4.8.5 Model Weight Maps
For problem set-up, we estimate weight maps on Ω for the prediction models using
Akaike weights, which are based on the Akaike Information Criterion (AIC). AIC
provides a practical measure of the tradeoff between model fitness and complexity by
estimating the theoretical Kullback-Leibler (KL) “distance”, or loss of information,
between an approximating model and full reality [27]. Assuming normally distributed
errors with constant variance and small sample sizes, the corrected-AIC (AICc) can
be estimated as:



























j=1 nt,j is the total number of experimental data and nt,j is the number
of sampled time points for the jth measured output. The second term, where denotes
the number of uncertain parameters for the ith model, is the bias-correction factor
for the AIC (the factor 2 was introduced for historical reasons) and the third term
is an additional correction factor for small sample sizes. Note that the first term
includes the squared residuals between experimental data (ŷ(u, t)) and their ith model
counterpart (y(i)(u)). Under realistic conditions, ŷ(u, t) are sampled at discrete input
quantities and time points and the number of data can vary between outputs. To
generate a continuous approximation of ŷ(u, t) over Ω, a piecewise linear interpolant
is constructed using the Matlab function griddatan. That is,
˜̂y(u, t) =
ŷ(u, t) u ∈ Ω̂, t ∈ T̂L(ŷ(Ω̂, T̂ )|(u, t)) otherwise, (4.4)
where Ω̂ and T̂ denote the discrete experimental input and observation time spaces,
respectively, and L is an operator denoting (nu+1)-dimensional linear interpolation
between existing points over Ω̂ and T̂ by means of Delaunay triangulation. In regions
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not explicitly measured, interpolated data (˜̂y(u, t)) are used in place of ŷ(u, t) when
computing AICc values.
It is important to note that only relative AICc values are meaningful due to the
metric being a relative rather than absolute estimate of KL distance. It follows that







where ∆(i) = AICc(i)(u)−min([AICc(1)(u), ..., AICc(nM )(u)]). The weight ω(i)(u) is
interpreted as the strength of evidence in support, or relative probability, of the ith
model being the KL best model from the set of models given the supporting data [27].
The weight maps for Model Z, Model L and Model K based on the data described
in Section 4.8.2 are provided in Figure A.2.
4.8.6 Open-Loop Model Predictive Control with Multiple Models
The multiple-model control strategy is built around the conventional MPC frame-
work to reduce the computational complexity of the open-loop control problem. At
each time interval, the controller surveys the possible trajectories stemming from the
current state and selects the control input sequence over the control horizon (Hu)
so that the predicted outputs track the desired trajectories over the finite prediction
horizon (Hp). The first control input of the selected sequence is used to update the
states of the prediction models and then stored as one entry in the final control se-
quence U∗ so the procedure can repeat as the prediction horizon slides along for the
remaining time intervals.
The objective functions used to quantify controller performance penalizes the error
between the predicted outputs for the ith model and the desired trajectories and a
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1 (tk|u(t0, . . . , tk)), . . . , z
(i)
nz (tk+Hp |u(t0, . . . , tk+Hu−1))] and Sk =
[s1(tk), . . . , snz(tk+Hp)] are the predicted and target outputs over Hp, respectively,
Uk = [u1(tk|tk), . . . , unu(tk+Hu−1|tk)] are the discrete controller inputs over Hu. The
proposed formulation assumes uj(tk+m|tk) = 0 for j = 1, . . . , nu and m = Hu, . . . , Hp
to reflect that manipulated variables are often applied as boluses in the considered
biological context. The horizons Hu and Hp were each chosen to be one to prevent
controllers from being overly conservative. Q and R are diagonal weighting matrices
associated with the error and control effort, respectively, which were each chosen to




k is approximated using sparse grid interpolation (similar to Sec-
tion 4.8.4) to form an input-domain interpolant with which the value of each objective
can be estimated for any point in the input space. If the approximations are suffi-
ciently accurate, no further evaluations of the objective function or underlying state
space model are required since the interpolants are generated prior to optimization
during each time interval.
4.8.7 Pareto Front Identification
We define the multiobjective optimization problem at the kth time interval as
follows (with the standard Pareto interpretation of minimizers):















k variable denotes the objective function for the i
th model defined by (4.6) and
the design variable Uk is constrained to Ω defining biologically relevant limits. Herein
we employ the normalized normal constraint method (NNC) for generating the Pareto
solutions Upk for its ability to generate a well-distributed set of global Pareto points
( [42], refer to the original manuscript for further details).
NNC provides a geometrically intuitive approach to multiobjective optimization
that is illustrated in Figure A.3. It first builds a plane in the normalized objective
space (called the utopia hyperplane) through all individual (normalized) minima Φ̄(i)∗,
and second, generates equally distributed points in this plane Φ̄up by systematically
varying weights for each objective. Then for each point Φ̄upj ∈ Φ̄up, the corresponding
solution Φ̄pj on the Pareto front Φ̄
p is found by minimizing the single (normalized)
objective Φ̄(nM ) with added constraints. In addition to the original constraints, the
feasible space is further restricted by adding nM − 1 hyperplanes through Φ̄upj that
are each normal to the nM − 1 utopia plane vectors. Successive optimization runs are
performed for the remaining points in Φ̄up. By translating the constraining normal
hyperplanes between runs, we can see that the corresponding solution set along the
leading edge of the objective space is generated. Since some of these points may
represent non-Pareto optimal or dominated solutions, the NNC algorithm is coupled
with a Pareto filter to remove such points.
4.8.8 Input Selection and Model Weight Adaptation
The optimal control sequence for the kth time interval is selected from the set of
Pareto solutions Upk by ranking them using the objective
U∗k = arg min
u∈Upk
Φ̄>k (u)W (u)Φ̄k(u), (4.8)
where Φ̄k(u) = [Φ̄
(1)
k (u), . . . , Φ̄
(nM )
k (u)]
> and W (u) = diag([ω(1)(u), . . . , ω(nM )(u)]>)
are vectors of objective function values and Akaike weights, respectively, correspond-
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Fig. 4.9.: Illustration of control input selection with model weight adaptation. For
a given prediction time interval in the control process, Pareto-optimal control inputs
are computed by the multi-model MPC strategy by solving (4.7), which then enter an
iterative process of control input selection and weight adaptation. (A) First, Pareto
points are ranked with an initial weight vector ω0 and the optimal point (example:
) is selected using (4.8). (B) Next, the input vector corresponding to the selected
optimal point (u1, ) is identified. If the input vector continues to change above
a pre-defined threshold, the process continues to the next iteration. (C) Given the
current input vector (u1), a new weight vector (ω(u1), ) is computed. The process
continues and repeats (example: •, then ?) until the aforementioned stopping criterion
is met. The final input vector (un, ?) is returned to the main control loop as the best
compromise control strategy and used to update the prediction models in preparation
for the next prediction time interval.
The models weights are adapted to accommodate the most relevant experimental
data to ensure the best possible open-loop performance (Figure 4.9). At the first
time interval, u is undetermined so the initial weights are computed considering the
entire training data set. After the Pareto points Up1 are specified by solving (4.7),
they are ranked using (4.8) with the initial weights (Figure 4.9A) and the input vector
corresponding to the best ranked point is taken as a temporary solution u1 (Figure
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4.9B). The weights are then recalibrated at the value u1 (Figure 4.9C) and U
p
1 ranked
again with the best ranked input vector taken as the new temporary solution u2 and
so on. Updates continue until the model weights or control inputs no longer change
above a prescribed threshold or the maximum allowable updates is reached. If a limit
cycle is detected, (4.8) is recomputed by averaging the models weights in the cycle as
a tie-breaker. The final input sequence is used to update the prediction models and
appended to the growing open-loop control sequence U∗ as the prediction horizon
slides along.
4.8.9 Statistical Analysis
All statistical analysis was performed using SigmaStat v3.5 (Systat Software, Inc).
Time-course data are shown as mean±standard error at each time point. Statistical
differences between groups (p≤0.05) are determined using one-way analysis of vari-
ance (ANOVA) followed by the Tukey multiple comparisons test. Target tracking
performance values, as measured by squared error between target profiles and con-
trolled plants, were log-transformed where appropriate to satisfy the normality and
equal variance conditions for the ANOVA and Tukey tests.
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5. RESOLVING EARLY SIGNALING EVENTS IN
T-CELL ACTIVATION LEADING TO IL-2 AND FOXP3
TRANSCRIPTION
5.1 Preface
The study described in this chapter presented a mathematical model of early T-
cell signal transduction that forms the basis of the controller presented in Chapter 6.
This model focused on the early steps in TCR trafficking and signal amplification by
kinases, phosphatases and other second messengers, as well as CD28 coreceptor signal-
ing and transcription of IL-2 and FOXP3. The model was analyzed to investigate how
signal intensity and feedback regulation affect TCR- and coreceptor-mediated signal
transduction and their downstream transcriptional profiles to predict the outcome for
a variety of stimulatory and knockdown experiments. The material presented in this
chapter was originally published in the MDPI Processes journal [1]:
Perley, J.P.; Mikolajczak, J.; Buzzard, G.T.; Harrison, M.L.; Rundell, A.E. Re-
solving Early Signaling Events in T-Cell Activation Leading to IL-2 and FOXP3
Transcription. Processes 2014, 2, 867-900.
5.2 Abstract
Signal intensity and feedback regulation are known to be major factors in the sig-
naling events stemming from the T-cell receptor (TCR) and its various coreceptors,
but the exact nature of these relationships remains in question. We present a math-
ematical model of the complex signaling network involved in T-cell activation with
cross-talk between the Erk, calcium, PKCθ and mTOR signaling pathways. The
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model parameters are adjusted to fit new and published data on TCR trafficking,
Zap70, calcium, Erk and IκBα signaling. The regulation of the early signaling events
by phosphatases, CD45 and SHP1, and the TCR dynamics are critical to determining
the behavior of the model. Additional model corroboration is provided through quan-
titative and qualitative agreement with experimental data collected under different
stimulating and knockout conditions. The resulting model is analyzed to investigate
how signal intensity and feedback regulation affect TCR- and coreceptor-mediated
signal transduction and their downstream transcriptional profiles to predict the out-
come for a variety of stimulatory and knockdown experiments. Analysis of the model
shows that: (1) SHP1 negative feedback is necessary for preventing hyperactivity in
TCR signaling; (2) CD45 is required for TCR signaling, but also partially suppresses
it at high expression levels; and (3) elevated FOXP3 and reduced IL-2 signaling, an
expression profile often associated with T regulatory cells (Tregs), is observed when
the system is subjected to weak TCR and CD28 costimulation or a severe reduction
in CD45 activity.
5.3 Introduction
The actions of CD4+ T-cells are controlled by the stimulatory signals and cytokine
milieu in their surrounding tissue environment [2, 3]. Extracellular signals naturally
drive CD4+ T-cells to activate and assume one of many important immunological
roles, each characterized by a distinct profile of signaling events and cytokine secre-
tion. These signals are processed by the intracellular signaling pathways to alter the
transcription profiles that direct T-cell activation and differentiation. To explore this
process from a quantitative perspective, a mathematical model is constructed from
the known molecular interactions and regulations.
This model encompasses the signal transduction events relating to the process of
directing gene expression that ultimately determine the actions or immunological role
of the T-cell. This process begins at the engagement of the T-cell receptor (TCR) to
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cognate peptide-bound major histocompatibility complexes (pMHC) on the surface
of antigen-presenting cells (APCs) [4–6]. TCR engagement triggers a number of early
phosphorylation and dephosphorylation events. The CD45 phosphatase primes the
CD4 coreceptor-associated 56-kD lymphocyte-specific tyrosine kinase (Lck), a mem-
ber of the sarcoma (Src) family of kinases (SFK) [7, 8], by removing the inhibitory
phosphate group from the Y505 residue [9,10]. Primed Lck is activated by autophos-
phorylation at Y394, mediated by receptor clustering [10]. Activated Lck phospho-
rylates the immunoreceptor tyrosine-based activation motifs (ITAMs) on the TCR-
associated CD3 ζ-chain. The zeta-chain-associated protein kinase 70 (Zap70) binds
with high affinity to doubly phosphorylated ζ-chain ITAMs through its two Src homol-
ogy 2 (SH2) domains and is activated by Lck-mediated phosphorylation of its Y319
and Y493 residues [11–13]. Zap70 facilitates the activation of phospholipase C-γ1
(PLCγ1), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to second
messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) [14–16]. IP3
migrates to the cytoplasm to regulate intracellular calcium (Ca2+) flux from the en-
doplasmic reticulum [14,17,18], a key modulator of nuclear factor of activated T-cells
(NFAT) [19]. While IP3 migrates to the cytoplasm, DAG operates within the plane
of the cell membrane to activate two major signaling molecules: rat sarcoma (Ras)
and protein kinase Cθ (PKCθ) [20]. Ras triggers the extracellular signal-regulated
kinase (Erk) cascade that results in the activation of activator protein 1 (AP1) [21],
while PKCθ activates AP1 and the nuclear factor κB (NFκB) pathway [22–25]. Upon
entering the nucleus, transcription factors, such as NFAT, AP1, NFκB and others,
interact to support cooperative regulation of interleukin-2 (IL-2) and other genes
involved in T-cell activation [26,27].
A critical second signal driving T-cell activation and fate determination is achieved
by incorporating CD28-mediated costimulation [28] and its downstream signaling
events into the model. In spite of the ability of the TCR to upregulate factors neces-
sary for full activation, TCR-antigen recognition ultimately leads to anergy or a state
of hyporesponsiveness in the absence of a second signal [29]. Alternatively, TCR
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signaling with additional costimulation of CD28 on the surface of T-cells greatly
enhances IL-2 production, T-cell proliferation and the prevention of anergy. This
synergistic effect is believed to be mediated through PKCθ and Akt (also known
as protein kinase B), which recruit and regulate several signaling molecules, includ-
ing NFκB [24, 30] and mammalian target for rapamycin (mTOR) [31]. The ser-
ine/threonine protein kinase mTOR is another important player in CD4+ T-cell ac-
tivation. mTOR complex 1 (mTORC1) has many known functions, including the
ability to control the expression of forkhead box P3 (FOXP3), a master transcrip-
tional regulator in the development of T regulatory cells (Tregs) [31,32]. While much
less is known about mTORC2, it was recently shown to promote PKC, Akt and NFκB
signaling and to regulate T helper type 1 (Th1) and Th2 commitment [33].
A number of mathematical models exist that span the entirety or portions of
these T-cell signaling events. The models presented in [34,35] span these events and
are able to capture many dominant behaviors. However, these discrete-time logical
models do not support a detailed analysis of the interactions in a continuous state
and parameter space and the ability to predict responses to analog knockdown or
mutation scenarios. Other models are very detailed, but only consider portions of the
system, such as the MAPK [36] and NFκB [37, 38] pathways. Some of these models
consider every hypothesized molecular interaction or complex formation. This level of
detail is prohibitive to complete for the entire signaling network, predominantly due
to computational tractability, but also due to uncertainties in the existence or rates
of these events. A few models set out to address the role of location as a regulatory
event, analyzing T-cell signaling events within a spatial context [39,40]. These models
tend to be limited in scope in order to offset the added computational expense of such
an analysis. Our model differs from past approaches in that we consider a broad scope
of early TCR and CD28 signaling leading to gene transcription in continuous time,
consider only the major known phosphorylation, dephosphorylation, association and
dissociation events and address location through compartments and not as a partial
differential equation with diffusion.
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Here, we present a mathematical model of T-cell activation that focuses on the
early steps in TCR trafficking and signal amplification by kinases, phosphatases and
other second messengers, as well as CD28 coreceptor signaling and gene transcription
of IL-2 and FOXP3. Sections 5.4 and 5.5 describe the formulation of the model
and its fitting to training data. Model simulations and corroborating experimental
evidence are provided in Section 5.6, demonstrating the model’s ability to reproduce
many known experimental results. This section also describes predictions made by the
model about the roles of phosphatases CD45 and SHP1 in T-cell activation. Finally,
conclusions are summarized in Section 5.7.
5.4 Materials and Methods
This section provides an overview of the proposed T-cell activation model and
details the methods and materials employed in its development. These include the
computational methods and experimental datasets used for model parameter identi-
fication.
5.4.1 The Mathematical Model: Overview and Scope
The mathematical model reflects the current understanding of the intracellular
signaling events leading to T-cell activation. The reaction scheme, as shown in Fig-
ure 5.1, encompasses the primary events that occur upon TCR engagement and CD28
costimulation. Appendix B.1 describes each signaling element and assigns a symbol
and initial value for use in constructing the mathematical model. Appendix B.1 also
lists the rate equations, parameter values and summarizes the reactions primarily in
terms of protein binding, phosphate group transfers and kinase and phosphatase acti-
vation. The part of the model representing the TCR-mediated Erk pathway is based
on the ordinary differential equation (ODE) model developed by Zheng [41] with up-
dates in Perley et al. [42]. The Zheng model takes into account the major events of
early T-cell signaling leading to the activation of the protein tyrosine kinases Zap70
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and SFK, the downstream Erk pathway, as well as negative feedback regulation by
phosphatase SHP1.
The Zheng model was extended to specifically incorporate TCR trafficking, tuning
of CD45 and SHP1 phosphatase activity, refinement of Erk signaling with AP1 acti-
vation and the addition of the calcium, NFκB and mTOR pathways leading to IL-2
and FOXP3 transcription. These changes are further detailed in Section 5.5. Molecu-
lar association and complex dissociation are designed to obey the law of mass action,
i.e., assuming that the rate of a reaction is proportional to the product of reactant
concentrations. Most enzyme-catalyzed reactions utilize second-order kinetics derived
from a simplification of the Michaelis–Menten enzyme kinetics by assuming that the
substrate concentration is limiting. Such a simplification contributes to reducing the
complexity of the nonlinearities while retaining the structure of the pathway con-
nectivity. For reactions catalyzed by enzymes not explicitly included in this model,
the expression further reduces to first-order kinetics, where the enzyme concentration
becomes a constant. In addition, single molecular transitions are also governed by
first-order kinetics. Alternatively, enzyme-catalyzed reactions in which cooperative
binding between substrates plays a significant role utilize the Hill equation. Scenarios
characterized by these equations include the cooperative transcriptional regulation of
IL-2 and FOXP3 and the activation of certain enzymes. The model is also designed
to mimic the cell response to stimulation by αCD3, αCD28, phorbol 12-myristate
13-acetate (PMA) and the calcium ionophore ionomycin, as well as mimic perturba-
tions in kinase and phosphatase activity by various small molecule inhibitors. The
complete model consists of 48 ODEs with 154 reaction parameters and simulated in
































































































Mediated by activated PKCθ
Mediated by activated SFK (i.e. [SFK*]+[SFK*Zapp]+[SFK*S59p])
Mediated by ligand-bound TCR (i.e. [TCRb]+[TCRp])
Mediated by negative regulation of CD45 (i.e. [CD45n])





Fig. 5.1.: Reaction network of the T-cell activation model. Solid arrows denote reactions for which the forward and reverse
directions are indicated; dashed arrows connect reactions (either forward or reverse) with their catalysts. Colored arrows
denote reactions that are catalyzed by specific species as indicated. Symbols and reactions are described in Appendix B.1.
111
5.4.2 Global Sensitivity Analysis
Due to the size and complexity of the model, it is necessary to reduce the dimen-
sion of the uncertain parameter space to facilitate an effective and computationally
tractable analysis of the model. Parameter sensitivity analysis provides a powerful
tool for analyzing mathematical models of complex biological systems and can be used
to facilitate parameter estimation by identifying and ranking the various contributors
of parametric uncertainty in the model. Parameters with the lowest sensitivity ranks,
i.e., parameters whose uncertainty causes the least amount of variability in the out-
put space, can be neglected during the model fitting process and fixed at their initial
guesses. For the purpose of this study, a variance-based sensitivity analysis is used





where Si,j is the sensitivity index of the i− th output to the j − th parameter. The
sensitivity indices are numerically computed using Sobol’s method by the efficient
sparse-grid-based algorithm proposed by Buzzard [43, 44]. Parameters having little
effect on model outputs upon perturbation are determined to be insignificant and
fixed at their nominal values. Significant parameters are retained for parameter iden-
tification.
5.4.3 Parameter Identification
The ability of the model simulated with a given parameter vector to reproduce








with eti = C(ti)[y(ti)− ŷ(ti)] (5.2)
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where eti is the error at each sample time point, Wti is the inverse of the measurement
error covariance matrix at time ti, y(ti) and ŷ(ti) are the simulated model outputs
and the mean values of the available data at time ti, respectively, C(ti) is a binary
matrix that indicates which outputs are measured at time ti and Ns is the total
number of sampled time points. This cost function is computed in log space in order
to compress the range of and smooth the function, making its approximation with
sparse-grid interpolation more effective. The ‘1’ in the cost function is added to avoid
the singularity of log at zero.
Specific parameter values that are capable of producing data-consistent model
simulations are extracted directly from the literature whenever possible. For those not
found in the literature, they are either derived using known conditions or constraints
of the system or estimated from experimental data using a combination of manual
and automated calibration. First, the starting guess values are roughly estimated by
back-of-the-envelope calculations and manual tuning to within a reasonable level of
accuracy. This step is used to establish our parameter search space and its bounds,
defined to be a hypercube spanning the nominal parameter vector by an order of
magnitude both above and below. Next, Equation (5.2) is evaluated at a number of
samples from the parameter hypercube, generated using Latin hypercube sampling
in log space. Finally, starting from the parameter vector with the lowest sampled
cost, MATLAB’s nonlinear constrained optimization solver, fmincon, is employed
to identify the parameter vector that minimizes Equation (5.2) constrained within
the hypercube. To increase the chance of identifying the global minimizer, multiple
starting points were considered that span the region of low cost. This procedure of
automated parameter identification is aided by the use of sparse-grid interpolation, a
powerful tool for generating fast-evaluating approximations of mathematical models
[45].
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5.4.4 Experimental Datasets for Model Development
Experimental datasets for the purposes of model development are compiled from
the published literature or generated from experiments performed in our lab specifi-
cally for this manuscript. For datasets compiled from the published literature, only
those that are commensurate with our model in terms of cell type, stimuli, output
species and time scale are considered. Table 5.1 summarizes the attributes of the
compiled datasets used to train the model. These datasets consist of dynamics (i.e.,
time courses), dose response experiments (i.e., multiple doses of an input or stimulus)
and input response experiments (i.e., single doses of different input or stimuli combi-
nations). In order to compare the model and observed behaviors directly, simulations
are generated to mimic the experimental conditions used in our experimental set-ups
(see Appendices B.3 and B.4) or as indicated in the corresponding source articles.
Model simulations are shown with the corresponding data and error bars whenever
possible; however, for cases in which data could not be visualized on the same plot,
the reader is referred to the original source.
Table 5.1.: Description of experimental datasets used for model development.
Species Variable(s) Experiment
Type
Cell Type Figure Source(s)
TCR αCD3 Dynamic dose
response
Jurkat 5.2 [46,47]






Ca2+ αCD3 Dynamics Jurkat 5.6 B.3
IκBα αCD3+αCD28 Dynamics Jurkat 5.7 B.4
Akt, αCD3, Input response CD4+ T-cells 5.8 [33]
PKCθ αCD28 (murine)
5.5 Model Development
The following subsections describe the process of formulating the proposed T-cell
activation model as shown in Figure 5.1 from the original ODE model presented by
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Zheng [41]. These changes include the incorporation of TCR trafficking mechanisms,
tuning of CD45 and SHP1 phosphatase activity, refinement of Erk signaling with AP1
activation and the addition of the calcium, NFκB and mTOR pathways leading to
IL-2 and FOXP3 transcription. These changes are further detailed in the following
subsections.
5.5.1 Modeling TCR Trafficking
The TCR expression level at the cell surface is the result of a dynamic equilib-
rium maintained by the membrane expression of newly synthesized TCR, receptor
internalization, recycling to the cell surface and degradation [47, 48]. As depicted in
Figure 5.1, the TCR complex is represented in the model by five states: free TCR
(TCRf ), ligand-bound TCR (TCRb), phosphorylated ligand-bound TCR (TCRp),
internalized TCR (TCRi) and degraded TCR (TCRdeg). TCR trafficking is modeled
by allowing TCR complexes from all surface states (TCRf , TCRb and TCRp) to be
internalized [39]. Internalized TCR subunits can be degraded or recycled back to the
unbound state. Newly synthesized TCR contributes to the free receptor state with a
rate proportional to degraded TCR.
Early studies demonstrated that the TCR is a constitutively cycling receptor
[47, 48]. Thus, at steady state, a certain amount of TCR is endocytosed, while at
the same time, an equal amount of TCR is exocytosed. The associated model rate
parameters are set by the following observations. Several studies seem to agree that
the constitutive endocytic rate constant for the TCR in resting T-cells is ˜0.01 min−1,
meaning that ˜1% of the cell surface-expressed TCR is internalized each minute [47].
TCR ligation induces downregulation and degradation of the TCR in a dose-
dependent manner [46, 47]. In theory, TCR downregulation can be accomplished by
an increase in the endocytic rate constant, a decrease in the exocytic rate constant
or a combination of both. However, most studies found that TCR downregulation
is caused by an increase in the endocytic rate constant to ˜0.038 min−1 after TCR
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triggering [47], whereas the exocytic rate was constant. In addition, TCR degradation
was also found to accelerate after TCR ligation. The TCR subunits in non-stimulated
Jurkat cells were observed to degrade with rate constants of ˜0.0011 min−1, resulting
in a half-life of ˜10.5 h. Triggering of the TCR by anti-TCR Abs resulted in a three-
fold increase in the degradation rate constants to ˜0.0033 min−1, resulting in a half-life
of ˜3.5 h [46]. This process was modeled by making the receptor internalization and
degradation rate parameters functions related to T-cell activation. These mechanisms
were mathematically encoded in the model using:
k = kmin +
Xn
Xn +Kn
(kmax − kmin) (5.3)
Equation (5.3) ensures a continuous transition between the constitutive endocy-
tosis or degradation rates (kmin) and the ligand-induced rates (kmax) using a Hill
equation, where X is the induction substrate concentration, K is the substrate con-
centration of the transition midpoint and n is the Hill coefficient denoting positive
(n > 1) or negative (n < 1) cooperativity. Since the TCR cycling pathway is depen-
dent on the CD3γ di-leucine-based motif and is activated by PKC [47,48], for receptor
cycling, we set k = kint, X = [PKCθ], n = 2, and K is set to 5% of total PKCθ
with kmin = 0.01 min
−1 and kmax = 0.038 min
−1. Since the activation of Lck and
Zap70 leads to recruitment of Cbl and ubiquitination (Ub) of the CD3 and ζ chains
to induce degradation of the TCR in the lysosomes [47], for receptor degradation, we
set k = kdeg, X = [SFKact] + [SFKactZapp] + [SFKactS59p], n = 2, and K is set
to 5% of total SFK with kmin = 0.0011 min
−1 and kmax = 0.0033 min
−1.
At equilibrium without any stimulus, most studies also seem to agree that the
pool of recycling TCR was distributed with approximately 75%–85% at the cell sur-
face and 15%–25% inside the cells. Assuming the minimum constitutive rates for
internalization and degradation with 80% surface TCR and 20% inside the cell, of
which half are being degraded, we can compute the constitutive exocytosis rate as
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kexo = 0.0789 min
−1 and the constitutive synthesis rate as ksynth = kdegmin to achieve
the observed dynamic equilibrium in resting T-cells.
The resulting simulated surface and degraded TCR dynamics are consistent with
expectations at equilibrium and after receptor engagement with a ligand. The dose re-
sponse curves in Figure 5.2A and B show good agreement with the behaviors reported


















































Fig. 5.2.: Resting and ligand-induced (A) surface TCR expression and internalization
and (B) degradation activity in response to varying doses of αCD3 stimulation (data
shown in [46]).
5.5.2 Tuning the Roles of CD45 and SHP1
The protein tyrosine phosphatases, CD45 and SHP1, are central players in sig-
nal amplification following antigen recognition by the TCR and the activation of
many downstream second messenger and signaling molecules. CD45 is a leukocyte-
specific transmembrane glycoprotein and a receptor-like protein tyrosine phosphatase
(PTP) [9]. The SFK member Lck is the best characterized CD45 substrate in T-
cells [8]. Lck exists in dynamic equilibrium with three main sub-populations: (1)
open and activated (SFKact in the model); (2) open and not activated (“primed”)
(SFKdp); (3) closed and not activated (SFK) [10]. Phosphorylation of SFKs at the
negative regulatory site (Y505 in Lck) by the kinase Csk results in an intramolec-
ular interaction with the SH2 domain, creating a folded inactive conformation [49].
Dephosphorylation at this site by CD45 opens up the molecule, creating a “primed”
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molecule. Clustering of these primed SFKs results in the transphosphorylation of the
activation loop (Y394 in Lck), which displaces it from the catalytic site and creates an
active kinase by allowing substrate access. Dephosphorylation at this site by CD45
or other PTPs, such as SHP1, downregulates SFK activity and returns them to the
primed state [10]. Thus, CD45 functions as both a positive and negative regulator of
the T-cell antigen receptor and in setting the threshold of activation.
The dual role of CD45 as both positive and negative regulator of T-cell activation
is modulated in part by the distribution and movement of CD45 and its substrates
proximal to the receptor complex inside and outside lipid rafts. Lck inside lipid rafts
has been reported to be hyperphosphorylated and less active when CD45 is excluded
[10]. The engineered inclusion of CD45 to the lipid domains also decreases TCR
signaling, consistent with its ability to downregulate signaling by dephosphorylating
the positive regulatory site at later time points [10]. These observations show that the
localization of both CD45 and the SFKs can affect the phosphorylation state of SFKs.
It is believed that upon receptor-mediated clustering, the SFKs are activated and
often relocalize to lipid rafts, where the concentration of CD45 is much lower and the
kinases can experience sustained signaling. The later recruitment of CD45 to these
domains will then primarily dephosphorylate the activation site and downregulate
activity [10].
The model is augmented to include both the positive and negative regulatory roles
of CD45, as well as spatial localization effects, on T-cell activation with two explicit
states: CD45p and CD45n (see Figure 5.3). The first, CD45
p, reflects its ability
to activate substrates immediately following TCR triggering and promote signaling.
Initially, this state exists at a high level with its major role being to dephosphorylate
negative regulatory sites and “prime” SFKs (R2). Following TCR engagement, the re-
ceptor cluster formation (represented in simulation by ligand-bound TCR) separates
CD45 and its substrate. This causes CD45p to enter an ineffective state, an implicitly
modeled state called CD45 (R23), and decreases its ability to activate its substrate.
The second state, CD45n, represents the negative regulatory function of CD45 on
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SFK. Initially, this state is minimally active with most existing in the inactive state,
CD45. As TCR signaling progresses (represented in simulation by activated SFK),
CD45 is recruited back to the lipid rafts (R23a), where its ability to dephosphory-
late activated SFKs is the dominant role (R3, R4a, R22 and RTCRp). Since CD45
can possess both positive and negative roles simultaneously, the species CD45p and
CD45n are not mutually exclusive; however, the intersection between these two sets,
a CD45-related state possessing both roles (CD45pn), is not explicitly modeled or
tracked. CD45tr, representing completely inactive CD45 that is translocated away






Fig. 5.3.: Representation of the phosphatase CD45 in the model. The model states
CD45p and CD45n are represented by the regions outlined in blue and red, respec-
tively. CD45pn, which is the intersection between the two modeled states outlined in
purple, has both positive and negative roles, but is not explicitly modeled. CD45tr
represents completely inactive CD45 that is translocated away from its substrates
and is also not explicitly modeled.
In contrast to the dual role of CD45, Src homology region 2 domain-containing
phosphatase-1 (SHP1) functions primarily as a negative regulator of TCR signal trans-
duction. SHP1 associates with and negatively regulates the Syk family kinase Zap70
upon T-cell activation (R8 and R9), thereby suppressing TCR signaling [50]. SHP1
also forms a negative feedback loop that is composed of (1) SHP1 phosphorylation
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by activated Lck, (2) binding of phospho-SHP1 to Lck and (3) Lck inactivation by
SHP1-mediated dephosphorylation (R3) [51]. Erk, on the other hand, antagonizes
SHP1 activity by modifying Lck (S59 phosphorylated by MAPK/Erk), which inter-
feres with SHP1 recruitment and Lck inactivation [51,52]. These events are captured
by partitioning the SFK states with S59 phosphorylation (i.e., SFKdpS59p and
SFKactS59p) from those without (R20 and R21).
Parameters for this updated model structure, which include reactions R1-R10 and
R20-R23a, are trained to recapitulate the behaviors and roles of CD45 and SHP1 in
early TCR signaling. To effectively isolate the early TCR signaling module from
downstream feedback, the Erk positive feedback loop is suppressed with the presence
of the Mek1/2 inhibitor U0126. Figure 5.4 shows the changes in the Zap70-Y319
phosphorylation level with different doses of αCD3 stimulation in the presence of
U0126. The results show that with increasing doses of stimulation, the response of
Zap70 increases slowly initially, then rapidly between 2 and 5 µg/mL of αCD3 and
eventually saturates and even decreases slightly at the highest stimulus level (100
µg/mL). The dose response curve demonstrates the existence of a threshold αCD3
stimulation concentration. Below the threshold level, CD45 is unable to activate
enough SFK and indirectly Zap70 to overcome the negative regulation by SHP1 and
CD45 itself to sustain signaling. Once the threshold is crossed, the negative feedback
barrier caused by SHP1 is overcome, and Zap70 signaling increases rapidly and even-
tually saturates at a high stimulus level. The Zap70 dose response simulations show


































Fig. 5.4.: Zap70-Y319 phosphorylation in response to various doses of αCD3 stim-
ulation in the absence of Erk feedback. Jurkat cells were incubated in the presence
of a Mek1/2 inhibitor (2 µg/mL U0126) and stimulated with αCD3 at the indicated
concentrations. Samples were taken 5 min post-stimulation and analyzed by west-
ern blot. The data shown are the means and standard errors from at least three
independent experiments (data source: [41]).
5.5.3 Tuning Erk Signaling
The Erk signaling cascade plays an important role in IL-2 activation via the tran-
scription factor, AP1. Activated Zap70 mobilizes a number of adapter proteins to
the receptor complex, including linker of activated T-cells (LAT) and growth factor
receptor-bound protein 2 (Grb2) [53]. Son of Sevenless (SOS), a Ras guanine ex-
change factor (GEF), forms a complex with Grb2 and LAT to facilitate the activation
of Ras in T-cells. LAT also facilitates the activation of Ras through the RAS guanyl
nucleotide-releasing protein-1 (RasGRP1), which is itself activated by DAG [20]. Ras
triggers the extracellular signal-regulated kinase (Erk) cascade that results in the
activation of AP1 [21]. As mentioned in Section 5.5.2, Erk also promotes its own
activation by phosphorylating Lck at S59 and antagonizing SHP1 activity [51,52].
These reactions (R11-R19) are modeled using the first- and second-order mass
action kinetic equations of the base model presented by Zheng [41]. The kinetic
parameters in this module are fitted to Erk phosphorylation data presented by Perley
et al. [42]. Figure 5.5A,B shows the changes in the Erk phosphorylation with different
121
doses of the MKP inhibitor sanguinarine and Mek1/2 inhibitor U0126. For each
experiment, Jurkat cells were stimulated with 10 µg/mL αCD3, followed by a dose of
inhibitor once the indicated amount of time had past. Samples were taken before and
after the inhibitor dose administrations to show how the system changes over time
with varying degrees of inhibition. At the lowest concentrations (where inhibition is
negligible), the transient nature of Erk phosphorylation can be seen by the decreasing
level over time. As the inhibitor concentrations increase, a threshold is crossed,
resulting in more forceful inhibition: 10 µg/mL for sanguinarine and 1 µg/mL for
U0126. The phospho-Erk simulations show good agreement with the time course and
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Fig. 5.5.: Erk activation in response to various doses of (A) MKP inhibitor san-
guinarine and (B) Mek1/2 inhibitor U0126. Doses of sanguinarine and U0126 were
administered at 15 and 6 min post-stimulation (10 µg/mL αCD3), respectively. Sam-
ples of phospho-Erk were taken at indicated times relative to the inhibitor doses and
measured via western blot. The data shown are the means and standard errors from
at least three independent experiments (data source: [42]).
5.5.4 Modeling Calcium Signaling
Calcium is an important second messenger involved in a number of cellular pro-
cesses, including the activation of NFAT and IL-2. PLCγ1, activated by Zap70 via
LAT, hydrolyzes PIP2 to DAG and IP3 (R13) [14–16]. IP3 migrates to the cytoplasm
and interacts with IP3 receptors on the endoplasmic reticulum, inducing the release of
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stored calcium (Ca2+) (R27) [14, 17,18]. Calmodulin (CaM), a small calcium-sensing
protein and signal transducer, binds released Ca2+ ions (R28) and undergoes a con-
formational change to activate the calcium-dependent serine-threonine phosphatase
calcineurin (CN) (R29) [54]. Activated CN dephosphorylates the nuclear factor of ac-
tivated T-cell (NFAT) proteins, exposing their nuclear-localization signal (NLS) and
inducing nuclear translocation (R30) [19].
The model is modified to recapitulate calcium signaling with these reactions (R13,
R27-R30), modeled using first- and second-order mass action kinetic expressions sim-
ilar to that of the Erk signaling module. The kinetic parameters in this module are
fitted to Ca2+ flux data for which the experimental methodology is presented in Ap-
pendix B.3. Figure 5.6 shows the experimental observations of intracellular calcium
in Jurkat cells stimulated with 10 µg/mL αCD3 and the corresponding model sim-
ulation. Upon TCR stimulation, calcium ions are rapidly released from intracellular
stores, peaking after 2 min before returning to a slightly elevated level. It is evident
from the plot that the model readily captures the rapid transience of intracellular
calcium flux.
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Fig. 5.6.: Intracellular calcium release in response to stimulation with 10 µg/mL
αCD3. The data shown are the means and standard errors from 12 independent
experiments.
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5.5.5 Modeling CD28 Costimulation
In spite of the ability of the TCR to upregulate many factors necessary for full
activation, TCR-antigen recognition ultimately leads to anergy, or a state of hypore-
sponsiveness, in the absence of a second signal [29]. By contrast, signaling via CD28
on the surface of T-cells, in addition to TCR signaling, greatly enhances IL-2 produc-
tion, T-cell proliferation and the prevention of anergy. As a result, CD28-mediated
costimulation provides a critical second signal in T-cell activation and fate determi-
nation [28]. CD28 signaling is believed to be mediated by phosphoinositide 3-kinase
(PI3K) (R33) [55]. PI3K phosphorylates PIP2 to become phosphatidylinositol 3,4,5-
trisphosphate (PIP3), an activity that is directly antagonized by phosphatase and
tensin homolog (PTEN) (R34). PIP3 serves as pleckstrin homology (PH) domain
membrane anchors for 3-phosphoinositide-dependent kinase-1 (PDK1) (R35). PDK1
activation leads to the membrane recruitment of PKCθ (R36) and protein kinase B
(PKB, or Akt) (R40) to regulate several signaling pathways, including NFκB [24,30]
and mTOR [31].
The model is augmented to simulate the effects of CD28 costimulation on T-
cell activation. As with the other signaling modules, these reactions (R32-R35) are
modeled primarily using first- and second-order mass action kinetic expressions. The
corresponding kinetic parameters are tuned after accounting for downstream signaling
events, such as NFκB and mTOR signaling, which are described in the following
sections.
5.5.6 Modeling NFκB Signaling
Several lines of evidence indicate that the NFκB pathway is perhaps the most rele-
vant biochemical or transcriptional target for the costimulatory activity of CD28 [30].
TCR- and CD28-mediated induction of the NFκB signaling pathway intersect at the
central regulator, PKCθ (via mechanisms described in Section 5.5.5). PKCθ induces
NFκB signaling by activating IκB kinase (IKK) (R37) [22], which phosphorylates the
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inhibitor IκB (at positions S32 and S36). This triggers the rapid polyubiquitination
(at positions K21 and K22) and proteolysis of IκB in the 26S proteasome complex
(R38). IκB degradation exposes the nuclear localization signal of NFκB, allowing its
rapid translocation into the nucleus (R39) [24, 25].
Physiologically, the defining characteristic of IκBα is its ability to regulate rapid,
but transient, induction of NFκB activity, owing to the participation of IκBα in an
autoregulatory feedback loop. That is, the activation of NFκB causes the upregulation
of transcription of IκBα, which, in turn, serves to shut off its own nuclear localization
signal [37, 38]. This upregulation occurs due to the presence of κB sites in the IκBα
promoter. Thus, IκBα is thought to maintain the transient effect of inducing agents
on the transcription of NFκB responsive genes [24]. It was demonstrated that in
vivo degradation of IκBα is required for the appearance of NFκB in the nucleus. In
addition, some investigators were able to demonstrate by co-immunoprecipitating rel
proteins with IκBα, from stimulated cells treated with proteasome inhibitors to block
the degradation of phosphorylated IκBα, that IκBα undergoes degradation mediated
by the 26S proteasome after phosphorylation, but before dissociation [24].
We model the autoregulatory relationship between IκBα and NFκB (R38 and R39)
as a two-component negative feedback system:
˙[pIκBα] = [IKK]− α [pIκBα]− β [NFκB]
˙[NFκB] = γ [pIκBα]− δ [NFκB] (5.4)
The dynamic behavior of the negative feedback depends on the relative efficiency
of the feedback regulation (α and β) regulating oscillation persistence versus self-
regulation (γ and δ), causing oscillation damping. The output, NFκB, can range
from persistent oscillations (high feedback efficiency and no damping, α = δ = 0)
to gradual rising to a plateau level (low feedback efficiency and high damping). Fig-
ure 5.7 demonstrates the phosphorylation of IκBα by IKK, subsequent rapid degra-
dation by the 26S proteasome and synthesis of IκBα promoted by nuclear NFκB. The
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corresponding NFκB signal is also depicted. Model parameters are fitted to phospho-
IκBα data for which the experimental methodology is specified in Appendix B.4. In
our case, the fitted parameters correspond to damped oscillations (intermediate feed-
back efficiency and intermediate damping). Although we note that the sample size
is small, the model simulation does show good agreement with the trend seen in the
data.
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Fig. 5.7.: IκBα phosphorylation following 2 µg/mL αCD3 and αCD28 costimulation.
The data shown are quantified western blot data from one experiment.
5.5.7 Modeling mTOR Signaling
Mammalian target of rapamycin (mTOR) is an evolutionary conserved serine/threonine
protein kinase that is well known for its ability to control T-cell activation and differ-
entiation. mTOR is necessary for TCR-induced signaling to drive differentiation into
Th1, Th17 or Th2 effector types in vitro or in vivo under polarizing conditions. On the
other hand, mTOR-deficiency drives CD4+ T-cells to the generation of FOXP3+ T-
cells, even under normal activating conditions [31]. The ability of mTOR to regulate
the expression of FOXP3 makes it a key player in the development of Tregs [31,32].
TCR and CD28 costimulation leads to the membrane recruitment of Akt (via
mechanisms described in Section 5.5.5), where it is phosphorylated (at position T308)
by PDK1 (R40). Activated Akt phosphorylates tuberous sclerosis complex 2 (TSC2)
in an inhibitory manner, yielding a separation of the TSC1/TSC2 complex (R41). This
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causes Ras homolog enriched in brain (Rheb) to lose its GTPase-activating protein
(GAP) activity (R42). The resulting accumulation of Rheb-GTP promotes mTOR
complex 1 (mTORC1) function (R43), which acts to downregulate FOXP3 expression
(R47) [31]. By contrast, mTORC2 appears to be involved in cross-talk between Akt,
FOXP3, PKCθ and NFκB. mTORC2 was shown to promote phosphorylation of Akt
(R40) and PKC (R36), Akt activity, nuclear NFκB and to regulate Th1 and Th2
commitment in response to T-cell activation [33].
The model is augmented with the described reactions (R40-R47), which consist pri-
marily of first- and second-order mass action kinetic expressions. Hill equations are
employed in cases, such as PTEN deactivation by TCR triggering (R45), TSC2 phos-
phorylation (R41) and IL-2 (R46) and FOXP3 (R47) transcription, to better describe
apparent cooperativity between transcriptions factors [27, 32]. Kinetic parameters
are chosen to reproduce qualitative observations of Akt and PKC phosphorylation in
response to αCD3 and αCD28 costimulation originally reported by Lee et al. [33], the
results of which are shown in Figure 5.8. In the model, as with the data, while αCD3
and αCD28 are each capable of inducing Akt and PKCθ phosphorylation, both are
required to induce full activation of these pathways.












































































Data (Lee et 
al., 2010)
Simulation
Data (Lee et 
al., 2010)
Fig. 5.8.: T-cell signaling in response to doses of αCD3 and αCD28 as measured
by (A) P-Akt and (B) P-PKCθ. CD4+ T-cells were stimulated (40 min) with 0.5
mg/mL plate-bound αCD3, 2.5 mg/mL of soluble αCD28 or both. Bar graphs quan-
tify phosphorylation of Akt and PKC, with each sample normalized to the level of
unphosphorylated protein in one experiment representative of three replicates (data
source: [33]).
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5.6 Results and Discussion
The following results and discussion subsections are divided into two main groups.
First, the complete and calibrated model, as described in Section 5.5, is evaluated
against additional data not used in the model tuning process. This experimental
evidence and corroboration of the model’s predictive accuracy is described in Section
5.6.1. The sections that follow then describe predictions made using the model. As
mentioned in the introduction, these will mainly focus on the roles of signal strength
and feedback loops on the regulation of T-cell activation.
5.6.1 Model Corroboration
Experimental Datasets for Model Corroboration
Experimental datasets for the purposes of model corroboration are compiled from
the published literature. Only those that are commensurate with our model in terms
of cell type, stimuli, output species and time scale are considered. Table 5.2 sum-
marizes the attributes of the compiled dataset. Each dataset is used to analyze the
model’s ability to recapitulate the dynamics of the biological system as indicated.
These datasets consist of dynamics (i.e., time courses), dose responses (i.e., multiple
doses of an input or stimulus), input responses (i.e., single doses of different input
or stimuli combinations) and knockdown or knockout (i.e., activity of a particular
species is reduced or eliminated) experiments. In order to compare the model and
observed behaviors directly, simulations are generated to mimic the experimental con-
ditions used in the published experimental set-ups. Model simulations are shown with
the corresponding data and error bars whenever possible.
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Table 5.2.: Description of experimental datasets used for model corroboration.
Species Variable(s) Experiment
Type












Input response Jurkat 5.10 [28]
Lck, Erk CD45 Knockdown Murine DP
thymocytes
5.11 [56]








Corroboration of Signaling Events and Transcription Factor Activation
In order to corroborate the model, we perform several in silico experiments and
compare the simulations to published experimental results (described in Table 5.2).
Figure 5.9A shows the changes in the intracellular calcium release in response to
different combinations of stimuli. As shown in the figure, only αCD3 and ionomycin
are capable of inducing calcium signaling, with ionomycin (administered with PMA)
being the stronger of the two inducers. For the most part, the model simulations are
in good qualitative agreement with the observations reported by Smeets et al. [28];
however, there are two noticeable discrepancies. First, these data show that the
model slightly overestimates the system’s calcium sensitivity to ionomycin stimulation
relative to that of αCD3. Since the model is shown to fit calcium signaling quite well
(see Figure 5.6), more information on the effects of ionomycin would likely resolve
this issue. Second, the model’s predicted calcium response demonstrates a slight
sensitivity to PMA, a trend that is not observed in the data. This model behavior is
likely caused by the presence of the positive feedback loop mediated by Erk. PMA
is considered a DAG substitute, activating the substrates of DAG, such as RasGRP,
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which leads to the activation of Erk. Erk, in turn, promotes signaling by preventing
SFK from activating the SHP1 negative feedback loop. In the model, the effect of
elevated SFK facilitates further signaling through LAT, PLCγ, IP3 and eventually
calcium. This may be evidence that the model, particularly the positive feedback

























































































































Fig. 5.9.: Intracellular calcium and NFAT signaling in response to various combi-
nations of stimuli. (A) Jurkat cells were stimulated as indicated (αCD3, αCD28,
ionomycin: 1 µg/mL; PMA: 10 ng/mL), and intracellular Ca2+ release was moni-
tored over time (data sampled from [28]). Solid lines represent corresponding model
simulations. (B) NFAT activity in response to 10 µg/mL αCD3 stimulation and
varying doses of calcineurin inhibitor cyclosporin A (CsA). The data are measured at
30 min post-stimulation (data sampled from [54]).
Figure 5.9B shows changes in nuclear translocation of NFAT, a downstream target
of calcium signaling, with varying doses of the calcineurin inhibitor cyclosporin A
(CsA). Model simulations show excellent agreement with the observations reported
by Clipstone et al. [54] in terms of half-maximal inhibitory concentration (IC50) at ˜3.5
ng/mL CsA. However, the model does appear to be slightly less sensitive to changes
in inhibitor concentrations, as the slopes of the two curves are slightly different.
Figure 5.10 shows the activity of transcription factors NFAT, NFκB and AP1, as
well as IL-2 synthesis in response to different combinations of stimuli. While there
are a few obvious quantitative discrepancies between the model simulations and the
data presented by Smeets et al., there is good qualitative agreement among them in
the input/output relationships. Nuclear localization of NFAT is only achieved when
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stimulating with combinations involving αCD3 (Figure 5.10A). This is because NFAT
translocation requires strong calcium signaling, which αCD28 and PMA stimulation
alone could not induce, consistent with [18] and Figure 5.9A. On the other hand,
both αCD3 and PMA are sufficient to induce nuclear localization of NFκB and AP1
(Figure 5.10B,C). This is promoted by αCD28, but a combination of αCD3 and PMA
have the greatest influence on translocation. IL-2 transcription in response to these
same stimuli is shown in Figure 5.10D. The results indicate that TCR signaling is
necessary for IL-2 transcription, but not sufficient. Coupling with CD28 coreceptor
signaling causes a moderate increase in IL-2 transcription, but coupling with PMA
results in the greatest observed increase, consistent with [18,28]. These experimental
results corroborate the model and suggest that it is capable of accurately recapitu-
lating the transcription profiles and, indirectly, the upstream signaling pathways, for


































































































































Fig. 5.10.: Activity of transcription factors (A) NFAT, (B) NFκB and (C) AP1, as
well as (D) synthesis of IL-2 in response to various combinations of stimuli (αCD3,
αCD28: 1 µg/mL; PMA: 10 ng/mL). Activity was measured 15 min post-stimulation
(data sampled from [28]). Left and right axes correspond to model simulations and
measured relative absorbance values, respectively.
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Corroboration of CD45 Activity
In this model, CD45 exists initially as fully active (proximal to the SFKs), then is
deactivated (translocates away from the SFKs) by the formation of the TCR complex.
At later time points, CD45 is reintroduced to the receptor cluster with an increased
negative regulatory role. This results in dephosphorylating active SFK and phospho-
rylated ligand-bound TCR, thus terminating the TCR signal. Figure 5.11A depicts
Lck-Y505 phosphorylation as a function of CD45 activity after 15 min of stimulation.
At normal expression levels (i.e., 100% of WT), Y505 phosphorylation is reduced by
approximately 75%. Phosphorylation at Y505 is inversely related to CD45 activity,
which is corroborated by the observations of McNeill et al. [56]. The model is able to
approximate the data from 100% WT activity down through 5% WT activity very
well. Only when CD45 is completely suppressed do the model and data diverge,
although the trend is still present.
132












































0 20 40 60 80 100






1 10 1 0































































































Fig. 5.11.: Downstream TCR signaling in response to CD45 knockdown. (A) Model
simulations of Lck phosphorylation at the negative regulatory residue Y505 as a
function of CD45 activity (data sampled from [56]). (B) Model simulations of Erk
phosphorylation 3 min after stimulation with 0 or 50 µg/mL αCD3 as a function
of CD45 activity (data sampled from [56]). (C) Model simulations of intracellular
calcium release over time in wild-type (WT) and CD45 knockdown mutant (5% of
WT activity) stimulated with 10 µg/mL αCD3 at 90 s as a function of CD45 activity
(data sampled from [57]).
In CD45-null thymocytes, the p56Lck and p59Fyn tyrosine kinases are hyperphos-
phorylated, and p56Lck is found in its inactive conformation [57]. Both basal and
TCR-stimulated tyrosine phosphorylation of TCRζ and CD3ε are also much reduced.
These defects are associated with the failure of Zap70 kinase recruitment to the TCRζ
chain; however, TCR-induced signaling is not entirely ablated. Figure 5.11B shows
Erk phosphorylation as a function of αCD3 stimulation and CD45 activity. It is
clearly evident that pErk increases with CD45 activity; however, above ˜50%, there
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is qualitative switch, and pErk begins to decrease as CD45 expression approaches
wild-type levels, which is also corroborated by observations by McNeill et al. [56].
Furthermore, significant inositol phosphate and calcium signals are observed in
CD45-null thymocytes. In our simulation, the CD45 defect is approximated with a
knockdown to 5% of WT activity as complete CD45 knockout suppressed all signal-
ing. Although greatly reduced from the nominal system, calcium signaling does not
appear to be insignificant in CD45-defective CD4+ T-cells (Figure 5.11C). The molec-
ular analysis presented by Stone et al. suggests that the threshold for TCR signal
transduction is greatly increased in CD45-null T-cells, thus explaining the profound
defects in thymic development [57].
Corroboration of SHP1 Activity
SHP1 functions as a negative regulator by deactivating Zap70 and SFK upon T-
cell activation [50]. SHP1 also forms a negative feedback loop that is composed of
SHP1 phosphorylation by activated Lck, binding of phospho-SHP1 to Lck and Lck
inactivation by SHP1-mediated dephosphorylation [51]. To evaluate the ability of
the model to capture the role of SHP1 feedback on T-cell activation, we simulate the
SHP1 knockdown experiment presented by [50]. Figure 5.12 shows the stimulation
of the IL-2 reporter with different combinations of stimuli and two different levels
of SHP1 activity. Model-simulated results and data are depicted by bars and dots,
respectively. In the wild-type system, neither PMA nor αCD3 alone are sufficient to
upregulate IL-2 transcription. However, the combination of the two is able to generate
a substantial signal. Pairing PMA with ionomycin produces the maximally-observed
signal. In the SHP1-knockdown system, IL-2 synthesis is drastically increased as
a result of αCD3 and PMA + αCD3 stimulation, thus demonstrating the lack of
inhibition. PMA + ionomycin stimulation is not affected by SHP1 knockdown because
SHP1 functions upstream of their substrates: RasGRP1, PKCθ and calcium. The
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experimental results show mostly good agreement with the model, suggesting that






























































Fig. 5.12.: IL-2 reporter stimulation in response to SHP1 knockdown. The model
simulates the wild-type and SHP1 knockdown mutant (C453S mutation, resulting in
catalytically inactive SHP1) stimulated with 10 µg/mL αCD3. IL-2 reporter stimu-
lation was measured 2 h post-stimulation (data sampled from [50]).
5.6.2 Weak CD28 Costimulation Predicted to Elevate FOXP3 Transcrip-
tion
TCR signal intensity and costimulation is known to differentially affect the acti-
vation of T-cells. We study this by performing a two-way dose response experiment,
measuring the effects of αCD3 and αCD28 on IL-2 and FOXP3 transcription. Fig-
ure 5.13A,B shows IL-2 and FOXP3 transcription, respectively, following 30 min of
stimulation by various combinations of αCD3 and αCD28. At trivial doses of both
stimuli, neither species is active, indicating that the cell is at rest. At high doses
of both stimuli, IL-2 is the dominant species, indicating that the cell is fully active.
However, when costimulation through CD28 is relatively weak, the balance of dom-
inance shifts toward FOXP3, while leaving IL-2 at a much reduced level. Indeed,
this behavior is corroborated by the observations by Kretschmer et al. [58] that weak
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TCR signals and limited costimulation have been linked to FOXP3 induction and the
development of the regulatory phenotype in CD4+ T-cells.





































































































































Fig. 5.13.: (A) IL-2 and (B) FOXP3 transcription in response to stimulation by
combinations of αCD3 and αCD28. Results show outputs 30 min after stimulation.
5.6.3 Reduced CD45 Activity Predicted to Elevate FOXP3 Transcription
We investigate the roles of CD45 and SHP1 on T-cell activation by simulating
a two-way knockdown response experiment and measuring the effects on a small
number of important outputs. Figure 5.14A–F show the model response to various
CD45- and SHP1-knockdown scenarios. SHP1 clearly has the effect of downregulating
most species playing a role in T-cell activation. As SHP1 activity is reduced (i.e.,
moving top to bottom on the right axis in each plot), calcium, Erk, PKCθ and
IL-2 are all upregulated. This is due to the loss of their transient behaviors and
constitutive activation at elevated levels. For CD45, on the other hand, the analysis
demonstrates a dual role as both activator and inhibitor of T-cell activation. As
CD45 activity is reduced (i.e., moving right to left on the top axis in each plot),
TCR signaling increases until CD45 activity reaches ˜1%–10% of the wild-type, then
decreases to complete inactivation as CD45 is completely suppressed. This result
indicates that CD45 is required for TCR signaling, without which the pool of SFKs
would remain in the closed and inactive state; however, the highest level of activation
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is not actually achieved for wild-type CD45 expression, but rather at a reduced rate
between approximately 1%–10% of the wild-type with intact SHP1 activity. Stronger



















































































































Fig. 5.14.: Model response to various CD45- and SHP1-knockdown scenarios. (A)
Intracellular calcium; (B) Erk; (C) PKCθ; (D) Akt; (E) IL-2; and (F) FOXP3 tran-
scription factor activation in systems with various levels of CD45 and SHP1 down-
regulation. Note that downregulation is shown as percentages of wild-type activity
(i.e., 100% corresponds to normal function, 0% corresponds to full knockout). Results
show outputs 30 min after stimulation by 10 µg/mL αCD3 and αCD28.
It is evident that the system is quite sensitive to CD45 activity, particularly at the
lower end of expression. By contrast, SHP1 is much more effective closer to wild-type
levels; however, its activity is heavily dependent on the presence or absence of CD45.
The results suggest that there exists a distinct threshold of CD45 activity (˜1% of
WT) that may be critical to determining the outcome of TCR-mediated activation.
Below this threshold, the system is presumably unable to activate with every state
remaining at baseline. However, at the threshold and above, the signaling molecules
relating to Th development become active and the system is rescued. Recently, Mc-
Neill et al. reported that only 3% of normal CD45 activity is sufficient to reconstitute
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CD45-deficient mice with normal numbers of mature T-cells, biased toward CD4+
T-cell lineage commitment [56].
CD45 also appears to have an effect on the activation of FOXP3. At total
CD45 suppression, the cell remains unresponsive, even at full stimulation. For wild-
type activity, TCR signaling promotes mTORC1 activation, thereby also suppress-
ing FOXP3. However, a reduction in CD45 activity to around the aforementioned
threshold actually induces a substantial upregulation in FOXP3 expression while IL-2
remains low. This may be due to the transcriptional regulators of FOXP3 becom-
ing sufficiently induced, while signaling remains too low to promote mTOR-mediated
inhibition. This result suggests that CD45 downregulation may lead to weak IL-2
induction and increased FOXP3 expression, which is often observed in Treg lineage
commitment.
5.7 Conclusions
Signal intensity and feedback regulation are known to be major determinants
of the signaling profile for the TCR and its various coreceptors. While the exact
nature of these relationships remains under investigation, it is believed to involve
a complex signaling network with cross-talk between the calcium, Erk, PKCθ and
mTOR signaling pathways.
In this manuscript, we present a mathematical model encompassing the signal
transduction events relating to the process of TCR-mediated cell activation and gene
expression. The model is able to reproduce key behaviors in: (1) ligand-induced TCR
trafficking, synthesis and degradation; (2) early kinase and phosphatase interactions
between SFK, Zap70, CD45 and SHP1; (3) CD28 costimulation; and (4) downstream
signal transduction pathways leading to IL-2 and FOXP3 synthesis, including calcium,
Erk, PKCθ and mTOR.
In addition to corroborating many experimentally-observed behaviors, the model
is able to provide insight into the positive and negative regulatory roles of the phos-
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phatases CD45 and SHP1 during T-cell activation. Analysis of the model demon-
strates that: (1) SHP1 negative feedback is necessary for preventing hyperactivity in
TCR signaling; (2) CD45 is required for TCR signaling, but also partially suppresses
it at high activity levels; and (3) elevated FOXP3 and reduced IL-2 signaling, an
expression profile often observed in developing Tregs, can be achieved either by weak
TCR and CD28 stimulation or a severe reduction in CD45 activity. However, we
do note that further investigation and experimental evidence is required in order to
corroborate these predictions.
While the proposed model is a demonstrably powerful tool for predicting many
events involved in CD4+ T-cell activation, there are certain caveats that need to be
considered to accurately define the model’s scope and capability. First, as a finite
mathematical approximation, this model is inherently an abstraction of the biological
reality. As such, the model does not attempt to explain every possible mechanism
involved in the processes in question. For example, the Foxo family protein, Foxo1,
is thought to bind to the FOXP3 locus and induce FOXP3 gene transcription. Foxo1
activity is subject to modulation by Akt kinase signaling, and Tregs have dampened
Akt signaling in response to TCR stimulation compared with conventional T-cells.
However, it is not within the scope of this work to test and corroborate every one
of these mechanisms. Second, the purpose of the model is to simulate the dynamics
of a small number of key species involved in T-cell activation or, more specifically,
and clinically relevant, activation of human primary CD4+ T lymphocytes. Due to
practical limitations on the availability of experimental data, however, the model
is partially calibrated with datasets from alternate sources, including Jurkat cells.
While Jurkat cells are an immortalized cell line of human T lymphocytes, they share
many similarities with their primary counterparts and are very useful in studying T-
cell signaling and IL-2 production. However, we do recognize that this constitutes an
amalgamation of data from a variety of sources and that further investigation using
primary T-cells is highly desirable.
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As demonstrated in this manuscript, the mathematical model captures the key
events in TCR and CD28 co-mediated signal transduction events leading to IL-2 and
FOXP3 activation. As such, the model enables researchers to study these processes
with a combination of broad scope, using a large-scale highly-connected network and
with quantitative detail and accuracy not allowed by comparable models. In the
future, we plan to use this mathematical model to design informative and hypothesis-
driven experiments to refine our understanding of the dynamical nature of CD4+
T-cell activation. Our goal is to use such a model as a foundation for the design
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6. MODEL-BASED EXPERIMENT DESIGN AND
PREDICTIVE CONTROL STRATEGY FOR TARGETED
MANIPULATION OF CD4+ T CELL SIGNALING
6.1 Preface
The material presented in this chapter is at this time being prepared for submission
as a journal article.
6.2 Abstract
Balance between subgroups of activated CD4+ T cells is critical to an effective and
controlled adaptive immune response against internal and external threats. Hypo- or
hyperactivity in T helper (Th) and regulatory (Treg) groups have been implicated
in numerous forms of autoimmunity and cancer. In many cases, the source of dis-
ease lies in the intracellular mechanisms (e.g., interleukin-2 (IL-2) and forkhead box
P3 (FOXP3)) that control the recognition and interpretation of extracellular signals
leading to CD4+ T cell activation and differentiation. Thus, the precise manipula-
tion of these activities may enable effective targeted therapies. Here we present a
computational method to aid in the design of experimental strategies to robustly
control intracellular signaling during CD4+ T cell activation. To this end, we em-
ployed model-based design of experiments (MBDOE) theory to create and refine a
mathematical model of IL-2 and FOXP3 signaling. The MBDOE strategy success-
fully designed laboratory experiments (i.e., input dosing and measurement schedules)
to drastically reduce the dynamical uncertainty in the model. These tuned model sce-
narios were able to improve the effectiveness of an adaptively-weighted multi- model
predictive control (AWMMPC) algorithm in driving in vitro IL-2 and FOXP3 signal-
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ing levels representing Th activation, Treg activation, and T cell anergy, in some cases
by up to four times better. This study provides a practical and systematic strategy for
efficiently improving and utilizing the collective predictive capability of mathematical
models to robustly control intracellular signaling in CD4+ T cells without feedback.
6.3 Introduction
A functional immune system effectively balances the tasks of recognizing and elimi-
nating foreign threats with maintaining tolerance to self-antigens. Activated CD4+ T
cells are critical to this balance through a variety of effector functions during im-
mune reactions from promoting the recruitment and expansion of B cells, cytotoxic
T cells, macrophages and other pro-inflammatory immune cells [1–3] to suppress-
ing excessive reactions to auto- and allo-antigens [3–5]. However, disruptions to the
homeostasis within the CD4+ T cell populations, particularly among members of the
pro-inflammatory T helper cell (Th, e.g. Th1, Th2, Th9, Th17 and Th22) group and
the immunosuppressive regulatory T cell (Treg), are known to cause numerous autoim-
mune disorders [6] and cancers [7–9], type 1 diabetes [10], increased susceptibility to
the human immunodeficiency virus (HIV) [11] and transplant rejection [12–14] among
others.
In many cases, the source of disease lies in the intracellular mechanisms that
control the recognition and interpretation of activation signals for CD4+ T cell phe-
notype commitment, expansion and plasticity. These processes are initiated by the
transmembrane T cell receptor (TCR) complex and co-receptor stimulation by a va-
riety of secreted cytokines and environmental factors. Ligation of the TCR and its
co-receptors, particularly CD28, leads to signal transduction culminating in the tran-
scription of interleukin-2 (IL-2) and forkhead box P3 (FOXP3), each respectively
critical to the development of CD4+ Th cells [1–3] and Treg cells [3,5]. Aberrant regu-
lation of components in these signaling pathways have been linked to severe-combined
immunodeficiency (SCID) [15], autoimmune hepatitis [16], myasthenia gravis [17],
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multiple sclerosis [18], autoreactive T cells [19], and acute lymphoblastic [20] and
myelogenous [21, 22] leukemias. However, recent studies have shown the efficacy
of pharmacological modulation of early signal transduction events as a promising
mechanism for directing T cell activity, including phenotype commitment and plas-
ticity [23–25] and the treatment of autoimmunity and cancer [26]. Thus, strategies
that enable the predictable manipulation of T cell behavior via intracellular signal-
ing pathways could revolutionize how we study biological processes in research and
generate new clinical therapies in medicine.
Modern control techniques developed for biomedical systems increasingly rely on
predictive mathematical models to help design the system perturbations (or control
inputs) necessary to direct complex biological phenomena. Such models serve to
encapsulate our current understanding of the biological system, can indicate gaps
in that understanding, and provide the basis for the rational design of experiments
and clinical intervention [25, 27–34] (note: [34] is Chapter 5). Indeed, the coupling
of model-based control tools with real-time quantitative measurement feedback has
proved very effective in a wide variety of biomedical applications (e.g., automated
biomass production and cell culturing [35–38], diabetes management and the artificial
pancreas [39–42], anesthesia administration [43, 44], circadian rhythm entrainment
[45], cell differentiation [46,47] and synthetic biology-based gene expression [48–52]).
However, the challenges with applying control theory to intracellular signaling systems
are two-fold: the current experimental techniques are too slow to enable effective
measurement feedback for the rapidly evolving intracellular signaling dynamics [53,
54] (note: [54] is Chapter 4), and these techniques—often producing sparse, noisy,
and semi-quantitative data—may also be insufficient to unambiguously discriminate
between a wide variety of network topologies, functional representations, and kinetic
rates, thus enabling the existence of multiple data-consistent models and parameter
scenarios [55]. When applying control-theoretic techniques, the input doses predicted
to elicit a desired behavior or outcome may be different for each model, an effect that
may worsen when extrapolating predictions to novel scenarios. Without performing
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the experiments, it would be quite difficult to, a prior, determine the ‘best’ model;
furthermore, the best model may change depending upon the experimental objectives.
Whether designing exploratory experiments to gain information or therapeutic dose
scheduling in a clinical setting, selecting the best model or combination of models is
an important challenge to control theorists for Systems Biology applications [56].
Here we develop a practical computational framework to facilitate the rational de-
sign of experimental strategies to predictably and reliably control intracellular signal-
ing leading to CD4+ T cell differentiation. To this end, we first augment a published
mathematical model of CD4+ T cell activation to reflect the predicted pharmacoki-
netic/pharmacodynamic (PK/PD) relationships among several important signaling
readouts and potential input reagents. Next, we employ model-based design of ex-
periments (MBDOE) theory to design a series of informative laboratory experiments
to resolve the dynamical uncertainty in those PK/PD relationships. Finally, we adapt
a model predictive control (MPC) algorithm featuring multiple adaptively-weighted
mathematical models (AWMMPC) to design input reagent dosing schedules capa-
ble of driving CD4+ T cell dynamics along three biologically-relevant trajectories:
Treg activation and development, Th activation and development, and T cell anergy
(or hyporesponsiveness). Thus, this study presents and corroborates computational
procedures for the design of experimental strategies to produce resource-efficient and
dynamically-informative observations of biological systems and reliably control intra-
cellular signaling in CD4+ T cells without the availability of real-time feedback.
6.4 Results and Discussion
6.4.1 Framing the Biological Objective: CD4+ T Cell Activation Leading
to Differentiation
A critical first event for CD4+ T cell phenotype commitment, expansion and plas-
ticity is the activation of the TCR and CD28 signaling pathways (depicted in Figure
6.1). This process begins at the engagement of the TCR to the first signal—cognate
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peptide-bound major histocompatibility complexes (pMHC) on the surface of antigen-
presenting cells (APCs) [57–59]—which in turn triggers a number of early phospho-
rylation and dephosphorylation events. Prior to TCR engagement, the CD45 phos-
phatase primes sarcoma (Src) family of kinases (SFK) members [60,61] by removing
inhibitory phosphate groups (Y505 on LCK) [62,63]. Following ligation, primed SFKs
are activated by receptor-mediated autophosphorylation (Y394 on LCK) [63], which
in turn doubly phosphorylate the immunoreceptor tyrosine-based activation motifs
(ITAMs) on the TCR-associated CD3 ζ-chain. These provide docking sites for the Src
homology 2 (SH2) domains of the zeta-chain-associated protein kinase 70 (ZAP-70),
a Syk family kinase, allowing ZAP-70 to be activated by SFK-mediated phosphory-
lation of its Y319 and Y493 residues [64–66]. ZAP–70-activated phospholipase C-
γ1 (PLCγ1) then hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to second
messengers inositol 1,4,5-trisphosphate (IP3) [67–69], which migrates to the cytoplasm
to release intracellular calcium (Ca2+) from the endoplasmic reticulum [67,70,71] and
activate nuclear factor of activated T-cells (NFAT) [72], and diacylglycerol (DAG),
which operates within the cell membrane to activate rat sarcoma (Ras) and protein
kinase Cθ (PKCθ) [73]. Ras triggers the extracellular signal-regulated kinase (ERK)
cascade that results in the activation of activator protein-1 (AP-1) [74], whereas PKCθ
activates both AP-1 and the nuclear factor κB (NFκB) pathway [75–78]. Upon enter-
ing the nucleus, the NFAT, AP-1 and NFκB transcription factors interact to support
cooperative regulation of IL-2 and other related genes [79, 80].
The second signal driving T-cell activation and fate determination is provided by
CD28-mediated costimulation [24]. CD28 signaling is mediated through PKCθ and
AKT, which recruit and regulate several signaling molecules, including NFκB [77,81]
and mammalian target for rapamycin (mTOR) [82], the catalytic subunit in two
structurally-distinct complexes. The serine/threonine protein kinase mTOR complex
1 (mTORC1) is noteworthy for its control over the expression of FOXP3, the master
transcriptional regulator in the development of Tregs [82, 83]. The second mTOR
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complex (mTORC2) promotes PKC, AKT and NFκB signaling and is critical to Th1
and Th2 commitment [84].
The relative strengths of the TCR and CD28 signals are known to differentially
affect activation and lineage commitment in CD4+ T cells. TCR ligation ultimately
leads to anergy or a state of hyporesponsiveness in the absence of a second signal [85].
The addition of CD28 costimulation on the surface of T cells greatly enhances IL-
2 production, T cell proliferation and the prevention of anergy. Strong TCR and
CD28 signals suppress FOXP3 and force IL-2 to become the dominant species, indi-
cating that the cell is fully active. However, a weak CD28 signal shifts the balance
of dominance toward FOXP3, leaving IL-2 at a much reduced level. Indeed, weak to
moderate CD28 costimulation have been linked to FOXP3 induction and the develop-
ment of the regulatory phenotype in CD4+ T cells [86]. Because of their significance
in the larger context of the immune response, we selected the following three activa-
tion profiles as the biological objectives for our control strategies: IL-2 activation and
FOXP3 suppression (Th activation and development); IL-2 suppression and FOXP3





































































































Fig. 6.1.: Reaction network of the T-cell activation model. TCR-mediated signal
transduction is initiated when the receptor binds to a peptide-MHC complex pre-
sented by an antigen-presenting cell. Engagement of the TCR leads to the recruit-
ment of LCK and FYN, which phosphorylate the ITAMs of the TCR. This provides
docking sites for the SH2 domains of ZAP-70, allowing ZAP-70 to be phosphorylated
and activated by LCK. Once activated, ZAP-70 phosphorylates the adaptor proteins
SLP-76 and LAT. This, coupled with CD28 costimulation, results in calcium mobi-
lization, activation of the MAPKs and PI3Ks, nuclear localization of NFAT, AP-1
and NFκB, and the transcription of IL-2 and FOXP3, each respectively critical to
the development of CD4+ Th and Treg cells. Activation and inhibition reactions are
denoted by black arrows and red diamonds, respectively. Input reagents are depicted
near their respective target substrates in shaded boxes (color code: green = activa-
tion; red = inhibition). Yellow circles denote phosphorylation. Other symbols and
reactions are described in Perley et al. [34] (Chapter 5).
6.4.2 Mathematical Modeling of TCR-Mediated Signaling in CD4+ T
Cells
To facilitate a comprehensive representation of the dynamics associated with the
TCR- and CD28-associated signaling pathways which initiate CD4+ T cell activa-
152
tion and lead to Th and Treg differentiation, we constructed an ordinary differential
equation (ODE)-based computational model of the major events involved, including
receptor trafficking, kinase and phosphatase activity, calcium mobilization, nuclear
translocation of transcription factors, and gene transcription (summarized in the block
diagram in Figure 6.2A). This model is based on one originally proposed by Perley
et al. [34] (Chapter 5), which we modified to reflect the current understanding of
these signaling events and to incorporate mechanisms for perturbing the system with
small-molecule inhibitors and activators (i.e. input reagents). Molecular association
and complex dissociation are designed to obey the Law of Mass Action, i.e., assuming
that the rate of a reaction is proportional to the product of reactant concentrations.
Most enzyme-catalyzed reactions utilize second-order kinetics derived from a simpli-
fication of the Michaelis-Menten enzyme kinetics by assuming the substrate concen-
tration is limiting. For reactions catalyzed by enzymes not explicitly included in this
model, the expression reduces to first-order kinetics where the enzyme concentration
becomes a constant. Single molecular transitions are also governed by first-order ki-
netics. Enzyme-catalyzed reactions in which cooperative binding between substrates
plays a significant role utilize the Hill equation. Scenarios characterized by these
equations include the cooperative transcriptional regulation of IL-2 and FOXP3 and
the activation of certain enzymes. The model consists of 49 species pertinent to TCR-
and CD28-mediated signaling with 154 reaction parameters. A detailed account of
the symbols, rate equations, and reaction interpretations can be found in Perley et
al. [34] (Chapter 5).
The model has been designed to recapitulate important T cell signaling behaviors
upon stimulation and perturbation, specifically, with respect to (1) Treg development
(low IL-2, high FOXP3), (2) Th development (high IL-2, low FOXP3) and (3) T
cell anergy (low IL-2, low FOXP3) (Figure 6.2B). To enable these outcomes, the
model features 11 possible input reagents that are capable of perturbing the system.
These input reagents, which include anti-human CD3, anti-human CD28, phorbol
12-myristate 13-acetate (PMA, a PKC stimulator), ionomycin (a calcium ionophore),
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sanguinarine (an MKP inhibitor), U0126 (a MEK1/2 inhibitor), cyclosporin A (a cal-
cineurin inhibitor), 7-Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3d]pyrimidin-4-
ylamine (an LCK inhibitor), wortmannin (a PI3K inhibitor), AEB071 (a PKCθ in-
hibitor), and rapamycin (an mTOR inhibitor), are described in the table in Figure
6.2C. Input doses are assumed to be administered in bolus form and the effects are
neither instantaneous nor permanent. Their pharmacodynamic effects on the system
are characterized by modulating the kinetic parameters associated with their respec-
tive substrates using the Hill equation (Figure 6.2D), thereby raising the total number
of parameters to 198. For reference, these input reagents are depicted in Figure 6.1
as shaded boxes near their respective target substrates.
Other specific modifications to the original model, including revised definitions of
the SFK-related states (Figure C.1), the addition of PK/PD models for several key




B Table: Desired Cell Responses and Corresponding Signaling Targets
Target
Desired Cell Response IL-2 FOXP3
Regulatory T cell activation and development Low High
Helper T cell activation and development High Low
T cell anergy (hyporesponsiveness) Low Low
Table: Potential Input Reagents to Induce System Perturbations and Achieve Targets
Input Reagent Mechanism of Action Potency (Ki) Reference
PMA Synthetic DAG analogue: activation of 
PKC/RasGRP/ERK; IL-2 production (in 
combination with ionomycin).




Ionomycin Calcium ionophore: increased intracellular 
calcium; NFAT activation; IL-2 production (in 
combination with PMA).




U0126 Functional inhibition of MEK1/2 kinase 
activity: ERK phosphorylation; AP-1 activity.
41 nM (MEK activity, cell-free assay)
109 nM (p-ERK, cell-free assay)
Favata (1998)
iLck Function inhibition of LCK kinase activity: 
ZAP-70 activation; IL-2 production.
1-40 nM (IL-2 production, Jurkat) Arnold (2000)
Cyclosporin A Functional inhibition of calcineurin
phosphatase activity: NFAT nuclear 
localization; IL-2 production.
2-5 nM (NFAT activity, Jurkat) Borel (1976)
Clipstone (1992)
Wortmannin Functional inhibition of PI3K activity: CD28-
mediated formation of PIP3; IL-2 production; 
T cell proliferation.
1-10 nM (Class I PI3Ks)
50-450 nM (Class II PI3Ks)






Function inhibition of PKC kinase activity: 
NFκB activity; IL-2 production.
0.22 nM (PKCθ activity, cell-free assay)
50 nM (IL-2 secretion, Jurkat)
Evenou (2009)
Smeets (2012)
Rapamycin Functional inhibition of mTOR kinase 
activity: p70 S6K activation; FOXP3 
suppression; anergy suppression.
0.05-0.2 nM (p70 S6K activation, D10 cells)
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Fig. 6.2.: A computational strategy to control intracellular signaling events during
CD4+ T cell activation. (A). Summary of important signaling events during CD4+ T
cell activation. TCR-mediated signal transduction is initiated when the receptor
binds to a peptide-MHC complex presented by an antigen-presenting cell. Engage-
ment of the TCR leads to the clustering and activation of receptor-bound kinases.
This, coupled with CD28 costimulation, results in calcium mobilization, activation
of the MAPKs and PI3Ks, nuclear localization of NFAT, AP-1 and NFκB, and the
transcription of IL-2 and FOXP3, each respectively critical to the development of
CD4+ Th and Treg cells. (B) Biological phenotypes serving as the primary objectives
of the model-building and experiment design activities in this study. (C) Implemented
input reagents to induce the target phenotypes described in (B) and their respective
properties and sources. (D) Example mathematical equations used to describe the
PK/PD effects of the input reagents. (E) Input sensitivity effects on the model out-
puts IL-2 and FOXP3 in terms of fold change from baseline activity (i.e., activity
induced by 5 µg/mL anti-human CD3 + 5 µg/mL anti-human CD28 stimulation).
(F) Outline of the MBDOE strategy to select (1) the optimal input sequence and (2)
optimal output measurements to resolve dynamical uncertainty in the model. (G)
Outline of the AWMMPC strategy to control CD4+ T cell activation given modeling
uncertainty without the availability of real-time measurement feedback.
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6.4.3 Initial Identification of the Acceptable Parameter Space
In preparation for the design of informative experiments, we first performed an
initial calibration of the model. This was done by identifying the regions of the
parameter space capable of producing model simulations that are consistent with
existing experimental data. This calibration was conducted using published experi-
mental data chosen based on their commensurability with the model in terms of cell
type, stimuli, output species and time scale, as well as those employed to tune the
original model [34] (Chapter 5) for continuity. These datasets, summarized in Table
6.1, consisted of time-course dynamics, dose responses, and input responses (i.e., sin-
gle doses of different input or stimuli separately or in combinations) and were used
to collectively fit free model parameters for which reliable published values were not
found.
Table 6.1.: Modular design for initial acceptable parameter space identification.
Output(s) Inputs(s) Experiment
Type(s)
Uncertain Parameters Figure(s) Source(s)
P–ZAP-70 αCD3 Dose response R10kf, R10kr, R5kr, R5kf, R9kr1,
R21kf, R8kr1, R21kr, R8kf1, R9kf2,






R18kf, R18kr, R17kf, R17kr, R16kf,
R16kr, R10kf, R15kr, R11kf, R10kr,
nsang, ksang, nu0126, ku0126











R10kf, R13kf, R12kf, R12kr, R11kf,
R27kf, R27kr, R13bkr, R8kr1, wcd3,
npma, kpma, wpma, niono, kiono,
wiono, ncsa, kcsa
6.3C, G, I [24,34,88] (Ch. 5)
PIP3 Wortmannin Dose response R45kr, R45kf2, R45k, R34kr1, R33kf3,
R34kf, R8kr1, R10kf, wcd28, nwort,
kwort
6.3D [89]
IL-2 AEB071 Dose response R46kf, R46kr2, R10kf, R46kr1, R47kf,
R46k3, R38kf, R17kf, R11kf, R46k2,
R18kf, naeb, kaeb
6.3E [24]
IL-2 iLck Dose response R46kf, R46kr2, R10kf, R46kr1, R47kf,
R46k3, R38kf, R17kf, R11kf, R46k2,
R18kf, nilck, kilck
6.3E [24]







R13kf, R12kf, R27kf, R11kf, R13bkr,
R10kf, wcd3, npma, kpma, wpma,
niono, kiono, wiono








R38kf, R39kf, R38kr2, R37kr, R38kr1,
R37kf1, R37kf2, R33kf3, R10kf, R32kf,
R40kf3, R36kr, R33kr, R40kr, R8kf1,
wcd3, wcd28







Input response R10kf, R38kf, R18kf, R26kf3, R26kr,
R39kf, R38kr2, R13kf, R12kf, R11kf,
R16kf, wcd3, wcd28, npma, kpma,
wpma, niono, kiono, wiono
6.3I [24]
Experiment types: dynamics = time courses; dose response = multiple magnitudes of input/stimuli doses; input response = single
doses of different input or stimuli applied separately or in combination. Abbreviations: cd3 (anti-human CD3), cd28 (anti-human
CD28), pma (phorbol 12-myristate 13-acetate), iono (Ionomycin), sang (Sanguinarine), csa (Cyclosporin A), wort (Wortmannin), aeb
(AEB071), rapa (Rapamycin), and ilck (7-Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3d]pyrimidin-4-ylamine).
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The size and complexity of the model made it necessary to reduce the dimension
of the uncertain parameter space to enable computationally-tractable data fitting.
Sensitivity analysis provides a powerful tool for analyzing mathematical models of
complex biological systems and facilitates parameter estimation by identifying and
ranking the various contributors to parametric uncertainty. These methods quantify
the identifiability of key parameters through their sensitivity vectors. Parameters
with the lowest sensitivity ranks, i.e., parameters whose uncertainty causes the least
amount of variability in the output space, can be neglected during the model fitting
process and fixed at their initial estimates. Local methods quantify model behavior
near a nominal point in the parameter space; global sensitivity analysis determines
the variation in the output over a wide range of parameter values and enable the
analysis of interaction effects among parameters, thus making it more suitable for
analysis of signal transduction pathway models than a local method.
Here we employed the enhanced Elementary Effects (EE) global sensitivity method
[91, 92] to determine which parameters may be considered negligible, linear and ad-
ditive, nonlinear, or involve interactions with other parameters (see Section 6.5.3 for
details). To facilitate the parameter selection process, the sensitivity indices were
computed for the model outputs for which we had experimental data or planned to
manipulate as part of the control process and were standardized so that parameters
could be ranked for each output independently (Figure C.2). In total, 74 of the 198
reaction and PK/PD parameters were categorized as sensitive.
Since only a fraction of the sensitive parameters were influential for a given model
output, the dimension of the uncertain parameter space was reduced through modu-
larization based on the datasets available. Sensitive model parameters were grouped
into modules based on relevancy to each of the presented datasets, effectively trans-
forming the task from a single 74-dimensional optimization problem into 10 smaller
problems of four to 19 dimensions each (as indicated in Table 6.1). Parameter vec-
tors found to be acceptable (see Section 6.5.4 for definition) after the initial screen
through the individual modules were combined and re-screened using the aggregate
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dataset to identify the final set of acceptable parameter vectors (see Section 6.5.5 for
method details).
Figure 6.3 shows the range of the sampled model simulations, the calibration data
and the corresponding acceptable model trajectories following calibration. As illus-
trated in the figure, a number of species are well-constrained by the existing data,
most notably phospho-ERK (panel B) and intracellular calcium (panels G and I). One
important conclusion that can be drawn from these results is that the effectiveness of
an experiment in constraining the dynamics of the system depends not only on the
quantity and dispersion of the data, but on which outputs were observed and at what
point during the reaction as well. This is exemplified by the experiments involving
PIP3 and NFκB. In panel D, observations of PIP3 were taken five minutes following
stimulation with anti-CD3 and anti-CD28, which, according to the model, is likely
when the dynamics of PIP3 would be the least uncertain. Similarly, measurements
of NFκB (panel I) were taken prematurely and failed to take full advantage of the
available information content. Thus, despite their accuracy, these measurements are
relatively uninformative and ultimately fail to adequately constrain their respective
species over the vast majority of the time course. Any decisions made with these pre-
dictions would suffer as a result, thereby motivating the implementation of MBDOE
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Intracellular Calcium, NFkB, c-Jun vs. αCD3 (1 µg/mL), αCD28 (1 µg/mL), PMA (10 ng/mL), Ionomycin (1 µg/mL) or combinations thereofI
Fig. 6.3.: Initial model parameter screen and resulting data-consistent trajectories.
The range of the sampled model simulations, the calibration data and the correspond-
ing acceptable model trajectories following parameter identification. Gray areas rep-
resent all screened trajectories and blue areas represent the subset of data-consistent
trajectories considering all included data (see Table 6.1 for details). The magenta line
denotes the single best trajectory. Error bars show data mean ± standard deviation.
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6.4.4 Resolving Dynamical Uncertainty through Model-Based Design of
Experiments
We employed model-based design of experiments (MBDOE) theory to intelligently
and systematically design a set of laboratory experiments to resolve the dynamical
behavior of the T cell activation network and refine the mathematical model used
to approximate it. To ensure that the PK/PD properties of the input reagents were
adequately resolved, we designed eight individual experiments: one for each potential
input reagent and one for the baseline (unperturbed) system. In each case, the
algorithm, based on the algorithm developed by Mdluli et al. [93], identified the
input magnitude and time schedule and measurement schedule that minimized the
expected posterior uncertainty in the output dynamics (Figure 6.2F, see Section 6.5.6
for methodology). The full complement of designed experiments are detailed in the
table in Figure 6.4A and the individual results for the inputs AEB071 (Figure C.5),
CsA (Figure C.6), iLck (Figure C.7), PMA (Figure C.8), Rapamycin (Figure C.9),
U0126 (Figure C.10) and Wortmannin (Figure C.11) are presented in the supporting
information along with the complete definition of the experiment design space for
each experiment designed.
The “Baseline” case is presented in Figure 6.4B as an illustrative example. The
subpanels show the acceptable dynamics range before and after data gathering as
well as the in vitro measurements (all taken from the same time course experiment).
Figure 6.4C shows the reduction in maximum dynamical uncertainty of the individ-
ual outputs for all experiments performed. Since the MBDOE procedure designed
measurements in parallel rather than in succession, the reduction was evaluated with
all new measurements considered. As shown, several of the input reagents proved
capable of resolving the dynamical uncertainty in the model. Most notably, the LCK
inhibitor reduced the variance in all eight model outputs by at least 50% and by
over 70% in all except FOXP3 using four measurements. Among the other cases,
the amount of reduction varied more widely, ranging between 0 and 90% of initial
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variance (median: 58%) and requiring between three and six measurements. Of the
eight available outputs, only mTORC1, NFκB, AP-1 and FOXP3 were measured at
least once with FOXP3 being the most frequently sampled species.
The reduction in dynamical uncertainty did not necessarily correlate with a res-
olution of the parameter estimates. Figure 6.4D shows the half-maximal inhibitory
concentration (i.e., IC50) and Hill coefficient for the six inhibitory input reagents:
AEB071 (PKCθ inhibitor), CsA (calcineurin inhibitor), iLck (LCK inhibitor), Ra-
pamycin (mTOR inhibitor), U0126 (MEK1/2 inhibitor) and Wortmannin (PI3K in-
hibitor). While these parameter estimates generally experienced varying degrees of re-
finement as a consequence of the data collection, many of them remain quite “sloppy,”
with some uncertainty regions still spanning multiple orders of magnitude. Even so,
by employing intelligently-designed experiments to increase the predictive certainty
of the model, any implementation of MPC based on this model is now more likely to
be successful, despite residual sloppiness in the parameters.
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Table: MBDOE-designed experiments to reduce dynamical uncertainty in the model output states.
Scenario Applied Inputs Input Magnitudes Input Times (min) Measured Outputs Measurement Times (min) Figure
Baseline [αCD3, αCD28] [5, 5] [0, 0] [P–mTORC1, NFκB, NFκB, P–AP-1, FOXP3, P–AP-1] [15, 25, 40, 40, 60, 60] 4B, S4
AEB071 [αCD3, αCD28, AEB071] [5, 5, 0.046] [0, 0, 5] [P–AP-1, NFκB, NFκB, FOXP3] [10, 25, 40, 50] S5
CsA [αCD3, αCD28, CsA] [5, 5, 0.01] [0, 0, 5] [FOXP3, FOXP3, FOXP3] [10, 25, 60] S6
iLck [αCD3, αCD28, iLck] [5, 5, 0.215] [0, 0, 5] [FOXP3, NFκB, P–AP-1, FOXP3] [25, 35, 35, 40] S7
PMA [αCD3, αCD28, PMA] [5, 5, 100] [0, 0, 5] [NFκB, NFκB, P–AP-1] [25, 35, 60] S8
Rapamycin [αCD3, αCD28, Rapamycin] [5, 5, 0.022] [0, 0, 5] [FOXP3, P–AP-1, NFκB, NFκB, FOXP3] [15, 20, 20, 35, 45] S9
U0126 [αCD3, αCD28, U0126] [5, 5, 4.642] [0, 0, 5] [P–mTORC1, P–AP-1, FOXP3, NFκB, FOXP3, FOXP3] [10, 10, 15, 25, 40, 60] S10
Wortmannin [αCD3, αCD28, Wortmannin] [5, 5, 1] [0, 0, 5] [NFκB, FOXP3, NFκB, FOXP3] [20, 25, 35, 50] S11





Fig. 6.4.: Resolving dynamical uncertainty through MBDOE. (A) MBDOE-designed
experiments to resolve dynamical uncertainty in the model outputs in response to
various inputs. (B) Illustrative results from a designed experiment. Experimental
measurements and simulated dynamics are from the designed “Baseline” experiment
to resolve base model parameters without additional inputs (baseline stimulation: 5
µg/mL anti-human CD3 + 5 µg/mL anti-human CD28). The ranges of acceptable
model simulations before and after all proposed measurements have been gathered
are denoted by the gray- and blue-shaded regions, respectively. Error bars show
data mean ± standard deviation for 2× 104 cells from a single experiment (i.e., n =
1). (C) Reduction in maximum dynamical variance (normalized by maximum initial
variance) in each output after all designed experiments have been performed and
proposed measurements gathered. For reference, the observed variance reduction in
(B) are reported in the “Baseline” group; data for the other groups are shown in the
supporting figures. (D) Projection of the acceptable parameter space onto the several
PK/PD parameters axes before and after performing the designed experiments (color
code: gray = screened parameters; blue = acceptable parameters after initial model
calibration; magenta = acceptable parameters following application of MBDOE).
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6.4.5 Model Predictive Control to Modulate T Cell Activation Toward
Differentiation
The effectiveness of the MBDOE strategy was assessed by employing the re-
sultant models to design a series of input dosing schedules to direct the signaling
pathways toward biologically-relevant endpoints, in particular with respect to Th and
Treg differentiation and activation status. Specifically, we selected Treg activation and
development, Th activation and development, and anergy as the biological targets for
the control strategies (listed in Figure 6.2B). A cursory analysis of the input sensitiv-
ity of the model (Figure 6.2E) indicated that none of the available input reagents were
able to regulate the outputs independently of one another, but the target responses
may still be achievable through the application of multiple inputs in combination.
For example, FOXP3+ Tregs could be achieved through application of the inhibitors
wortmannin or rapamycin, and IL–2-producing Th cells achieved through PMA, ion-
omycin, or a combination of both. The PKC inhibitor AEB071 demonstrated great
promise for achieving the third target, T cell anergy. Based on this analysis, we
selected PMA, ionomycin, AEB071 and rapamycin as input reagents to potentially
induce the desired output responses when used separately or in combination.
Because IL-2 is a secreted cytokine and generally requires several hours to generate
a measurable signal, we required a more immediate signaling mechanism to act as a
predictive surrogate for IL-2. Herein, we employed intracellular calcium, AP-1 and
NFκB in such a role as their signaling profiles are positively correlated with that of
IL-2 secretion [24].
To investigate the usefulness of MBDOE in facilitating the application of MPC,
two prediction model banks were formulated: one comprised of model parameter sce-
narios initially calibrated using the originally available datasets (AWMMPC only),
and the other comprised of parameters scenarios additionally tuned through the MB-
DOE strategy (AWMMPC+MBDOE). In both cases, the model bank was populated
by selecting the single best-fitting model parameter scenario for each of the four se-
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lected input reagents. Thus, the prediction model bank for each case contained four
parameter scenarios, where each parameter scenario was fitted considering only the
data involving a single input reagent and within each case’s respective datasets (i.e.
initial dataset vs. initial dataset + MBDOE generated data).
Figure 6.5 shows the results from one of the controller-designed experiments. In
this scenario, the control strategy attempted to drive the T cell signaling profile to
resemble one of activated Treg cells, specifically, high FOXP3 signaling and IL-2 sup-
pression. In terms of the IL-2 surrogates, this equates to depressed NFκB signaling
while calcium mobilization and AP-1 activation remain high. Panels A and B show
the controller-derived input dose schedules and adaptive model weights for the con-
trol strategies unaided (AWMMPC only) and aided (AWMMPC+MBDOE) by addi-
tional MBDOE-based model tuning, respectively. For this scenario, both strategies
prescribed some combination of ionomycin and rapamycin, albeit in varying concen-
trations, as the primary mechanism of action. The main distinction between the two
strategies is the increased reliance of AWMMPC+MBDOE on the mTOR inhibitor
rapamycin (Panel B). This is indicated by the higher model weights associated with
the model parameter scenario tuned to the effects of rapamycin (MRapa, right panel)
and a corresponding increased application of rapamycin doses (left panel). The control
actions involving the other input reagents were adjusted accordingly by the control
algorithm.
Figure 6.5C shows the experimental measurements following the in vitro imple-
mentation of the prescribed input dosing schedules. These data indicated that in
both cases intracellular calcium mobilization and FOXP3 signaling increased as a re-
sult of the application of ionomycin and rapamycin, while NFκB and AP-1 signaling
decreased relative to that induced by baseline stimulation (defined as 5 µg/mL αCD3
+ 5 µg/mL αCD28). Whereas intracellular calcium, NFκB and FOXP3 signals were
improved by the application of the control actions, the signals for AP-1 actually re-
ceded slightly from their target value. These are, of course, relative to the baseline
signal and still represent signals elevated from resting levels.
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The ability for each strategy to achieve the desired outcome was evaluated using
the reduction in relative target error (see Section 6.5.8 for calculation). Figure 6.5D
shows the target errors relative to the case of baseline stimulation for each combination
of controller and target. For the current scenario (top panel), the application of
AWMMPC improved the target performance by nearly 30% relative to the baseline
case; the application of MBDOE-based model tuning further improved the control
performance by an additional 20%. These trends were repeated by the other two
scenarios as well (Figures C.13 and C.14). These results confirm the ability of this
MBDOE strategy to improve open-loop control to successful mitigate the degradation
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Scenario 1: Treg cells
(low IL-2, high FOXP3)
Scenario 2: T cell anergy
(low IL-2, low FOXP3)
Scenario 3: Th cells
(high IL-2, low FOXP3)
AWMMPC+MBDOE (models with initial calibration and additional tuning via MBDOE)





Fig. 6.5.: Open-loop control of T cell signaling improved through MBDOE-based
model tuning. Controller-designed experiment to induce a Treg-like signaling profile
(target scenario 1). Controller-designed input reagent dosing schedules and adaptive
model weights (left and right panels, respectively) for the two cases: (A) AWMMPC
based on initially calibrated models only (AWMMPC only) and (B) AWMMPC with
additional tuning through MBDOE (AWMMPC+MBDOE). (C) In vitro measure-
ments of intracellular calcium, AP-1, NFκB and FOXP3 at 60 minutes following
application of the input schedules specified in (A) and (B). Relative fluorescence
measured using multi-channel flow cytometry (see Methods for details). Resting: no
stimulation; Baseline stimulation: 5 µg/mL αCD3 + 5 µg/mL αCD28; AWMMPC
only: baseline stimulation + input schedule from (A); AWMMPC+MBDOE: baseline
stimulation + input schedule from (B). Black arrows denote the means of the baseline
responses and red arrows denote the target regions for the controllers. (D) Control
performances for the three prescribed target scenarios, quantified as the percent re-
duction in target error relative to the baseline response (i.e. black arrows in (C)).
Bars denote the mean value of five independent experiments and error bars denote the
corresponding standard deviations. The asterisk (*) denotes statistical significance
between groups (p ≤ 0.05).
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6.4.6 Conclusion
Modern control theory is increasingly utilized in a wide variety of biomedical
applications ranging a variety of fields including bioreactor cell culturing [36, 37],
circadian rhythm entrainment [45], diabetes monitoring [39, 40] and general anes-
thesia [43, 44], but has seen limited application to intracellular signal transduction
systems. This is primarily due to the large degree of uncertainty in the pathway
details and their respective mathematical models. Furthermore, there routinely ex-
ist practical limitations on controller implementation that are not commonly present
in chemical, mechanical and electrical systems. For instance, most applications rely
upon computer-based feedback control: a computer in the loop uses system mea-
surements to inform control decisions. While closed-loop control is known to be
more robust to disturbances and uncertainty, its utility is often limited by the scale,
complexity and velocity of intracellular signaling events and inadequacy of real-time
measurement assays. In these cases, the control strategy would rely solely upon prior
information gleaned from preexisting experimental data and design the experiments
in advance without measurements to inform future steps. Techniques to control such
systems rely on predictive mathematical models to help determine appropriate sys-
tem perturbations (or control actions) to direct complex biological phenomena. Such
models serve to encapsulate our current understanding of the biological system, can
indicate gaps in that understanding, and provide the basis for the rational design
of experiments and clinical intervention. The objective of this work is to develop a
method to systematically and optimally combine prior experimental information with
the predictive capacity of multiple mathematical models and parameter scenarios to
effectively drive the dynamics of critical signaling molecules control the short- and
long-term behaviors of T cells.
Thus, we have developed a practical framework for efficiently calibrating math-
ematical models and integrating their collective predictions to generate predictable
open-loop dynamical responses in highly uncertain cell systems. First, we employed a
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systematic computational strategy to efficiently design laboratory experiments to re-
solve the uncertainty in the system dynamics. Representatives of the remaining data-
consistent parameter scenarios were then used to inform an adaptive multi-scenario-
based control strategy to realize biologically important endpoints. The embedded
model weight maps enabled the controller to estimate the likelihood of each model
in any feasible control scenario based on prior training data. The adaptive weighting
strategy allowed the controller to purposefully select subsets of the training data so
that control decisions were made considering only the most relevant information at
each time interval. Our open-loop controller design pairs model predictive control
with an adaptive model weighting system based in information theory to create a
cohesive strategy for systematically utilizing the most relevant knowledge embedded
within limited training data in a computationally tractable manner. In laboratory
experiments, the coupling of MBDOE with AWMMPC successfully reduced the open-
loop target error by up to 70% relative to baseline cases and improved performance
by up to four times better when compared with AWMMPC on its own.
As more information is gathered on complex pathologies and diseases, we expect
that advanced computational methods and control theory will take on increasingly
important roles in the design of treatments aimed at restoring health. We anticipate
that control engineering will become a tool for designing therapies directed at regu-
lating pathological cellular processes such as cancer and autoimmune disorders. The
combined power of control theory and synthetic biology will provide a new research
platform for understanding and treating diseases at the cellular level through planned
gene expression and signaling pathway manipulations. This study provided an ex-
perimentally corroborated control methodology that utilizes the knowledge encoded
within multiple mathematical models and parameter scenarios on signal transduc-
tion pathways to effectively design experimental perturbations that direct the cell
response in a desired manner. Strategies that enable the predictable manipulation of
T cell behavior via intracellular signaling pathways will help advance best practices
in model-based control applications for medicine.
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6.5 Materials and Methods
6.5.1 Modeling and Simulation
All algorithms and simulations were generated in MATLAB R2015a (The Math-
Works, Inc., Natick, Massachusetts, United States). Simulations of the ODE model
were performed using the built-in ode15s numerical integration function.
6.5.2 Mathematical Definition of the Model
The model considered in this work was developed as a system of nonlinear ordinary
differential equations (ODEs), defined generally as
M (i) =
ẋ





where the states, inputs, parameters and measured outputs are x ∈ Rnx , u ∈ Rnu , θ ∈
Ω ∈ Rnθ and y ∈ Rny , respectively. The functions f : Rnx×Rnu → Rnx and g : Rnx →
Rny are twice continuously differentiable functions representing the system dynamics
and measured outputs, respectively. Throughout this work, a subscript index is used
to denote a location within the referenced vector, whereas a superscript is used denote
an independent sample (or scenario or variant) of the referenced variable, for example,
to track multiple model parameter scenarios. Unless necessary for readability, these
indices may be excluded to simplify the notation.
6.5.3 Parameter Sensitivity Analysis
The Elementary Effects (EE) method, originally proposed by Morris [91] and
enhanced by Campolongo et al. [92], was used to determine which parameters are
categorized as negligible, linear and additive, nonlinear, or involved interactions with
other parameters. The method relies on a repetition of individually randomized one-
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at-a-time (OAT) experiments to determine the elementary effects in the parameter
region on interest (ΩSA). For a given sample from ΩSA (θ
(j)), the elementary effect
of the ith parameter is defined as
di(θ
(j)) =
y(θ(j) + ei∆)− y(θ(j))
∆
, (6.2)
where ∆ is the perturbation factor, ei is a vector of zeros with a unit at its i
th
component, and θ(j) = {θ1, θ2, ..., θnθ} is any selected sample in ΩSA such that the
transformed point (θ + ei∆) remains in ΩSA for each index i = 1, ..., nθ. The finite
distribution of elementary effects associated with the ith parameter is obtained by
randomly sampling different θ from ΩSA and is denoted by Fi, i.e. di(θ
(j)) ∼ Fi.
These elementary effects are averaged over a number of samples from Fi to reflect
the mean sensitivity over ΩSA. The sensitivity measure Si of an output y with respect








(j)) is the elementary effect of the ith parameter at the jth sample and r is
the total number of samples (r = 1000 herein). To estimate the sensitivity indices
efficiently, Morris suggests sampling r elementary effects from each Fi via an efficient
design that constructs r trajectories of (nθ + 1) points in the parameter space, each
providing nθ elementary effects, one per parameter. Thus, the computational cost of
the experiment is r(nθ + 1) model evaluations. The sensitivity indices are normalized
to ensure that the use of different units does not affect the sensitivity analysis results.
Perturbation factor values, sampling strategies, and normalization procedures were
selected in accordance with the propositions by Campolongo et al. [92].
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6.5.4 Definition of Parameter Acceptability
The quality of a given parameter vector in reproducing available experimental








with eti = C(ti)[y(ti)− ŷ(ti)], (6.4)
where eti is the error at each sample time point, Wti is the inverse of the measurement
error covariance matrix at time ti, y(ti) and ŷ(ti) are the simulated model outputs
and the mean values of the available data at time ti, respectively, C(ti) is a binary
matrix that indicates which outputs are measured at time ti, and Ns is the total
number of sampled time points. This cost function is computed in log space in
order to compress and smooth the function, making its approximation with sparse-
grid interpolation more effective. The ‘1’ in the cost function is added to avoid the
singularity of log at zero.
We categorized a parameter vector as acceptable if the corresponding objective
function value was less than a predetermined acceptability threshold (TA). The ac-
ceptability region of the objective function was defined as






 = log10(1 + α2Nst), (6.5)
where the variance for each measurement is given by σ2i , α is assigned based on
how many standard deviations of the experimental data the dynamics should be
within (here α = 2, representing approximately the 95% confidence interval assuming
measurements are independently distributed), and Nst is the total number of unique
measurements taken (i.e. replicates are not counted). It follows that the set of
acceptable parameter vectors is defined as ΩA = {θ|ψ(θ) < TA, θ ∈ Ω}, where TA =
0.699.
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6.5.5 Selection of Representative Parameter Vectors
Discrete set proxies of the acceptable parameter space were generated using three
procedures. First, specific parameter values were extracted directly from literature
whenever possible. For those not found in literature, they were either derived using
known system conditions or constraints, or estimated from experimental data using
a combination of manual and automated calibration. In these cases, an initial search
hypercube spanning the sensitive parameters, the bounds of which were defined to
be an order of magnitude both above and below the nominal parameter value. Next,
Equation 6.4 was evaluated for 1×105 Latin Hypercube Samples in the log parameter
search hypercube. This procedure of automated parameter identification was aided
by the use of sparse-grid interpolation, a powerful tool for generating fast-evaluating
approximations of mathematical models [94]. The LHS samples on the sparse grid
that satisfied the acceptability threshold defined in Equation 6.5 were combined to
form the discrete representation of ΩA. To promote computational tractability, the
density of ΩA was reduced to a small subset of strategically-placed representative
parameters. The process of selecting representative parameters via dynamics-based
clustering is detailed in [93].
6.5.6 Model-Based Design of Experiments (MBDOE)
As in Mdluli et al. [93], we defined an experiment (D) to be the combination of
a piecewise input sequence u(t) = {uj(t) : τj ≤ t ≤ τj+1, j = 1, 2, ..., nts} and set of
measurement pairs M = {(mk, tk) : k = 1, 2, ..., K} ∈ M, where mk and tk are the
measurement species and times, respectively. The optimal experiment to resolve the
target system dynamics, D∗ ∈ D, was defined to be one that maximized a measure of
the information gained from an experiment, or alternatively, minimized the posterior










max(var(x(T )(t, θ))|M), t ∈ [τi, τf ], θ ∈ ΩA, (6.7)
is the cumulative maximum variance across all states x(T ) in the target system, as-
suming the measurements M exist.
The ideal implementation of an algorithm to solve the above optimization problem
would solve for the optimal input vector and measurements simultaneously, however,
this would have been computationally intractable due to dimensionality. Therefore,
the algorithm was designed to first solve for the optimal input vector,
u∗ = argmin
uj∈Rnu
γ(u), j = 1, ..., nts , (6.8)
by minimizing the TDU at each iteration assuming the single best measurement is
taken. Once the optimal input vector u∗ is discovered, it is incorporated into the
target system. This allows the measurement selection process to use an optimally
perturbed system to maximize the information gained on the input/output relation-
ships, which is critical in the context of MPC. The target system then undergoes a
second optimization to determine the optimal measurement pairs M∗. When com-
bined, the optimal input vector and measurement pairs form D∗ from Equation 6.6.
6.5.7 Adaptively-Weighted Multiple Model Predictive Control Strategy
(AWMMPC)
The algorithm proposed by Perley et al. [54] (Chapter 4) was augmented to better
accommodate multi-input, multi-output (MIMO) systems. Central to the theory of
the method is a suitably-populated model prediction bank, M = {M (1), M (2), ...,
M (nM )}. Herein, four model parameter scenarios were selected for each model bank,
sampled from the acceptable parameter spaces discovered during initial parameter
identification (for AWMMPC) or after implementation of the MBDOE strategy (for
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AWMMPC+MBDOE). Each parameter scenario is representative of one of the dis-
tinct input reagents considered. Specifically, the representative parameter scenario
was selected to be the best-fitting scenario when considering only the data avail-
able to relevant case (i.e. AWMMPC vs. AWMMPC+MBDOE) and involving the
corresponding input reagent.
The models follow the general form shown in Equation 6.1, but are augmented by
z(i) = h(i)(x(i)), (6.9)
where z(i) ∈ Rnz denotes the controlled outputs (herein, intracellular calcium, AP-1,
NFκB and FOXP3) of the ith model and h : Rnx → Rnz is a twice continuously
differentiable function transforming the model states to the controlled outputs.
Controller performance was quantified with an objective function that penalizes
the error between the predicted outputs for the ith model and the reference trajectories
over the prediction horizon Hp and a measure of the control effort over the input
horizon Hu starting at time tk, as in
Φ
(i)
k = log10(1 + φ
(i)














1 (tk|u(t0, . . . , tk)), . . ., z
(i)
nz (tk+Hp |u(t0, . . . , tk+Hu−1))] and Sk =
[s1(tk), . . ., snz(tk+Hp)] are the predicted and reference outputs over Hp, respectively,
the vector Uk = [u1(tk|tk), . . ., unu(tk+Hu−1|tk)] is the discrete control input sequence
over Hu (herein, Hu = 1 and Hp = 2). Q and R are diagonal weighting matrices
(herein, both identity matrices) specifying the relative importance of each controlled
output to one another and the relative importance of target tracking and resource
economy to the overall controller performance, respectively. As with Equation 6.4, the
control objective is converted to log-space to smooth the cost surfaces and facilitate
optimization.
The objective functions for the candidate models are arranged into a multiobjec-
tive optimization problem to accommodate the use of adaptive weights. We define the
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multiobjective problem at the kth time interval as follows (with the standard Pareto
interpretation of minimizers):














k denotes the objective function of the i
th model defined by Equation
6.10 and the design variable Uk is constrained to Ωu defining biologically relevant
limits. Herein we employ the normalized normal constraint method (NNC) for gener-
ating the Pareto solutions Upk for its ability to generate a well-distributed set of global
Pareto points (refer to [95] for further details).
The optimal control sequence for the kth time interval is selected from the set of
Pareto solutions Upk by ranking them using the objective
U∗k = arg min
u∈Upk
Φ̄>k (u)W (u)Φ̄k(u), (6.12)
where Φ̄k(u) = [Φ̄
(1)
k (u), . . . , Φ̄
(nM )
k (u)]
> and W (u) = diag([ω(1)(u), . . . , ω(nM )(u)]>)
are vectors of objective function values and model weights, respectively, corresponding
to the control input vector u ∈ Upk .
We define the model weights on the bounded permissible input space Ωu for the







where ∆(i) = AICc(i)(u)−min([AICc(1)(u), ..., AICc(nM )(u)]), which are based on the
corrected-Akaike Information Criterion (AICc) [96]. The weight ω(i)(u) is interpreted
as the strength of evidence in support, or relative probability, of the ith model being
the Kullback-Leibler best model from the set of models given the supporting data [96].
The models weights are adapted as in [54] (Chapter 4) to accommodate the most
relevant experimental data to ensure the best possible open-loop performance.
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6.5.8 Evaluation of Controller Performance
Control performance was measured by how much closer (than the baseline case)
each control strategy was able to drive the measured outputs to the desire target
values at the chosen time point. This is called the reduction in target error and was
presented as a percent of the target error in the baseline case. To calculate the metric,
we first computed the target errors for five independent experiments as the square




(ȳi − si)2 (6.14)
where ȳi and si are the measured mean and target value, respectively, for the i
th
of ny output species in the j
th experiment (see Table C.2, upper block, for values).
The target error value for each replicate was then normalized by the values from
the baseline experiment that was performed simultaneously with cells from the same
batch to account for differences among cell passages. This also provides target error
as a fraction of the error resulting in the baseline case. Error values were subtracted
from one then multiplied by ‘100’ to indicate the reduction in target error (relative
to the baseline case) as a percent (see Table C.2, lower block, for values).
6.5.9 Input Reagents
Inhibitors selectively targeting the pathways considered in this study were 7-
Cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3d]pyrimidin-4-ylamine (Lck inhibitor;
Sigma Aldrich, #C8863), AEB071/Sotrastaurin (PKCθ inhibitor; Selleck Chemicals,
#S2791), Cyclosporin A (calcineurin inhibitor; Cell Signaling Technology, #9973S),
Ionomycin (Sigma Aldrich, #I0634), PMA (Sigma Aldrich, #P1585), Rapamycin
(mTOR inhibitor; Cell Signaling Technology, #9904S), U0126 (Mek1/2 inhibitor;
Cell Signaling Technology, #9903S) and Wortmannin (PI3K inhibitor; Cell Signaling
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Technology, #9951S). All compounds were dissolved in 100% DMSO. Maximal and
final concentration of DMSO used in the culture assays was 0.1% v/v.
6.5.10 Cell Culture
Jurkat cells (clone E6-1, ATCC TIB-152) were cultured in RPMI 1640 Medium
(Gibco, #A10491-01) supplemented with 7.5% heat-inactivated fetal bovine serum
(JR Scientific, #43640-100), 50 µM 2-Mercaptoethanol (Bio-Rad, #161-0710), 50
µg/mL streptomycin and 50 units/mL penicillin (JR Scientific, Inc, #20001-100) in
an incubator at 37◦C in humidified air containing 5% carbon dioxide.
On the day of an experiment, cells in log-phase growth aliquoted into treatments
at a density of 2 × 107 cells per treatment. Each treatment was stimulated using
anti-human CD3 (clone: UCHT-1, eBioscience, #14-0038), anti-human CD28 (clone:
CD28.2, eBioscience, #14-0289), or combinations thereof, at 37◦C in a water bath.
The cells were then treated with the indicated inhibitor, dissolved in DMSO, at the
indicated time points and concentrations. The control group was treated with the
same amount of DMSO. Samples of 2×106 cells were harvested at the indicated time
points and stored on ice for immediate processing for flow cytometric analysis.
6.5.11 Antibodies
Phosphoproteins were stained for flow cytometric analysis using the following anti-
bodies: PE-CF594 mouse anti-ERK1/2 (pT202/pY204) (BD Biosciences, #562644),
PE mouse anti-Akt (pT308) (BD Biosciences, #558275), Alexa Fluor 647 mouse anti-
mTOR (pS2448) (BD Biosciences, #564242), and rabbit anti-human PKCθ (pT538)
(Life Technologies, #700043) with Alexa Fluor 647 goat anti-rabbit IgG (H+L) sec-
ondary antibody (Life Technologies, #A-21245).
Transcription factors were stained using the following antibodies: PE-CF594
mouse anti-human FOXP3 (BD Biosciences, #562421), PE rabbit anti-c-Jun (pS73)
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(Cell Signaling Technology, #8752S), and Alexa Fluor 647 rabbit anti-NFκB p65
(pS536) (Cell Signaling Technology, #4887S).
Calcium signaling was monitored using Calcium Sensor Dye eFluor 514 (eBio-
science, #65-0859-70).
6.5.12 Staining and Flow Cytometric Analysis of Intracellular Phospho-
proteins in Human PBMCs/Cell Lines
Harvested cells were transferred in 100 µL aliquots at a density of 1-10×106
cells/mL into a 96-well plate. Cells were washed twice with sodium azide- and protein-
free 1X PBS using centrifugation at 600g for 5-8 minutes to pellet the cells. Following
the last wash, the cells were stained with 100 µL of the Fixable Viability Stain 520
(BD Biosciences, #564407) working solution, thoroughly mixed, and incubated pro-
tected from light for 30 minutes at 4◦C. The cells were then washed twice with Stain
Buffer (FBS) (BD Biosciences, #554656), again using centrifugation at 600g for 5-8
minutes to pellet the cells. Immediately following the final wash, the cells were fixed
by adding an equal volume of pre-warmed Fixation Buffer (BD Biosciences, #554655),
thoroughly mixed, and incubated in the dark at 37◦C for 10-12 minutes. Following
removal of the fixation buffer, the cell was disrupted by vortexing and permeabilized
by adding 100 µL of ice-cold Perm Buffer III (BD Biosciences, #558050), thoroughly
mixed, and incubated for 30 minutes on ice. After the cells were washed twice with
Stain Buffer, the recommended volume of fluorochrome-conjugated antibody cocktail
was added to each well, thoroughly mixed, and incubated at room temperature for
60 minutes protected from light. The cells were then washed twice more with Stain
Buffer, resuspended in approximately 200 µL of Stain Buffer, and analyzed using a
Beckman Coulter FC500 flow cytometer.
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6.5.13 Staining and Flow Cytometric Analysis of Transcription Factors
in Human PBMCs/Cell Lines
Harvested cells were aliquoted and stained with Fixable Viability Stain 520 as
in the previous section. Following the last wash, the cells were resuspended in 200
µL of freshly prepared 1X Fix/Perm Buffer working solution from the Transcription
Factor Buffer Set (BD Biosciences, #562574), thoroughly mixed, and incubated 4◦C
for 40-50 minutes protected from light. Following removal of the Fix/Perm buffer by
centrifugation at 350g and at 4◦C for 6 minutes, the cells were washed twice in 200
µL Perm/Wash Buffer, again using centrifugation to pellet the cells. On the final
pellet, 80-100 µL of 1X Perm/Wash Buffer and the fluorescent antibodies specific for
intracellular proteins were added to each well. The plate was thoroughly mixed and
incubated at 4◦C for 40-50 minutes protected from light. The cells were then washed
twice more with Perm/Wash Buffer, resuspended in approximately 200 µL of Stain
Buffer, and analyzed using a Beckman Coulter FC500 flow cytometer.
6.5.14 Staining and Flow Cytometric Analysis of Calcium Flux
Jurkat cells were harvested, washed and loaded with Calcium Sensor Dye eFluor
514 (eBioscience, #65-0859-70) for 30 minutes at 37◦C. Continuous measurements
were acquired on a Beckman Coulter FC500 flow cytometer. The addition of stimuli
and/or inhibitors during continuous acquisition was achieved by quickly removing the
cells from the flow cytometer, performing the necessary adjustments, and immediately
placing the cells back on the flow cytometer for continued acquisition.
6.5.15 Statistical Analysis
All statistical analyses were performed using MATLAB R2015a (The MathWorks,
Inc., Natick, Massachusetts, United States). Time-course data are shown as mean ±
standard deviation at each time point. Statistical differences between groups (p≤0.05)
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are determined using one-way analysis of variance (ANOVA) followed by the Tukey
multiple comparisons test. Target performance values were log-transformed where
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7. CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE WORK
This chapter summarizes the major results of this thesis, discusses the broader impact
of the work, and provides recommendations for future work.
7.1 Conclusions
CD4+ T cell activation plays an important role in the adaptive cell-mediated im-
mune response and its aberrant regulation leads to inflammatory diseases and cancer.
The ability to predictably manipulate T cell behavior is thus critical for successfully
translating benchtop experiments into clinical therapies to reduce patient morbid-
ity and mortality. The aim of this work is establish a control-theoretic approach,
supported by experimental evidence, to facilitate the design of experimental strate-
gies to predictably manipulate T cell behavior via intracellular signaling pathways.
A successful strategy could improve how we study biological processes and generate
effective clinical therapies to treat T cell-related pathologies.
The control of biological processes is uniquely hindered by the complexities of
cell function and the limitations of experimental practice, such as the lack of rapid
quantitative measurement assays to achieve real-time feedback. Thus, techniques
to control such systems increasingly rely on predictive mathematical models to help
determine appropriate pharmaceutical dosing schedules to elicit the desired response.
Such models serve to encapsulate our current understanding of biological systems,
can indicate gaps in that understanding, and have the potential to provide a basis for
the rational design of experiments, clinical interventions; however, these models are
often rough approximations of reality because the biological mechanisms are not well
understood and efforts to experimentally resolve model uncertainties are impeded by
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resource costs and a dearth of feasible inputs and measurements. This work presents a
progressive development of model-based control strategies addressing these issues with
increasingly realistic scenarios requiring more robust controllers, and culminating into
an integrated approach to the predictive modeling and manipulation of intracellular
signaling dynamics in CD4+ T cells. The presented methodology specifically addresses
the integration of multiple prediction models into a control-theoretic framework to
improve the effectiveness and robustness of open-loop control actions.
In Chapter 2, the groundwork for the effective use of multiple prediction models
within a control-theoretic framework was laid. The main issue concerning the use of
multiple prediction models in a controller design is the selection of the compromise
control solution from multiple competing sources of information. This competition
arises from a variety of sources, such as discrepancies among the prediction models
in terms of topology and scale. Prediction models with varying network topologies
required a transformation of the state space in order to achieve outputs that are
commensurate with one another. These adjustments could also include temporal
scaling, state combinations and feature normalization. In this chapter, the first and
simplest strategy was proposed, which was to define the compromise control action
to be the optimal solution of the uniformly-weighted aggregate of the independent
cost manifolds. This method enable control of uncertain nonlinear systems by using
qualitative features to generate predictable dynamical responses. However, much
information about the predictive capacity of each model was lost by simply averaging
the cost surfaces to generate the compromise solution, necessitating the improvements
described in the following chapter.
Chapter 3 presents technical improvements to the methodology presented in the
previous chapter for the effective use of multiple prediction models within an open-
loop MPC framework. The improvements followed the revelation that models that
are equally consistent with existing data may not be all equal—that is, the predic-
tive accuracy of a model may have considerable variation depending on the planned
experiment and may not extrapolate well to novel scenarios. In open-loop, a high
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quality prediction model bank is paramount for successful control. To account for
model variability, an adaptive model weighting strategy was introduce. This process
was designed to account for the fact that models differ in their ability to accurately
reflect the system dynamics under different experimental conditions. Both simulated
and laboratory case studies confirmed that this approach was more effective at man-
aging model uncertainties and could successfully drive the Jurkat T cell system along
the desired trajectory when implemented in the laboratory.
That approach was extend in Chapter 4, which introduced the concept of the
model weight maps and the use of multiobjective optimization to facilitate model
weight adaptation. The purpose of the weight maps were to inform the controller of
the tendency for models to differ in their ability to accurately reproduce the system
dynamics under different experimental perturbations. These maps were constructed
using preexisting experimental data and reflected the changing model likelihoods
over the admissible control input space. Likelihoods in unsampled regions of the
design space were estimated through interpolation/extrapolation of the experimental
data. The control optimization problem was recast into a multiobjective framework
to facilitate model weight adaptation. This allowed the controller to have the most
updated estimates of the model weights when calculating the optimal compromise
control action. These approaches were shown to reduce lag in the open-loop control
input calculations and substantially improved target tracking in both simulated and
laboratory settings.
In Chapter 5, a mathematical model of early T cell signal transduction was de-
veloped and expanded to better characterize the larger events involved in T cell
activation, such as transcription factor nuclear localization and gene transcription.
This model focused on the expanding the early steps in TCR trafficking and sig-
nal amplification by kinases, phosphatases and other second messengers, as well as
CD28 coreceptor signaling and transcription of IL-2 and FOXP3. The model was
analyzed to investigate how signal intensity and feedback regulation affect TCR- and
coreceptor-mediated signal transduction and their downstream transcriptional pro-
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files to predict the outcome for a variety of stimulatory and knockdown experiments.
The ultimate objective was to develop a mathematical model to improve our under-
standing of the early signaling events involved in T cell activation leading to Th and
Treg differentiation, using IL-2 and FOXP3 transcription as biomarkers. The purpose
of this model and realized in Chapter 6, for which it was employed to facilitate the
design of experiments.
Chapter 6 represents the culmination of all previous modeling, analysis, and con-
trol techniques into a unified approach to design experimental strategies to predictably
and reliable direct intracellular signaling in CD4+ T cells. This approach has two
stages: (1) the resource-efficient calibration of a prediction model bank, and (2) the
scheduling of input reagent doses for predictable and reliable control of intracellular
signaling. In the first stage, the model was used to design optimal combinations of
inputs and measurements to improve the model’s ability to capture important in-
put/output behaviors that are critical to the successful implementation of MPC. In
the second stage, the calibrated models serve as the basis for a custom model pre-
dictive control strategy to derive input reagent dosing schedules to force the system
dynamics along prescribed trajectories. The main objective of this study was to
provide a practical—and experimentally corroborated—means for improving our un-
derstanding of intracellular signaling and utilizing the collective predictive capability
of multiple models to design robust control inputs that effectively direct CD4+ T cell
behavior without feedback.
This dissertation presents a comprehensive quantitative approach, founded on the
principles of Systems Biology, Information and Control theory, to facilitate the design
of experimental strategies to predictably manipulate intracellular signaling in CD4+ T
cells. The crux of this work is the effective use of information encoded in multiple
data-supported models to ensure robust control of the cellular process in spite of the
inherent limitations. The integrated model-based approach is expected to facilitate
the study of this class of systems, altering the design from comprehensive and ad
hoc experimental strategies to deliberate and effective ones. Furthermore, the robust
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control of CD4+ T cell signaling processes could yield alternative strategies for the
design of personalized therapies for autoimmunity, cancer and other immune-related
pathologies.
7.2 Future Work
Proposed ideas for future work cover two areas: (1) the further expansion of the
model for better resolution of the CD4+ T cell differentiation process, and (2) closing
the control loop to improve long-term control of CD4+ T cell differentiation.
7.2.1 CD4+ T Cell Differentiation Model
Naive CD4+ T cells undergo massive proliferation and differentiation into at least
four distinct helper T cell subsets after recognition of foreign antigenderived pep-
tides. Each subset expresses a distinct set of genes that encode a unique profile of
transcription factors and hallmark cytokines. The cytokine environment created by
activated CD4+ T cells and their neighbors during the course of differentiation is a
major determinant for the helper T cell fate.
The T cell model presented in this work captures the TCR- and CD28-mediated
intracellular signaling events leading to the activation of IL-2 and FOXP3, which
are necessary for Th and Treg cell differentiation. One aspect of differentiation not
capture by the model is the strong positive feedback required to sustain activation
for full differentiation, e.g. exogenous IL-2 and IL-2R-mediated signaling, and the
strong polarizing conditions that regulate each CD4+ T cell subset.
Th1 and Th2
The master regulatory factor T-bet and the cytokines interferon-γ (IFN-γ) and
IL-12 have central roles in Th1 differentiation. In developing Th1 cells, IL-2-driven
activation of STAT5 controls the binding of T-bet to the promoter of the gene Ifng,
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which promotes the production of IFN-γ and the positive feedback process through
which Th1 differentiation proceeds. IL-2 and STAT5 further promote the completion
of Th1 differentiation because it regulates induction of the IL-12 receptor, which has
a central role in both the induction of T-bet and the production of IFN-γ [1].
In vitro Th2 differentiation requires stimulation via the T cell antigen receptor
(TCR), IL-4-mediated activation of STAT6, which jointly induce the expression of
the master regulatory factor GATA-3, and endogenous IL-2. Another main determi-
nant of Th2 differentiation is the strength of signals generated by engagement of the
TCR. When naive CD4+ T cells receive strong TCR signals, prolonged and intense ac-
tivation of the ERK pathway results not only in the failure to upregulate TCR-driven
early expression of GATA-3 but also in transient inhibition of IL-2-mediated activa-
tion of STAT5, despite the abundant IL-2 production and IL-2R expression, which
stunts the early production of IL-4 and Th2 differentiation. In contrast, when naive
CD4+ T cells receive weak TCR signals, the degree of activation of the ERK pathway
is not strong enough to suppress TCR-driven early expression of GATA-3 or to block
STAT5 activation in response to small amounts of IL-2. This enables the cells to
generate early production of IL-4 and to undergo subsequent Th2 differentiation [1].
Th17 and Treg
TGF-β and IL-2 are essential for the differentiation of peripheral naive CD4+ T
cells into FOXP3+ cells with regulatory ability: iTregs . During early Th17 differentia-
tion phase, naive CD4+ T cells require a combination of the cytokines IL-6 and TGF-
β, as well as strong TCR signals and costimulation to induce the expression of RORγt
and Th17 cytokines. However, when naive CD4
+ T cells receive weak TCR signals
under Th17-polarizing conditions, the differentiation of FOXP3-expressing iTreg cells
is favored. This is because that even though weak TCR signals induce only small
amounts of IL-2 production and IL-2R expression, its subsequent activation of STAT5
blocks IL-17A production. This induces FOXP3 expression, which in turn suppresses
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the induction of RORγt in favor of iTreg differentiation. In contrast, despite abundant
IL-2 production and IL-2R expression, transient inhibition of STAT5 by strong TCR
signals fails to induce FOXP3 and instead allows the expression of genes encoding
RORγt and other Th17 cytokines [1].
Concluding Remark
Incorporation of these mechanisms into the model would enable us to design exper-
iments to direct the precise selection of a desire CD4+ T cell subset. Strategies that
achieve this would be very beneficial for treating pathologies related to an imbalance
among the various CD4+ T cell subsets.
7.2.2 Closing the Loop
The control methodology lends its well to be generalized for closed-loop formula-
tion. Although not able to capture the rapid dynamics of certain signaling molecules,
behaviors that evolve over longer time scales such as gene transcripts and biomarkers
of cell differentiation would benefit greatly. Closing the loop would enable system
output measurements to inform future model predictions and model weight estima-
tion as they are received. To effectively close the loop, three important considerations
must be address, which are: state estimation to reduce measurement noise, incorpo-
rating new measurements into the adaptive weighting strategy, and computational
efficiency. In theory, these procedures would allow the weights to characterize the
entire input space through explicit mappings (initially fixed) that evolve over time as
new data are observed and ensure that the control procedure is able to adjust for the
changing conditions of the experimental system.
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State Estimation Using Nonlinear Filtering
State measurement fidelity is critical for robust closed-loop controller performance.
Since biological systems are rife with process and measurement noise, nonlinear fil-
tering would be necessary to facilitate good state estimation based on measurement
feedback. The most popular recursive filtering techniques consist of two main steps:
x+(tk) = x
−(tk) +K(tk)(ŷ(tk)− y−(tk)). (7.1)
First, states (x−(tk)) are predicted using a dynamical model, then corrected with an
observation model (K(tk)(ŷ(tk)−y−(tk))) so that the error covariance are minimized.
The extended Kalman filter (EKF) is the simplest of these, but performance degrades
rapidly with increased nonlinearities and non-Gaussian errors. This is because the
error covariance is approximated by a Gaussian random variable and propagated
through linearization of the nonlinear system.
To facilitate nonlinear state estimation, we will use the unscented Kalman filter
(UKF) [2]. UKF addresses the problems of the EKF by propagating deterministically-
sampled points, based on the prior mean and covariance, through the nonlinear func-
tions representing the actual system. This technique has been shown to be far su-
perior in resolving the true posterior mean and covariance [2, 3]. In addition, UKF
is typically easier to implement because it eliminates the need to explicitly compute
Jacobians.
Model Adaptation with Measurement Feedback
Updates to the model weighting strategy are needed to take full advantage of the
newly acquired data. In the traditional sense, each point on the weight maps corre-
sponds to a set of inputs that was applied to the experimental system in the model
calibration stage of the process, from which time-course data would be collected.
These data would be compared against a simulation from each model with the same
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input conditions and the resulting AICc values converted to weights. Considered to-
gether, the ensemble of weights constituted a map by which the relative probability
of a given model could be estimated for any admissible control input. The iterative
nature of the closed loop formulation, where new data are added sequentially in time,
directly implies an iterative formulation for the model updating strategy. There are
two alternative methods that could be used to achieve model updating: 1) iterative
weight estimation and 2) iterative weight and parameter estimation.
To iterative update the model weights only, we would need to ensure that our
prediction model bank remains able to capture the dynamics of the system before
taking into account the new data. This would be done by determining how well the
model predictions track the target trajectories. If there are models with tracking error
below a specified threshold, then we could assume the target trajectories remain in
the reachable space and the prediction models are adequate. Next, we would update
the model weights. For some time instant tk, the optimal control inputs u
∗
k ∈ Ωu
would be implemented and the system outputs ŷ(u∗k, tk) observed. These data would
then compared to model simulations y(i)(u∗k, tk) generated under the same conditions
and compute new model probabilities.
The second method involves both weight and model parameter updates. As output
measurements are received, it may become necessary to update the prediction models
as there may be discrepancies among the model predictions and the actual system
response. For example, while checking for model tracking performance as described
above, we may find that there are no or relatively few models with adequate tracking
performance. In this case, we would need to consider alternative models. The next
model bank would be constructed by generating parameter scenarios consistent with
the new observations using sparse grid-based optimization. In this technique, sparse
grid interpolants act as surrogates for the control input-driven model dynamics over
the parameter space. The grids will be screened for acceptable parameter scenarios
(i.e. consistent within observation error), from which multi-start local optimization
is commenced. The resulting scenarios will then be clustered based on dynamics to
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reduce the final set of models. The model bank will be augmented by this set or
have some poorly tracking models replaced by it. Since some or all of the prediction
models are changing, we must adapt the model weight maps accordingly. This will
most likely require a complete recalculation of the maps.
Potential Risks
There are three primary risks here that could potentially be detrimental to con-
troller performance in closed-loop: state estimation error, computational expense and
slow data acquisition. State estimators typically have decent performance on fully-
and even mostly-observable systems. However, for high-dimensional systems with rel-
atively few observable states, even the best estimators can fail. Should this occur, we
could attempt a remedy by fixing certain non-observable states and thorough evalua-
tion of the procedures on simulated test cases. The iterative parameter identification
procedure is advantageous because it allows the controller to maintain a prediction
model bank with the most accurate possible representation of the actual system at
successive time points. However, online parameter identification is expected to be
very computationally expensive. Alternatively, iteratively updating the weights alone
should be far more efficient. Finally, slow data acquisition may cause time delays that
degrade controller performance. Experimental protocols should be optimized to em-
ploy rapid and automated data acquisition techniques (e.g. flow cytometry) rather
than tradition methods (e.g. Western blots) whenever possible. An alternative com-
putational approach may be to build scenario trees through model simulations to
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A. SUPPORTING INFORMATION: MULTIPLE




A.1.1 Control Reagent Dose Response Model
In this section we describe our modifications to the original mathematical models
in order to simulate the observed behaviors of the chosen reagents as a practical
means of control. To do this, we make several assumptions. First, we assume that each
control reagent dose is administered in bolus form, but the effect of the control reagent
is not instantaneous. After peak activity is reached, the control reagent is metabolized
and the concentration returns to zero after a considerable period of time. According

















where uj(k) is the administered concentration of the j
th control reagent at the kth
administration time point τj,i(k), and τj,r and τj,d are parameters characterizing the
response time and duration of action for the jth control reagent (Figure A.1A). The
Heaviside step function, denoted by 1+(·), ensures that control reagents are only
effective after administration. To characterize the effect of the control reagent con-
centration on the dynamics of the simulated system, we refer to Figure 4.1, which
shows a generalized diagram of the Erk activation cascade and the substrates upon



















































































Fig. A.1.: Illustration of control reagent dose response model. (A) Effective dose as
a function of time. (B) Effective parameter value as a function of time.
which is responsible for catalyzing the dephosphorylation of Erk. Therefore, the ad-
dition of sanguinarine serves to reduce the rate of this reaction. Likewise, U0126 is
an inhibitor of Mek, which catalyzes the phosphorylation of Erk. Thus, the addition
of U0126 serves to reduce this reaction rate. The hypothetical reagents aZAP and
iZAP have similar effects, but act on the targets of ZAP70 activity. These effects






where kj is the nominal value of the affected parameter and cj is a scaling factor used
to adjust the sensitivity of the reaction rate to the reagent concentration. The gener-
alized profile of kj,eff (t) is illustrated in Figure A.1B. The affected model equations,
parameters and their nominal values and associated scaling factors are presented in
Table A.1.
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Table A.1.: Model equations and parameters modified to simulate action of sanguinar-
ine and U0126.


















dt = 2k2[ppMek][Erk] + 2k1[ppErk]− k2 = 1.6667× 10
−5
k1[pErk]− k2[ppMek][pErk] c2 = 60
d[ppErk]
















1For the Zheng model, Erk* corresponds to activated Erk (i.e. [pErk] + [ppErk])
and k1 and k2 to parameters r18kr and r18kf , respectively.
2For the Lipniacki
model, k1 and k2 correspond to parameters e2 and e1, respectively.
3For the Klamt
model, Erk* corresponds to activated Erk (i.e. [pErk] + [ppErk]) and k1 and k2
are new parameters. Additional parameter τdx is multiplied to all reaction rates to
ensure that dynamics are on the same time scale as other models and pre-existing
experimental data.
Table A.2.: Model equations and parameters modified to simulate action of aZAP
and iZAP.
Model Parameters Nominal Values
Zheng
aZAP (r11kf) k1 = 7.8768× 10−8; c1 = 1;
iZAP (1/r11kf) k2 = 1/k1; c2 = 10;
Lipniacki
aZAP (ml) k1 = 2.5252× 10−5; c1 = 1;
iZAP (1/ml) k2 = 1/k1; c2 = 10;
Klamt
aZAP (kzap70) k1 = 1; c1 = 1;
iZAP (1/kzap70) k2 = 1; c2 = 1;
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A.1.2 Normalization of Output Trajectories for Comparison across Mod-
els
All model output trajectories were normalized with respect to the unperturbed
output trajectory (i.e. no input reagents given) according to the following:
ȳ
(i)
j (u, t) =
y
(i)















j (0, t)) − b
(i)
j is the gain
factor. These constants correspond to the initial value and the range of the unper-
turbed trajectory, respectively. The factors for all three models are provided in Table
A.3.























A.2 Supporting Figures for Materials and Methods (Section 4.8)
The following figures are supplementary to Materials and Methods (Section 4.8).
Figure A.2 accompanies Model Weight Maps (Section 4.8.5) and shows the weight
maps for all three prediction models based on the training data displayed in Figure
4.8. Figure A.3 accompanies Pareto Front Identification (Section 4.8.7) and provides
an intuitive geometric representation of the normalized normal constraint (NNC)
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Fig. A.3.: Illustration of the normalized normal constraint (NNC) method in a 2D
objective space.
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A.3 In Silico Experiments for Realistic Control Reagents
The following figures are the results of all simulated experiments. Each figure
corresponds to a different combination of the target output trajectory (i.e. where
(toff , pss) = {(8,0), (15,0), (22,0), (8,0.25), (15,0.25), (22,0.25), (8,0.5), (15,0.5),
(22,0.5), (30,1)}) and the plant or simulated experimental system (i.e. Model Z,
Model L and Model K). Each figure shows (A-E) the control input dosing schedules
for the matched and mismatched single-model controllers (SZ , SL and SK) and the
multiple-model controllers with fixed equal weights (Meq) and with adaptive Akaike
weights (Maw), (F) the Akaike weights for Maw, (G) the target trajectory (black) and
simulated plant responses controlled by SZ (blue), SL (green), SK (red), Meq (cyan)
and Maw (magenta), and (H) the target tracking performance as measured by squared
error.
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Fig. A.4.: Results for target (toff , pss) = (8,0) and plant Model Z: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.5.: Results for target (toff , pss) = (8,0) and plant Model L: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.6.: Results for target (toff , pss) = (8,0) and plant Model K: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.7.: Results for target (toff , pss) = (15,0) and plant Model Z: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.8.: Results for target (toff , pss) = (15,0) and plant Model L: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.9.: Results for target (toff , pss) = (15,0) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.10.: Results for target (toff , pss) = (22,0) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.11.: Results for target (toff , pss) = (22,0) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.12.: Results for target (toff , pss) = (22,0) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
209









































































*Matched model and plant
Akaike Weights (ω)




Fig. A.13.: Results for target (toff , pss) = (8,0.25) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.14.: Results for target (toff , pss) = (8,0.25) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.15.: Results for target (toff , pss) = (8,0.25) and plant Model K: (A-E) Con-
trol inputs, (F) Model weights, (G) plant simulations, and (H) target tracking per-
formance.
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Fig. A.16.: Results for target (toff , pss) = (15,0.25) and plant Model Z: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.17.: Results for target (toff , pss) = (15,0.25) and plant Model L: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.18.: Results for target (toff , pss) = (15,0.25) and plant Model K: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.19.: Results for target (toff , pss) = (22,0.25) and plant Model Z: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.20.: Results for target (toff , pss) = (22,0.25) and plant Model L: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.21.: Results for target (toff , pss) = (22,0.25) and plant Model K: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.22.: Results for target (toff , pss) = (8,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.23.: Results for target (toff , pss) = (8,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.24.: Results for target (toff , pss) = (8,0.5) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.25.: Results for target (toff , pss) = (15,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.26.: Results for target (toff , pss) = (15,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
216









































































*Matched model and plant
Akaike Weights (ω)




Fig. A.27.: Results for target (toff , pss) = (15,0.5) and plant Model K: (A-E) Con-
trol inputs, (F) Model weights, (G) plant simulations, and (H) target tracking per-
formance.









































































*Matched model and plant
Akaike Weights (ω)




Fig. A.28.: Results for target (toff , pss) = (22,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.29.: Results for target (toff , pss) = (22,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.30.: Results for target (toff , pss) = (8,0.5) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.31.: Results for target (toff , pss) = (30,1) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.32.: Results for target (toff , pss) = (30,1) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.33.: Results for target (toff , pss) = (30,1) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
A.4 In Silico Experiments for Hypothetical Control Reagents
The following figures are the results of all simulated experiments. Each figure
corresponds to a different combination of the target output trajectory (i.e. where
(toff , pss) = {(8,0), (15,0), (22,0) , (8,0.25), (15,0.25), (22,0.25), (8,0.5), (15,0.5),
(22,0.5), (30,1)}) and the plant or simulated experimental system (i.e. Model Z,
Model L and Model K). Each figure shows (A-E) the control input dosing schedules
for the matched and mismatched single-model controllers (SZ , SL and SK) and the
multiple-model controllers with fixed equal weights (Meq) and with adaptive Akaike
weights (Maw), (F) the Akaike weights for Maw, (G) the target trajectory (black) and
simulated plant responses controlled by SZ (blue), SL (green), SK (red), Meq (cyan)
and Maw (magenta), and (H) the target tracking performance as measured by squared
error.
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Fig. A.34.: Results for target (toff , pss) = (8,0) and plant Model Z: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.35.: Results for target (toff , pss) = (8,0) and plant Model L: (A-E) Control in-
puts, (F) Model weights, (G) plant simulations, and (H) target tracking performance.
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Fig. A.36.: Results for target (toff , pss) = (8,0) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.37.: Results for target (toff , pss) = (15,0) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
222



































































Plant Dynamics (L) Squared Error




Fig. A.38.: Results for target (toff , pss) = (15,0) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.39.: Results for target (toff , pss) = (15,0) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.40.: Results for target (toff , pss) = (22,0) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.41.: Results for target (toff , pss) = (22,0) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.42.: Results for target (toff , pss) = (22,0) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.43.: Results for target (toff , pss) = (8,0.25) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.44.: Results for target (toff , pss) = (8,0.25) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.45.: Results for target (toff , pss) = (8,0.25) and plant Model K: (A-E) Con-
trol inputs, (F) Model weights, (G) plant simulations, and (H) target tracking per-
formance.
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Fig. A.46.: Results for target (toff , pss) = (15,0.25) and plant Model Z: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.47.: Results for target (toff , pss) = (15,0.25) and plant Model L: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.48.: Results for target (toff , pss) = (15,0.25) and plant Model K: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.49.: Results for target (toff , pss) = (22,0.25) and plant Model Z: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.50.: Results for target (toff , pss) = (22,0.25) and plant Model L: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.51.: Results for target (toff , pss) = (22,0.25) and plant Model K: (A-E)
Control inputs, (F) Model weights, (G) plant simulations, and (H) target tracking
performance.
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Fig. A.52.: Results for target (toff , pss) = (8,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Fig. A.53.: Results for target (toff , pss) = (8,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Plant Dynamics (K) Squared Error




Fig. A.54.: Results for target (toff , pss) = (8,0.5) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Plant Dynamics (Z) Squared Error




Fig. A.55.: Results for target (toff , pss) = (15,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Plant Dynamics (L) Squared Error




Fig. A.56.: Results for target (toff , pss) = (15,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.



































































Plant Dynamics (K) Squared Error




Fig. A.57.: Results for target (toff , pss) = (15,0.5) and plant Model K: (A-E) Con-
trol inputs, (F) Model weights, (G) plant simulations, and (H) target tracking per-
formance.
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Plant Dynamics (Z) Squared Error




Fig. A.58.: Results for target (toff , pss) = (22,0.5) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.



































































Plant Dynamics (L) Squared Error




Fig. A.59.: Results for target (toff , pss) = (22,0.5) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Plant Dynamics (K) Squared Error




Fig. A.60.: Results for target (toff , pss) = (8,0.5) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.



































































Plant Dynamics (Z) Squared Error




Fig. A.61.: Results for target (toff , pss) = (30,1) and plant Model Z: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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Plant Dynamics (L) Squared Error




Fig. A.62.: Results for target (toff , pss) = (30,1) and plant Model L: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.



































































Plant Dynamics (K) Squared Error




Fig. A.63.: Results for target (toff , pss) = (30,1) and plant Model K: (A-E) Control
inputs, (F) Model weights, (G) plant simulations, and (H) target tracking perfor-
mance.
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A.5 In Vitro Experiments using Jurkat T Lymphocytes
This section summarizes the results for all of our in vitro experiments using Jurkat
cell. The single-model controllers based on Model Z (SZ), Model L (SL) and Model K
(SK), and the multiple-model control with adaptive weights (Maw) were tested using
three different target profiles: (toff , pss) = {(8,0), (15,0), (22,0)}. These targets
correspond to full termination after 8, 15 and 22 minutes, respectively. Potential
control input dosing times were 3, 8, 13, 18 and 23 minutes post-stimulation. The
inputs quantities determined by each controller for all targets and time points are
presented in Table A.4. Table A.5 shows the Akaike weights computed for Maw for
all targets and time points. Figure 4.6 in the main text shows the quantified Western
blot data for all experiments.
Table A.4.: Control reagent dosing schedules for in vitro experiments.
Controller Reagent (µM)
Dosing Time (min)







Sanguinarine 0 0 0 0 0
U0126 0.2 6.0 2.0 0.5 0.3
SL
Sanguinarine 0 0 1.0 0.6 0.7
U0126 1.4 3.2 0 0 0
SK
Sanguinarine 0 0 0 0 0
U0126 0.2 6.0 5.5 2.9 2.1
Maw
Sanguinarine 0 0 0.5 0 0.4







Sanguinarine 1.1 5.3 0 0 0
U0126 0 0 2.1 6.8 0.9
SL
Sanguinarine 0 0.6 0 2.7 1.2
U0126 0.1 0.2 2.1 0 0
SK
Sanguinarine 0 0.1 0 0 0
U0126 0 0 1.8 8.4 3.5
Maw
Sanguinarine 1.1 5.3 0 0 0







Sanguinarine 1.0 6.4 12.4 0 0
U0126 0 0 0 0.3 9.1
SL
Sanguinarine 0 0.4 0.7 0 0
U0126 0.1 0 0 0.8 0.5
SK
Sanguinarine 0 0.3 0.1 0 0
U0126 0 0 0 0.5 8.4
Maw
Sanguinarine 1.0 6.4 12.4 0 0
U0126 0 0 0 0.3 10.0
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Table A.5.: Akaike weights (ω) determined by Maw for in vitro experiments.
Prediction Dosing Time (min)





1 Z 1 – – – 0.04
L – – – – –





2 Z 1 1 0.06 0.01 –
L – – – – –





3 Z 1 1 1 1 –
L – – – – –
K – – – – 1
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B. SUPPORTING INFORMATION: RESOLVING EARLY
SIGNALING EVENTS IN T-CELL ACTIVATION
LEADING TO IL-2 AND FOXP3 TRANSCRIPTION
B.1 Model Equations
Table B.1 presents a comprehensive list of all species illustrated in Figure 5.1 that
were chosen to participate in the model. The list also includes the rate equation
(further defined in Table B.2), biological meaning, the initial and total quantities for
each state in units of molecules and the source (if applicable) providing these values
or used to compute them. Stars (∗) denote active forms.
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Table B.1.: Summary of model states.
State Rate Equation Biological Meaning Initial Total Source
TCRb RTCRlig −RTCRp −
RiTCRb
Ligand-bound TCR 0 2× 105 [1]
TCRp RTCRp −RiTCRp Phosphorylated TCR-ζ chain 0 2× 105 [1]
TCRi RiTCRb +RiTCRp +
RiTCRf −RTCRexo −
RTCRdeg
Internalized TCR 2× 104 2× 105 [1, 2]
TCRdeg RTCRdeg −RTCRsynth Degraded TCR 2× 104 2× 105 [1, 2]
Zapb R1 −R8 Protein tyrosine kinase Zap70 bound to the
phosphorylated TCR-ζ chain
0 9.3× 104 [1]
Zap* R8 −R9 Activated Zap70 (phosphorylated at Y493 in the
activation loop)
0 9.3× 104 [1]
Zapp R9 −R4 +R5 Doubly phosphorylated Zap70 (at Y493 and Y319) 9× 103 9.3× 104 [1]
SFKdp R2 −R3 −R4 −R20 Src family kinases (including Lck and Fyn) with
dephosphorylated inhibitory site (Y505 on Lck)
100 1× 105 [1]
SFKdp-Zapp R4 −R4a Dephosphorylated SFK bound to pY319 of Zap70 0 9.3× 104 [1]
SFKdpS59p R20 −R22 Dephosphorylated SFK phosphorylated at serine-59
by activated Erk
0 1× 105 [1]
SFK* R3 +R5 −R21 Free fully activated SFK 0 1× 105 [1]
SFK*-Zapp R4a −R5 Fully activated SFK bound to pY319 of Zap70 0 9.3× 104 [1]
SFK*S59p R21 +R22 Fully activated SFK phosphorylated at serine-59 by
activated Erk
0 1× 105 [1]
CD45p −R23 Positive regulatory role of transmembrane tyrosine
phosphatase CD45
1× 105 1× 105 [1]
CD45n* R23a Negative regulatory role of CD45 0 1× 105 [1]
Cbpp R6 −R7 Phosphorylated transmembrane scaffold protein Cbp
(also known as PAG)
50 5× 104 [1]
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State Rate Equation Biological Meaning Initial Total Source
Csk* R7 Membrane-localized protein tyrosine kinase Csk
recruited by Cbpp
2.5× 103 5× 104 [1]
SHP1* R10 Tyrosine phosphatase SHP1 recruited to the
membrane and activated
0 1× 106 [1]
LATp R11 −R12 −R19 Phosphorylated transmembrane protein LAT at
tyrosine residues
0 5× 104 [1]
SOSb R19 LATp-bound scaffold protein Grb2 and guanine
nucleotide exchange factor SOS
0 5× 104 [1]
PLCγp R12 Activated phospholipase Cγ and bound to LATp 0 5× 104 [1]
DAG R13 −R13a −R14 Diacylglycerol 0 1× 107 [1]
IP3 R13 −R13b Inositol 1,4,5-triphosphate 0 1× 107 [1]
RasGRP* R14 Activated Ras guanine nucleotide releasing protein
(RasGRP)
0 1× 105 [1]
RasGTP R15 Guanine triphosphate (GTP)-bound Ras protein 0 1× 107 [1]
Raf* R16 Phosphorylated and activated mitogen-activated
protein (MAP) kinase kinase kinase Raf
0 4× 104 [1]
Mek* R17 Phosphorylated and activated MAP kinase kinase
Mek
0 2× 107 [1]
Erk* R18 Phosphorylated and activated MAP kinase (MAPK)
Erk
2.0960× 106 2× 107 [1]
AP1* R26 Activated transcription factor activator protein 1 0 2× 107 Derived
Ca2+ R27 −R28 Cytoplasmic calcium ions released from intracellular
stores (endoplasmic reticulum)
3.011× 104 1× 108 [3]
CaM* R28 Calcium-binding protein calmodulin bound to
calcium
0 1× 106 Derived
CN* R29 Activated calcium-dependent serine-threonine
phosphatase calcineurin
0 1× 106 Derived
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State Rate Equation Biological Meaning Initial Total Source
NFATn R30 Dephosphorylated NFAT with unobstructed nuclear
localization signal
0 1× 106 Derived
CD28* R32 Ligand-bound and activated CD28 coreceptor 0 2× 105 Derived
PI3K* R33 Activated phosphoinositide 3-kinase related kinase
(PI3K)
0 1× 104 Derived
PIP3 R34 Phosphatidylinositol 3,4,5-trisphosphate 0 1× 107 Derived
PDK1* R35 Activated 3-phosphoinositide-dependent kinase-1
(PDK1)
0 1× 104 Derived
PKCθ* R36 +R14a Active protein kinase C-θ 0 1× 104 Derived
IKK* R37 Activated IκB kinase 0 1× 104 Derived
IκBαp R38 Phosphorylated IκB marked for proteasomal
degradation
0 1× 104 Derived
NFκBn R39 Nuclear NFκB 0 1× 104 Derived
AKT* R40 Activated serine-threonine kinase Akt, also known as
protein kinase B (PKB)
0 1× 104 Derived
TSC1-TSC2 −R41 GTPase-activating protein (GAP) consisting of
tuberous sclerosis complex 1 (TSC1) and TSC2
1× 104 1× 104 Derived
RhebGTP −R42 GTP-bound Ras homolog enriched in brain (Rheb)
GTPase
5× 103 1× 104 Derived
mTORC1* R43 Activated mammalian target of rapamycin (mTOR)
complex 1
0 1× 104 Derived
mTORC2* R44 Activated mTORC2 0 1× 104 Derived
PTEN* R45 Activated phosphatase and tensin homolog (PTEN) 1× 104 1× 104 Derived
IL2 R46 Interleukin-2, a cytokine marking T-cell activation 0 1× 104 Derived
FOXP3 R47 Forkhead box P3, regulator of regulatory T-cell
development and function
0 1× 104 Derived
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Table B.2 presents a comprehensive list of all reaction equations used to model
the biochemical reactions of this system (illustrated in Figure 5.1). These expressions
form the basis for the rate equations of the ODE-based model presented in Table
B.1. The list includes the reaction identifier, mathematical equation and biological
meaning for each reaction.
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Table B.2.: Summary of model equations.
Reaction Equation Biological Meaning
RTCRlig = kf,r00 ∗ TCRlig ∗ TCRf − kr,r00 ∗ TCRb Association/dissociation of ligand and TCR complex
RTCRp = (kf1,r0 ∗ (SFKact+ SFKactS59p) + kf2,r0 ∗





RiTCRf = kint ∗ TCRf Internalization of free TCR
RiTCRb = kint ∗ TCRb Internalization of ligand-bound TCR
RiTCRp = kint ∗ TCRp Internalization of phosphorylated TCR
RTCRexo = kexo ∗ TCRi Exocytosis of internalized TCR
RTCRdeg = kdeg ∗ TCRi Degradation of internalized TCR
RTCRsynth = ksynth ∗ TCRdeg Synthesis of new TCR
R1 = kf,r1 ∗ (2∗TCRp−Zapb−Zapact− (Zapp−Zapp0)−
SrcbactZapp− SrcdpZapp) ∗ Zap− kr,r1 ∗ Zapb
Association/dissociation of phosphorylated TCR
complex and Zap70
R2 = kf,r2 ∗ CD45p ∗ SFK − kr,r2 ∗ Cskact ∗ SFKdp SFK dephosphorylation by CD45 and
re-phosphorylation by Csk* at the inhibitory site (Y505
in Lck, Y528 in Fyn)
R3 = (kf,r3 ∗ (TCRb + TCRp)) ∗ SFKdp− (kr1,r3 ∗
SHP1act+ kr3,r3 ∗ CD45n + kr2,r3) ∗ SFKact
SFK phosphorylation at the activation loop (Y394 in
Lck, Y417 in Fyn) by autophosphorylation (or by
another kinase) and dephosphorylation by SHP1
R4 = kf,r4 ∗ (Zapp−Zapp0) ∗SFKdp− kr,r4 ∗SFKdpZapp Association/dissociation of Zapp and SFKdp
R4a = kf,r4 ∗ (Zapp−Zapp0) ∗SFKdp− kr,r4 ∗SFKdpZapp TCR-mediated phosphorylation of Zapp-bound SFKdp
R5 = kf,r5 ∗SFKactZapp−kr,r5 ∗SFKact∗(Zapp−Zapp0) Dissociation/association of activated SFK and Zapp
R6 = (kf1,r6 ∗ (SFKact+ SFKactS59p) + kf2,r6) ∗ Cbp−
kr,r6 ∗ CD45p ∗ Cbpp
Cbp phosphorylation by activated SFK (or other
kinases) and dephosphorylation by CD45
R7 = kf,r7 ∗ Cbpp ∗ Csk − kr,r7 ∗ Cskact Cbpp-mediated activation of Csk
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Reaction Equation Biological Meaning
R8 = (kf1,r8 ∗ (SFKact+ SFKactS59p) + kf2,r8 ∗
SFKactZapp) ∗ Zapb− (kr1,r8 ∗ SHP1act+ kr2,r8) ∗
Zapact
Zap70 phosphorylation at the activation loop (Y493) by
activated SFK (SFK* and SFK*-Zapp) and
dephosphorylation by PTPs including SHP1
R9 = (kf1,r9 ∗ (Zapact+ (Zapp−Zapo0) + SFKactZapp+
SFKdpZapp) + kf2,r9 ∗ (SFKact+ SFKactS59p) +
kf3,r9 ∗ SFKactZapp) ∗Zapact− (kr1,r9 ∗ SHP1act+
kr2,r9) ∗ (Zapp− Zapp0)
Additional Zap70 phosphorylation at Y319 by activated
SFK and Zap70 and dephosphorylation by PTPs
including SHP1
R10 = kf,r10 ∗ SFKact ∗ SHP1− kr,r10 ∗ SHP1act SHP1 activation (by SFK*) and deactivation
R11 = kf,r11 ∗ (Zapact+ (Zapp− Zapp0) + SFKactZapp+
SFKdpZapp) ∗ LAT − (kr1,r11 ∗ SHP1act+ kr2,r11) ∗
LATp
LAT phosphorylation by activated Zap70 and
dephosphorylation SHP1
R12 = kf,r12 ∗ LATp ∗ PLCg − kr,r12 ∗ PLCgp PLCγ phosphorylation by LATp
R13 = kf,r13 ∗ PLCgp ∗ PIP2 PLCγ-mediated hydrolysis of PIP2 to IP3 and DAG
R13a = kr,r13a ∗DAG Degradation of DAG
R13b = kr,r13b ∗ IP3 Degradation of IP3
R14 = kf,r14 ∗DAG ∗RasGRP − kr,r14 ∗RasGRPact DAG-mediated activation of RasGRP
R14a = kf,r14a ∗DAG ∗ PKCθ DAG-mediated activation of PKCθ
R15 = (kf1,r15 ∗RasGRPact+ kf2,r15 ∗ SOSb) ∗RasGDP −
kr,r15 ∗RasGTP
RasGRP- and Grb2SOS-mediated activation of Ras
R16 = kf,r16 ∗RasGTP ∗ (Raf)− kr,r16 ∗Rafp Ras-mediated activation of Raf
R17 = kf,r17 ∗Rafp ∗Mek − kr,r17 ∗Mekp Rafp-mediated activation of Mek
R18 = kf,r18 ∗Mekp ∗ Erk − kr,r18 ∗ (Erkp− Erkp0) Mekp-mediated activation of Erk
R19 = kf,r19 ∗ LATp ∗Grb2SOS − kr,r19 ∗ SOSb LATp-mediated association and activation of the
Grb2-SOS complex
R20 = kf,r20 ∗SFKdp∗(Erkp−Erkp0)−kr,r20 ∗SFKdpS59p Erkp-mediated phosphorylation of SFKdp at serine-59
R21 = kf,r21∗SFKact∗(Erkp−Erkp0)−kr,r21∗SFKactS59p Erkp-mediated phosphorylation of SFKact at serine-59
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Reaction Equation Biological Meaning
R22 = (kf,r3 ∗ (TCRb + TCRp)) ∗ SFKdpS59p− (kr1,r3 ∗
SHP1act+ kr3,r3 ∗ CD45n + kr2,r3) ∗ SFKactS59p
TCR-mediated activation and SHP1-mediated
deactivation of SFK-s59p
R23 = kf,r23 ∗ (TCRb+ TCRp) ∗ CD45p − kr,r23 ∗
(CD45tot − CD45p)
Positive regulatory role of CD45 and translocation
caused by receptor cluster formation
R23a = kf,r23a ∗ (SFKact+ SFKactZapp+ SFKactS59p) ∗
CD45n − kr,r23a ∗ (CD45tot − CD45n)
Negative regulatory role of CD45 and recruitment to
receptor cluster
R26 = kf,r26 ∗ (Erkp− Erkp0) ∗ PKCθact ∗AP1− kr,r26 ∗
AP1act
Erkp- and PKCθ-mediated activation of AP1
R27 = kf,r27 ∗ IP3 ∗ Cas − kr,r27 ∗ (Ca− Ca0) IP3-induced calcium release into the cytoplasm
R28 = kf,r28 ∗ (Ca− Ca0) ∗ CaM − kr,r28 ∗ CaMact Association/dissociation of calcium and calmodulin
R29 = kf,r29 ∗ CaMact ∗ CN − kr,r29 ∗ CNact Calmodulin-mediated activation of calcineurin
R30 = kf,r30 ∗ CNact ∗NFATp− kr,r30 ∗NFATn Calcineurin-mediated dephosphorylation and nuclear
translocation of NFAT
R32 = kf,r32 ∗ CD28lig ∗ CD28f − kr,r32 ∗ CD28act Association/dissociation of ligand and CD28
R33 = kf,r33 ∗ CD28act ∗ (Zapact+ (Zapp− Zapp0) +
SFKdpZapp+ SFKactZapp) ∗ PI3K − kr,r33 ∗
PI3Kact
PI3K activation by CD28 and Zap70 and deactivation
R34 = kf,r34 ∗ PI3Kact ∗ PIP2− (kr1,r34 ∗ PTENact+
kr2,r34) ∗ PIP3
PI3K-mediated phosphorylation of PIP2 and
PTEN-mediated dephosphorylation of PIP3
R35 = kf,r35 ∗ PIP3 ∗ PDK1− kr,r35 ∗ PDK1act PIP3-mediated activation of PDK1
R36 = (kf1,r36 ∗ PDK1act+ kf2,r36 ∗mTORC2act) ∗
PKCθ − kr,r36 ∗ PKCθact
Activation of PKCθ mediated by PDK1, DAG, and
mTORC2
R37 = (kf1,r37 ∗ PKCθact+ kf2,r37 ∗Aktp) ∗ IKK − kr,r37 ∗
IKKact
PKCθ- and AKT-mediated activation of IKK
R38 = kf,r38 ∗ IKKact− kr1,r38 ∗ IkBp− kr2,r38 ∗NFkBn IKK-mediated phosphorylation and 26S
proteasome-mediated degradation of IκBα;
NFκB-induced synthesis of new IκBα
R39 = kf,r39 ∗ IkBp− kr,r39 ∗NFkBn Activation and nuclear translocation of NFκB
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Reaction Equation Biological Meaning
R40 = (kf1,r40 ∗ PDK1act+ kf2,r40 ∗mTORC2act+ kf3,r40 ∗
PDK1act ∗mTORC2act) ∗Akt− kr,r40 ∗Aktp
PDK1- and mTORC2-mediated phosphorylation of
AKT





∗ TSC − kr,r41 ∗ TSC2p AKT-mediated phosphorylation, dissociation, and
deactivation of TSC
R42 = kf,r42 ∗ TSC ∗RhebGTP − kr,r42 ∗RhebGDP GAP activity of TSC on Rheb
R43 = kf,r43 ∗ (RhebGTP −RhebGTP0) ∗mTORC1−
kr,r43 ∗mTORC1act
RhebGTP-mediated activation of mTORC1
R44 = kf,r44 ∗ PI3Kact ∗mTORC2− (kr1,r44 ∗
mTORC1act+ kr2,r44) ∗mTORC2act
PI3K-mediated activation and mTORC1-mediated
inhibition of mTORC2








TCR-mediated inhibition and FOXP3-mediated
activation of PTEN















− (kr1,r46 ∗FOXP3 + kr2,r46) ∗ IL2
AP1, NFAT, and NFkB regulate transcription of IL-2;
FOXP3-mediated inhibition of IL-2











(kr1,r47 ∗ (mTORC1 ∗mTORC2) + kr2,r47) ∗ FOXP3
AP1 and NFAT regulate transcription of FOXP3;
mTOR-mediated inhibition of FOXP3
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Table B.3 presents a comprehensive list of all reaction parameters included in the
model. The list also includes the biological meaning, value, 95% confidence interval (if
applicable), units and source (if applicable) for each parameter. For parameters not
provided by external sources, they are either estimated from data or explicitly derived
to satisfy a condition of the model, for example, to ensure equilibrium when the system
should be at rest. Confidence intervals are estimated for the model calibration data
(Table 5.1) using the likelihood ratio method [4].
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Table B.3.: Summary of model parameters.
Parameter Biological Meaning Value 95% CI Units Source
kf,r00 Association rate of ligand and TCR
complex
0.0900 [0.0558, 0.1231] (mol·min)−1 Fitted
kr,r00 Dissociation rate of ligand and
TCR complex
3× 10−4 [1.2346× 10−4, 5.5632× 10−4] min−1 Fitted
kf1,r0 Phosphorylation rate of
ligand-bound TCR mediated by
SFK* and SFK*-S59p
0.3000 [0.0475, 3.8961] (mol·min)−1 [1]
kf2,r0 Phosphorylation rate of
ligand-bound TCR mediated by
SFK*-Zapp
1.13·kf1,r0 (mol·min)−1 [1]
kr1,r0 Dephosphorylation rate of
ligand-bound TCR mediated by
activated SHP1
0.0022 [0.0015, 0.0221] (mol·min)−1 [1]
kr2,r0 Constitutive dephosphorylation
rate of ligand-bound TCR
16.1100 [1.0731, 61.7493] min−1 [1]
kr3,r0 Dephosphorylation rate of
ligand-bound TCR mediated by
activated CD45
0.0300 [8.1854× 10−4, 0.1574] (mol·min)−1 Fitted
kintmin Resting TCR internalization rate 0.0100 min
−1 [2]
kintmax Maximum induced TCR
internalization rate
0.0380 min−1 [2]
nint TCR internalization Hill coefficient 2 unitless Derived




kexo Constitutive TCR exocytosis rate 0.0789 min
−1 Derived
kdegmin Resting TCR degradation rate 0.0011 min
−1 [5]
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Parameter Biological Meaning Value 95% CI Units Source
kdegmax Maximum induced TCR
degradation rate
0.0033 min−1 [5]
ndeg TCR degradation Hill coefficient 2 unitless Derived




ksynth TCR synthesis rate kdegmin min
−1 Derived
kf,r1 Association rate of Zap70 to
phosphorylated TCRζ-chain
6× 10−4 [5.4721× 10−5, 9.6525× 10−4] (mol·min)−1 Fitted
kr,r1 Dissociation rate of Zap70 to
phosphorylated TCRζ-chain
1.2600 [0.4913, 41.7225] min−1 Fitted
kf,r2 Dephosphorylation rate of SFK at
the inhibitory site by CD45
3× 10−6 [2.0755× 10−6, 3.6068× 10−6] (mol·min)−1 Fitted
kr,r2 Phosphorylation rate of SFK at the
inhibitory site by Csk
0.1199 (mol·min)−1 Derived
kf,r3 Phosphorylation rate of SFKdp at
the activation site mediated by
TCRb and TCRp
13.7700 [1.3177, 75.4525] (mol·min)−1 Fitted
kr1,r3 Dephosphorylation rate of SFK* at




rate of SFK* at the activation site
kr2,r0 min
−1 [1]
kr3,r3 Dephosphorylation rate of SFK* at
the activation site by activated
CD45
kr3,r0 (mol·min)−1 Derived
kf,r4 Association rate of SFKdp to Zapp 0.0217 [2.169× 10−4, 2.1690] (mol·min)−1 Fitted
kr,r4 Dissociation rate of SFKdp to Zapp 0.0025 [2.415× 10−4, 0.0151] min−1 Fitted
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Parameter Biological Meaning Value 95% CI Units Source
kf,r4a Phosphorylation rate of
Zapp-bound SFKdp at the
activation site mediated by TCRb
and TCRp
kf,r3 (mol·min)−1 [1]
kr1,r4a Dephosphorylation rate of
Zapp-bound SFK* at the
activation site by activated SHP1
0.0068 [0.0012, 0.0641] (mol·min)−1 Fitted
kr2,r4a Constitutive dephosphorylation
rate of Zapp-bound SFK* at the
activation site
13.4040 [1.3409, 84.0744] min−1 Fitted
kr3,r4a Dephosphorylation rate of
Zapp-bound SFK* at the
activation site by activated CD45
0.0300 [0.0019, 0.3542] (mol·min)−1 Fitted
kf,r5 Dissociation rate of SFK* to Zapp 70.7880 [68.7880, 102.3198] min
−1 Fitted
kr,r5 Association rate of SFK* to Zapp kf,r4 (mol·min)−1 [1]
kf1,r6 Phosphorylation rate of Cbp by
SFK*
1.788× 10−6 [1.0338× 10−6, 1.788× 10−5] (mol·min)−1 Fitted
kf2,r6 Constitutive phosphorylation rate
of Cbp
0.0207 [0.0127, 0.1200] min−1 Fitted
kr,r6 Dephosphorylation rate of Cbpp by
CD45
1.9644× 10−4 (mol·min)−1 Derived
kf,r7 Association rate of Csk to Cbpp 6.984× 10−4 [1.2137× 10−5, 0.0070] (mol·min)−1 Fitted
kr,r7 Dissociation rate of Csk to Cbpp 0.6635 min
−1 Derived
kf1,r8 Phosphorylation rate of bound Zap
by SFK* and SFK*S59p
0.0021 [0.0015, 0.0022] (mol·min)−1 Fitted
kf2,r8 Phosphorylation rate of bound Zap
by SFK*-Zapp
1.13·kf1,r8 (mol·min)−1 [1]









kf1,r9 Phosphorylation rate of Zap* by
free and bound Zapp
3× 10−4 [3× 10−6, 3.6068× 10−4] (mol·min)−1 Fitted
kf2,r9 Phosphorylation rate of Zap* by
SFK* and SFK*S59p
kf1,r8 (mol·min)−1 [1]
kf3,r9 Phosphorylation rate of Zap* by
SFK*-Zapp
1.13·kf1,r8 (mol·min)−1 [1]







kf,r10 Activation rate of SHP1 by SFK* 8.19× 10−6 [8.1121× 10−6, 8.2192× 10−6] (mol·min)−1 Fitted
kr,r10 Deactivation rate of SHP1 0.3660 [0.3450, 0.3861] min
−1 Fitted
kf,r11 Phosphorylation rate of LAT by
activated Zap
3× 10−4 [2.5835× 10−4, 3.9477× 10−4] (mol·min)−1 Fitted
kr1,r11 Dephosphorylation rate of LAT by
activated SHP1
0.0020 [0.0017, 0.0025] (mol·min)−1 Fitted
kr2,r11 Constitutive dephosphorylation
rate of SHP1
90 [87.9332, 130.0896] min−1 Fitted
kf,r12 Association rate of PLCγ and
LATp (PLCγ is immediately
phosphorylated)
0.0030 [0.0021, 0.0033] (mol·min)−1 Fitted
kr,r12 Lumped rate of dephosphorylation
of PLCγ and its dissociation from
LATp
300 [295.1992, 302.0020] min−1 Fitted
kf,r13 PIP2 hydrolysis rate catalyzed by
PLCγp
3× 10−8 [2.9199× 10−8, 3.0011× 10−8] (mol·min)−1 Fitted
kr,r13a DAG degradation rate 2.4311 [1.3990, 2.9228] min
−1 Fitted
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kr,r13b IP3 degradation rate kr,r13a min
−1 Derived
kf,r14 Activation rate of RasGRP by
DAG
0.0030 [0.0025, 0.0052] (mol·min)−1 Fitted
kr,r14 Inactivation rate of RasGRP 30 [17.2632, 36.0679] min
−1 Fitted
kf,r14a Activation rate of PKCθ by DAG 3× 10−4 [2.7665× 10−5, 3.7263× 10−4] (mol·min)−1 Fitted
kf1,r15 Rate of Ras guanine nucleotide
exchange catalyzed by activated
RasGRP
1.2× 10−5 [8.3020× 10−6, 1.7345× 10−5] (mol·min)−1 Fitted
kf2,r15 Rate of Ras guanine nucleotide
exchange catalyzed by recruited
SOS
1.2× 10−6 [1.2111× 10−7, 8.3020× 10−6] (mol·min)−1 Fitted
kr,r15 Constitutive rate of RasGTP
hydrolysis to RasGDP
30 [24.9529, 43.3632] min−1 Derived
kf,r16 Activation rate of Raf by RasGTP 2.4× 10−4 [1.6604× 10−4, 2.8854× 10−4] (mol·min)−1 Fitted
kr,r16 Constitutive rate of Raf
inactivation by phosphatase
30 [24.9529, 43.3632] min−1 Derived
kf,r17 Activation rate of Mek by activated
Raf
0.0030 [0.0025, 0.0036] (mol·min)−1 Fitted
kr,r17 Constitutive rate of Mek
inactivation by phosphatase
30 [24.9529, 36.0679] min−1 Derived
kf,r18 Activation rate of Erk by activated
Mek
3× 10−6 [2.4953× 10−6, 3.6068× 10−6] (mol·min)−1 Fitted
kr,r18 Constitutive rate of Erk
inactivation by phosphatase
30 [24.9529, 36.0679] min−1 Derived
kf,r19 Association rate of Grb-SOS
complex to LATp
6× 10−4 [5.7393× 10−6, 9.151× 10−4] (mol·min)−1 Fitted
kr,r19 Dissociation rate of Grb-SOS
complex from LATp
30 [3.3632, 100] min−1 Derived
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kf,r20 Phosphorylation rate of SFKdp at
S59 by activated Erk
3× 10−5 [6.3433× 10−7, 0.0011] (mol·min)−1 Fitted
kr,r20 Constitutive dephosphorylation
rate of SFKdp at S59
30 [4.5543, 80.0101] min−1 Fitted
kf,r21 Phosphorylation rate of SFK* at
S59 by activated Erk
kf,r20 (mol·min)−1 [1]
kr,r21 Constitutive dephosphorylation
rate of SFK* at S59
kr,r20 min
−1 [1]
kf,r22 Phosphorylation rate of
SFKdpS59p at the activation site
mediated by TCRb and TCRp
kf,r3 (mol·min)−1 Derived
kr1,r22 Dephosphorylation rate of








kr3,r22 Dephosphorylation rate of
SFK*S59p at the activation site by
activated CD45
kr3,r3 (mol·min)−1 Derived
kf,r23 Translocation rate of CD45
mediated by receptor complex
3× 10−7 [6.5488× 10−8, 6.2679× 10−7] (mol·min)−1 Fitted
kr,r23 Constitutive return rate of CD45 0.0030 [9.1223× 10−5, 0.1009] min−1 Fitted
kf,r23a Activation rate of CD45 negative
regulator by SFK*
6× 10−7 [4.151× 10−7, 3.98× 10−5] (mol·min)−1 Fitted
kr,r23a Constitutive deactivation rate of
CD45 negative regulator
0.0030 [9.2531× 10−5, 0.0961] min−1 Fitted
kf,r26 Activation rate of AP1 by Erk*
and PKCθ*
3× 10−9 [3.3439× 10−10, 7.9843× 10−8] (mol2·min)−1 Fitted
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kr,r26 Constitutive deactivation rate of
AP1*
30 [23.1193, 43.8583] min−1 Fitted
kf,r27 Release rate of calcium stored in
the endoplasmic reticulum by IP3
0.0300 [0.0212, 0.0380] (mol·min)−1 Fitted
kr,r27 Constitutive calcium uptake rate 30 [19.0031, 54.1565] min
−1 Fitted
kf,r28 Association rate of calmodulin to
calcium
1.5× 10−8 [1.5267× 10−9, 1.0877× 10−6] (mol·min)−1 Fitted
kr,r28 Dissociation rate of calmodulin
from calcium
0.3000 [0.0182, 3.2856] min−1 Fitted
kf,r29 Activation rate of calcineurin by
calmodulin*
1.5× 10−7 [5.8843× 10−8, 8.6424× 10−6] (mol·min)−1 Fitted
kr,r29 Constitutive deactivation rate of
calcineurin*
0.3000 [0.0943, 19.1092] min−1 Fitted
kf,r30 Activation rate of NFAT (NFAT
immediately translocates to
nucleus)
1.5× 10−6 [1.0869× 10−6, 1.9341× 10−6] (mol·min)−1 Fitted
kr,r30 Constitutive deactivation rate of
NFAT
0.3000 [0.0210, 0.3433] min−1 Fitted
kf,r32 Association rate of ligand to CD28
coreceptor
0.0300 [0.0199, 0.0360] (mol·min)−1 Fitted
kr,r32 Dissociation rate of ligand from
CD28 coreceptor
6× 10−5 [1.8795× 10−5, 7.4673× 10−5] min−1 Fitted
kf,r33 Activation rate of PI3K by
ligand-bound CD28 and activated
Zap
3× 10−9 [3.9548× 10−10, 5.1943× 10−9] (mol2·min)−1 Fitted
kr,r33 Constitutive deactivation rate of
PI3K
30 [15.3560, 37.5731] min−1 Fitted
kf,r34 Phosphorylation rate of PIP2 by
PI3K*
3 [0.3923, 5.7161] (mol·min)−1 Fitted
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kr1,r34 Dephosphorylation rate of PIP3 by
PTEN*
30 [17.4422, 65.3412] (mol·min)−1 Fitted
kr2,r34 Constitutive dephosphorylation
rate of PIP3
1× 10−10 [5.1834× 10−11, 2.7164× 10−10] min−1 Fitted
kf,r35 Activation rate of PDK1 by PIP3 3× 10−5 [9.3939× 10−6, 5.7164× 10−5] (mol·min)−1 Fitted
kr,r35 Constitutive deactivation rate of
PDK1*
30 [5.4422, 40.4623] min−1 Fitted
kf1,r36 Activation rate of PKCθ by PDK1* 3× 10−6 [8.4379× 10−7, 1.0892× 10−5] (mol·min)−1 Fitted
kf2,r36 Activation rate of PKCθ by
mTORC2*
3× 10−5 [8.0982× 10−7, 9.9339× 10−5] (mol·min)−1 Fitted
kr,r36 Constitutive deactivation rate of
PKCθ*
0.3000 [0.1754, 1.3217] min−1 Fitted
kf1,r37 Activation rate of IKK by PKCθ* 0.0015 [9.0321× 10−4, 0.0065] (mol·min)−1 Fitted
kf2,r37 Activation rate of IKK by Aktp 0.0030 [0.0019, 0.0046] (mol·min)−1 Fitted
kr,r37 Constitutive deactivation rate of
IKK*
15 [5.3394, 48.7211] min−1 Fitted
kf,r38 Phosphorylation rate of IκBα by
IKK*
0.4500 [0.4109, 0.5512] min−1 Fitted
kr1,r38 Proteasomal degradation rate of
pIκBα
0.1500 [0.1093, 0.1978] min−1 Fitted
kr2,r38 Deactivation rate of IκBα by NFκB 0.1500 [0.0936, 0.2380] min
−1 Fitted
kf,r39 Activation rate of NFκB by IκBα
deactivation
0.1500 [0.0994, 0.2121] min−1 Fitted
kr,r39 Constitutive deactivation rate of
NFκB
0.0150 [0.0124, 0.0272] min−1 Fitted
kf1,r40 Phosphorylation rate of Akt by
PDK1*
1× 10−10 [7.9346× 10−11, 2.7832× 10−10] (mol·min)−1 Fitted
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kf2,r40 Phosphorylation rate of Akt by
mTORC2*
1× 10−10 [9.3976× 10−11, 1.7832× 10−10] (mol·min)−1 Fitted
kf3,r40 Phosphorylation rate of Akt by
PDK1* and mTORC2*
1× 10−8 [6.4853× 10−9, 5.7164× 10−8] (mol2·min)−1 Fitted
kr,r40 Dephosphorylation rate of Aktp by
phosphatases
1 [0.5422, 7.0427] min−1 Derived
kf,r41 Phosphorylation rate of the TSC2
subunit of the TSC1-TSC2 complex
(complex immediately dissociates)
10 [6.8726, 30.3895] min−1 Fitted
kr,r41 Dephosphorylation rate of TSC2p
and its association with TSC1
1 [0.3783, 8.2627] min−1 Derived
nr41 TSC2 phosphorylation Hill
coefficient
5 unitless Derived




kf,r42 Rate of Rheb guanine nucleotide
exchange catalyzed by TSC1-TSC2
complex
1× 10−4 [3.6763× 10−5, 9.9339× 10−4] (mol·min)−1 Derived
kr,r42 Rate of RhebGDP to RhebGTP
exchange
1 [0.3020, 10.5309] min−1 Derived
kf,r43 Activation rate of mTORC1 by
RhebGTP
1× 10−4 [6.3984× 10−5, 0.0047] (mol·min)−1 Fitted
kr,r43 Constitutive deactivation rate of
mTORC1*
1 [0.2653, 4.7164] min−1 Derived
kf,r44 Activation rate of mTORC2 by
PI3K*
0.0030 [2.7360e-4, 0.0993] (mol·min)−1 Fitted
kr1,r44 Deactivation rate of mTORC2* by
mTORC1
0.0030 [0.0023, 0.0102] (mol·min)−1 Fitted
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kr2,r44 Constitutive deactivation rate of
mTORC2*
3 [1.3631, 3.8319] min−1 Fitted
kf1,r45 Activation rate of PTEN by
FOXP3*
1× 10−4 [1.8647× 10−5, 0.0010] (mol·min)−1 Derived
kf2,r45 Constitutive activation of PTEN 1 [0.1925, 18.9529] min
−1 Derived
kr,r45 Deactivation of PTEN* by TCR
complex
20 [11.4372, 106.1915] min−1 Fitted
nr45 PTEN* deactivation Hill coefficient 10 unitless Derived




kf,r46 Activation rate of IL-2 activity 1× 104 [574.7247, 1.8543× 105] mol·min−1 Fitted
n1,r46 Hill coefficient for AP1-induced
IL-2 activity
2 unitless Derived
n2,r46 Hill coefficient for NFAT-induced
IL-2 activity
2 unitless Derived
n3,r46 Hill coefficient for NFκB-induced
IL-2 activity
2 unitless Derived
k1,r46 AP1 quantity producing
half-maximum IL-2 activity
0.1·[AP1]total mol Derived
k2,r46 NFAT quantity producing
half-maximum IL-2 activity
0.3·[NFAT]total mol Derived
k3,r46 NFκB quantity producing
half-maximum IL-2 activity
0.1·[NFκB]total mol Derived
kr1,r46 Deactivation rate of IL-2 activity
by FOXP3
1× 10−4 [3.4974× 10−5, 0.0093] (mol·min)−1 Fitted
kr2,r46 Constitutive deactivation rate of
IL-2
1 [0.1832, 8.9847] min−1 Derived
kf,r47 Activation rate of FOXP3 activity 1× 104 [748.5767, 2.4329× 104] mol·min−1 Fitted
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n1,r47 Hill coefficient for AP1-induced
FOXP3 activity
2 unitless Derived
n2,r47 Hill coefficient for NFAT-induced
FOXP3 activity
2 unitless Derived
k1,r47 AP1 quantity producing
half-maximum FOXP3 activity
0.1·[AP1]total mol Derived
k2,r47 NFAT quantity producing
half-maximum FOXP3 activity
0.1·[NFAT]total mol Derived
kr1,r47 Deactivation rate of FOXP3
activity by mTOR
2× 10−7 [7.3598× 10−8, 8.9275× 10−6] (mol·2min)−1 Fitted
kr2,r47 Constitutive deactivation rate of
FOXP3 activity
1 [0.3685, 4.7328] min−1 Derived
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B.2 Parameter Sensitivity Analysis
Figure B.1 shows the results of the parameter sensitivity analysis used to de-
termine which parameters should be considered for parameter identification. The
sensitivity indices are standardized by rows, enabling the parameters to be ranked
for each model state independently. For a given model state, a value shown in red
denotes that the state is relatively sensitive to perturbations in the corresponding
parameter. On the other hand, a value shown in green implies that the particular
state is insensitive to the parameter in question. As shown in Figure B.1, it can be
common for certain states to be only sensitive to a fraction of the parameters. This
blocking structure is leveraged during the parameter identification process to reduce








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































) for all t, normalized by row maximum
Fig. B.1.: Parameter sensitivity indices. Values are standardized by rows. Red =
most sensitive; Green = least sensitive.
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B.3 Calcium Flux Measurements
Jurkat T leukemia cells (Jurkat clone E6.1; ATCC) were harvested in log phase
growth (4–8 × 105 cell/mL), washed once with Hank’s Balanced Salt Solution (HBSS)
without phenol red. Phenol red-free, calcium containing HBSS (Lonza) was used for
the remainder of the experiment. Cells were resuspended at 2 × 106 cells/mL in
HBSS supplemented with 2.5 mM probenecid (unloaded control) or in HBSS with 1
µM Fluo-4 AM, 2.5 mM probenecid and 10 µL/mL PowerLoad (Invitrogen, Carlsbad,
USA). Cells were incubated for 30 min at room temperature in the dark. Following
incubation, cells were washed twice with 1 mL HBSS with 2.5 mM probenecid and
then resuspended in 100 µL HBSS plus 2.5 mM probenecid. Cells were loaded into a
black-walled, clear bottom 96-well plate. Wells with cells were surrounded two wells
deep with 100 µL water each as a temperature buffer. The plate was covered in foil,
and cells were allowed to settle for 5 min at 37 ◦C.
Fluorescence was measured on a BioTek plate reader (BioTek Instruments, Winooski,
USA) using the following parameters: excitation wavelength, 495 nm; emission, 520
nm; temperature, 37 ◦C. Prior to stimulation, a background reading was taken. The
plate was ejected from the plate reader and 10 µg/mL αCD3ε or 1 µg/mL ionomycin
(positive control) were added to the wells using a repeat dispense pipette. Following
the addition of stimulants, a kinetic measurement run was done over 5–10 min, mea-
suring fluorescence every 10 s. From the obtained data, the background reading was
subtracted.
B.4 Phospho-IκBα Measurements
Jurkat cells were grown in RPMI 1640 (Sigma-Aldrich, St. Louis, USA) supple-
mented with 7.5% heat-inactivated fetal bovine serum (Bio-West, Logan, USA), 1
mM sodium pyruvate (Life Technologies, Carlsbad, USA), 12.5 mM HEPES pH 7.4
(Sigma-Aldrich, St. Louis, USA), 12 µM sodium bicarbonate (Sigma-Aldrich, St.
Louis, USA) 50 µM 2-mercaptoethanol (Sigma-Aldrich, St. Louis, USA), 50 µg/mL
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streptomycin and 50 units/mL penicillin in an incubator at 37 ◦C in humidified air
containing 5% carbon dioxide. Cells were harvested in log-phase growth at a den-
sity of 1 × 107 cells per treatment. The treatments were stimulated with either 2
µg/mL αCD3 or 2 µg/mL αCD3 plus αCD28 in a 37 ◦C water bath for up to 30
min. Samples of 1 × 106 cells were taken at the indicated time points and lysed in
1% NP40 lysis buffer (1% NP40, 25 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1
mM NaV, 10 mM NaF, 10 µg/mL each of aprotinin and leupeptin) for 15 min on ice.
Lysates were centrifuged for 5 min at 18,000× g at 4 ◦C. The supernatant was added
to the same volume of 2X protein solubilizing mixture (PSM, 25% (w/v) sucrose,
2.5% (w/v) sodium dodecyl sulfate, 25 mM Tris, 2.5 mM EDTA, 0.05% bromophe-
nol blue) and boiled for five min. Proteins were separated via SDS-PAGE, blotted
for α-tubulin, phospho-IκB (S32/36) and IκB (Cell Signaling Technology, Beverly,
USA). IRDye 800 and 680 secondary anti-mouse and anti-rabbit antibodies (Li-Cor
Biosciences, Lincoln, USA) were used for signal detection using an Odyssey infrared
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C. SUPPORTING INFORMATION: MODEL-BASED
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STRATEGY FOR TARGETED MANIPULATION OF
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Fig. C.1.: Model representation of the LCK isoforms and their kinase activities. (A)
Original model representation of LCK isoforms from Zheng [1] and Perley et al. [2].
The original model has three main SFK-related states: SFK (closed), SFKdp (primed
via CD45), and SFK* (activated via ligand-bound TCR), some of whom are also ca-
pable of binding ZAP-70. These states are defined to denote the phosphorylation
status of SFK and vary greatly over time upon stimulation. (B) More recent works
have shown that SFK (particularly LCK) exists in four main forms, are constitutively
active, and the relative proportions of the different forms do not vary in response to
stimulation. The evidence also suggests that the clustering of active SFKs proximal
to the receptor complex is responsible for signal propagation [3]. Thus, the existing
model states were redefined to reflect the kinases’ ability to affect downstream activity
rather than simply phosphorylation status. The first assumption is that, while there
are four phosphorylation isoforms of LCK existing in free or clustered states, only
the active clustered isoforms are considered catalytically active (from the perspec-
tive of downstream TCR-mediated signaling). These states are represented by the
“SFK-Active” group. Isoforms with active kinase activity, but are not clustered, are
considered members of the “SFK-Primed” population. The closed isoform with the
single phosphate group on the inhibitory Y505 residue constitutes the final “SKF-
Inactive” group. Transitions between these groups (colored blocks) are explicitly
modeled, while transitions within colored blocks are considered implicit. Thus, the
model definitions now account for cluster membership and the potential to activate
downstream signaling rather than simply phosphorylation status.
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C.2 Revised Model of Input Reagent Effects
We revised the original model to improve and expand its ability to recapitulate
the T-cell response to modulation by various small-molecule inhibitors and activators.
As in the original model, we assume that each dose of input reagent is administered
in bolus form and the effects are neither instantaneous nor permanent. Accordingly,
we characterize the pharmacokinetic effects of the reagent with a simple model of the
















where uj(k) is the administered concentration of the j
th reagent at the kth adminis-
tration time point τj,i(k), and τj,r and τj,d are parameters characterizing the response
time and duration of action. The scaling factor cj is used to adjust the sensitivity of
the effective input concentration and the Heaviside step function, denoted by 1+(·),
ensures that pharmacological agents are only effective after administration.
The pharmacodynamic effects of the reagents on the system are characterized by
modulating the kinetic parameters associated with their respective substrates. These















for stimulatory input reagents, where θj,0 is the nominal value of the affected param-
eter, K is the half-maximal effect concentration and n is the cooperativity parameter
(n > 1 for positive cooperativity, n < 1 for negative cooperativity). The input
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reagents now simulated by the model are depicted in Figure 6.1 in colored boxes near






























































































































































































































































































































































































































































































































































































































































































































































































Fig. C.2.: Parameter sensitivity indices for model output variables. Sensitivity indices
are standardized by row to show the sensitive parameters for each model output.
Color code: red = large positive sensitivity; white = low sensitivity; blue = large
negative sensitivity.





























































































































































































































































































































































































































Fig. C.3.: Parameter groupings for modular parameter identification with relevant
data subsets. Sensitive parameters (horizontal axis) grouped by the relevant response
variables (vertical axis) for each training data subset (rows). Color code: red =
inclusion; white = exclusion.
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C.5 Effectiveness of MBDOE in Reducing Dynamical Uncertainty
A B C D
E F G H
I
Fig. C.4.: MBDOE-designed experiments for the baseline system. (A–H) Model sim-
ulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL anti-human
CD28) with in vitro measurements overlaid. The ranges of acceptable model simula-
tions before and after all proposed measurements have been gathered are denoted by
the gray- and blue-shaded regions, respectively. Error bars show data mean ± stan-
dard deviation for 2× 104 cells from a single experiment (i.e., n = 1). (I) Reduction
in maximum variance (normalized by maximum initial variance) in each state after
all proposed measurements have been gathered.
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Fig. C.5.: MBDOE-designed experiments to resolve the response to AEB071. (A–H)
Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 0.046 µM AEB071) with in vitro measurements overlaid. The
ranges of acceptable model simulations before and after all proposed measurements
have been gathered are denoted by the gray- and blue-shaded regions, respectively.
Error bars show data mean ± standard deviation for 2 × 104 cells from a single ex-
periment (i.e., n = 1). (I) Reduction in maximum variance (normalized by maximum
initial variance) in each state after all proposed measurements have been gathered.
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Fig. C.6.: MBDOE-designed experiments to resolve the response to CsA. (A–H)
Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 0.01 µM CsA) with in vitro measurements overlaid. The ranges
of acceptable model simulations before and after all proposed measurements have
been gathered are denoted by the gray- and blue-shaded regions, respectively. Error
bars show data mean ± standard deviation for 2× 104 cells from a single experiment
(i.e., n = 1). (I) Reduction in maximum variance (normalized by maximum initial
variance) in each state after all proposed measurements have been gathered.
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Fig. C.7.: MBDOE-designed experiments to resolve the response to iLck. (A–H)
Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 0.215 µM iLck) with in vitro measurements overlaid. The ranges
of acceptable model simulations before and after all proposed measurements have been
gathered are denoted by the gray- and blue-shaded regions, respectively. Error bars
show data mean ± standard deviation for 2×104 cells from a single experiment (i.e., n
= 1). (I) Reduction in maximum variance (normalized by maximum initial variance)
in each state after all proposed measurements have been gathered.
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Fig. C.8.: MBDOE-designed experiments to resolve the response to PMA. (A–H)
Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 100 ng/mL PMA) with in vitro measurements overlaid. The
ranges of acceptable model simulations before and after all proposed measurements
have been gathered are denoted by the gray- and blue-shaded regions, respectively.
Error bars show data mean ± standard deviation for 2 × 104 cells from a single ex-
periment (i.e., n = 1). (I) Reduction in maximum variance (normalized by maximum
initial variance) in each state after all proposed measurements have been gathered.
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Fig. C.9.: MBDOE-designed experiments to resolve the response to Rapamycin. (A–
H) Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 0.022 µM Rapamycin) with in vitro measurements overlaid.
Shaded regions denote the range of the model simulations that remain consistent with
each successive measurement. The ranges of acceptable model simulations before and
after all proposed measurements have been gathered are denoted by the gray- and
blue-shaded regions, respectively. Error bars show data mean ± standard deviation
for 2 × 104 cells from a single experiment (i.e., n = 1). (I) Reduction in maximum
variance (normalized by maximum initial variance) in each state after all proposed
measurements have been gathered.
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Fig. C.10.: MBDOE-designed experiments to resolve the response to U0126. (A–H)
Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5 µg/mL
anti-human CD28 + 4.64 µM U0126) with in vitro measurements overlaid. The ranges
of acceptable model simulations before and after all proposed measurements have been
gathered are denoted by the gray- and blue-shaded regions, respectively. Error bars
show data mean ± standard deviation for 2×104 cells from a single experiment (i.e., n
= 1). (I) Reduction in maximum variance (normalized by maximum initial variance)
in each state after all proposed measurements have been gathered.
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Fig. C.11.: MBDOE-designed experiments to resolve the response to Wortmannin.
(A–H) Model simulations given the optimal inputs (5 µg/mL anti-human CD3 + 5
µg/mL anti-human CD28 + 1 µM Wortmannin) with in vitro measurements overlaid.
The ranges of acceptable model simulations before and after all proposed measure-
ments have been gathered are denoted by the gray- and blue-shaded regions, respec-
tively. Error bars show data mean ± standard deviation for 2 × 104 cells from a
single experiment (i.e., n = 1). (I) Reduction in maximum variance (normalized by
maximum initial variance) in each state after all proposed measurements have been
gathered.
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C.6 Model Parameter Scenarios for AWMMPC Study
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Table C.1.: Model parameter scenarios for AWMMPC study.
Parameter M1PMA M1Iono M1AEB M1Rapa M2PMA M2Iono M2AEB M2Rapa
kilck 0.0010 8.4702× 10−4 0.0011 5.1342× 10−4 9.4568× 10−4 9.5815× 10−4 0.0015 4.2077× 10−4
nilck 1.3547 0.8445 1.1099 0.6635 1.0080 1.0587 0.9502 0.6885
kaeb 0.0030 0.0024 0.0040 0.0047 0.0043 0.0030 0.0037 0.0060
naeb 1.2336 0.7536 1.0466 1.3120 1.0735 0.6966 1.0500 1.4095
wcd28 1.1388 1.0940 1.0104 0.9538 1.0818 1.1257 1.0161 0.9781
wcd3 0.7635 1.0153 0.8234 0.9958 0.9427 1.0479 0.9365 0.9524
kcsa 0.0026 0.0044 0.0028 0.0035 0.0028 0.0035 0.0023 0.0037
ncsa 3.6499 7.7020 2.0801 6.5842 3.4538 7.3484 2.1253 6.1301
kiono 0.3531 0.2222 0.1689 0.2024 0.1983 0.2152 0.1895 0.1900
niono 2.4048 1.8828 1.8797 1.2633 1.5389 1.4577 1.5118 1.5455
wiono 2.0223 2.1936 2.4149 2.1663 2.5138 2.4973 2.5040 2.5239
kpma 16.8833 13.3303 8.5011 8.4980 10.3517 11.9145 9.3477 9.5763
npma 1.2058 1.2431 1.0221 0.9082 1.0727 1.0865 1.0716 0.9856
wpma 1.9947 2.0184 1.7382 1.9221 2.0151 2.0993 1.9927 2.0240
krapa 0.0070 0.0034 0.0051 0.0044 0.0063 0.0033 0.0061 0.0044
nrapa 1.6320 0.8121 3.1812 1.0054 1.6868 0.9800 2.1172 1.6382
ksang 38.4667 30.9840 17.4806 15.3386 39.2441 37.2815 13.3866 16.5112
nsang 1.0299 1.0208 2.3601 0.6149 0.8100 1.0037 2.2460 0.5033
ku0126 1.2589 0.8065 0.1401 0.7247 1.0031 0.7178 0.1716 0.8606
nu0126 2.9302 3.7284 1.0086 1.0738 2.3318 2.4578 1.1595 0.9238
kwort 0.0068 0.0017 0.0036 0.0012 0.0061 0.0019 0.0038 0.0011
nwort 0.3299 1.0289 0.9128 0.3446 0.4008 0.9983 0.8035 0.3462
R2kf 2.6928× 10−6 3.2952× 10−6 3.1944× 10−6 2.7227× 10−6 2.7997× 10−6 3.2299× 10−6 3.2295× 10−6 2.8475× 10−6
R3kf 18.7721 10.0597 14.7024 17.3065 14.6632 14.0027 13.9925 14.9098
R4akf 624.6930 620.1120 592.7486 556.3403 704.0894 646.8593 716.2513 721.3876
R5kf 59.4929 52.6738 70.5177 72.1725 70.5953 69.8409 72.7369 72.4576
R5kr 0.0318 0.0240 0.0199 0.0171 0.0218 0.0251 0.0208 0.0234
R8kf1 0.0020 0.0018 0.0026 0.0023 0.0023 0.0021 0.0021 0.0020
272
Parameter M1PMA M1Iono M1AEB M1Rapa M2PMA M2Iono M2AEB M2Rapa
R8kr1 0.0023 0.0019 0.0020 0.0025 0.0020 0.0022 0.0021 0.0021
R9kf2 0.0020 0.0019 0.0019 0.0023 0.0021 0.0023 0.0022 0.0023
R9kr1 0.0026 0.0019 0.0027 0.0020 0.0023 0.0021 0.0021 0.0020
R10kf 8.6374× 10−6 8.6380× 10−6 6.3147× 10−6 9.1008× 10−6 7.6944× 10−6 8.7536× 10−6 7.8270× 10−6 8.8371× 10−6
R10kr 0.5691 0.2653 0.2525 0.2791 0.4376 0.3623 0.3676 0.3591
R11kf 2.7731× 10−4 2.4282× 10−4 2.4250× 10−4 3.1792× 10−4 2.5629× 10−4 2.6062× 10−4 3.0631× 10−4 3.2228× 10−4
R12kf 0.0034 0.0022 0.0032 0.0037 0.0029 0.0029 0.0030 0.0028
R13kf 3.4775× 10−8 3.7805× 10−8 3.1309× 10−8 3.3093× 10−8 3.0931× 10−8 3.3016× 10−8 2.9395× 10−8 3.2572× 10−8
R13bkr 2.3220 2.1500 2.4536 2.2671 2.4384 2.4808 2.2813 2.2520
R15kr 29.9307 25.9127 30.2542 28.2328 28.5461 25.4980 30.8963 31.7794
R16kf 1.2456× 10−4 2.2249× 10−4 2.3303× 10−4 2.4298× 10−4 1.4142× 10−4 2.4290× 10−4 2.2623× 10−4 2.4419× 10−4
R16kr 42.6529 32.2148 28.4616 31.9864 36.9624 30.6767 30.7320 30.8107
R17kf 0.0036 0.0037 0.0033 0.0032 0.0043 0.0041 0.0028 0.0030
R17kr 15.8582 32.7496 24.5282 28.5782 18.8397 30.2628 30.5481 30.3481
R18kf 1.6944× 10−6 2.8238× 10−6 3.6671× 10−6 2.9519× 10−6 1.9306× 10−6 2.5066× 10−6 3.4077× 10−6 3.0665× 10−6
R18kr 22.7080 39.9134 25.2903 42.4766 36.4988 30.2891 28.9977 30.6543
R21kf 3.6930× 10−5 2.4907× 10−5 2.7721× 10−5 2.2018× 10−5 2.9288× 10−5 2.5699× 10−5 2.9258× 10−5 3.1686× 10−5
R21kr 31.5973 18.5544 32.3107 43.1149 29.9838 26.1898 29.5564 30.0999
R26kf3 7.7947× 10−11 7.5589× 10−11 1.1673× 10−10 9.2361× 10−11 8.8033× 10−11 8.6543× 10−11 9.8728× 10−11 8.7470× 10−11
R26kr 1.1808 1.5621 0.8588 1.1594 0.9468 1.2557 1.0283 0.9868
R27kf 0.0232 0.0233 0.0366 0.0235 0.0306 0.0276 0.0299 0.0307
R27kr 30.8950 35.1783 31.9023 28.6512 31.4083 30.1306 28.6821 31.5098
R32kf 0.0064 0.0079 0.0059 0.0066 0.0061 0.0063 0.0061 0.0061
R33kf3 2.9186× 10−9 2.1312× 10−9 3.0875× 10−9 2.0704× 10−9 2.7750× 10−9 2.9233× 10−9 3.1977× 10−9 2.7099× 10−9
R33kr 27.8614 28.1610 29.8467 32.2782 32.0291 29.0728 31.3411 29.9154
R34kf 2.8880 2.7325 3.4178 2.4681 2.9020 3.3198 3.4051 3.0010
R34kr1 31.7119 57.6686 30.7178 29.4249 32.5660 36.0893 30.4649 29.1127
R36kr 0.3363 0.3581 0.3645 0.3275 0.3040 0.3135 0.3191 0.2948
R37kf1 0.0017 0.0025 0.0019 0.0016 0.0014 0.0020 0.0015 0.0015
R37kf2 0.0037 0.0025 0.0032 0.0036 0.0031 0.0029 0.0029 0.0030
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Parameter M1PMA M1Iono M1AEB M1Rapa M2PMA M2Iono M2AEB M2Rapa
R37kr 13.9678 16.4537 13.5304 18.7752 16.0540 17.7446 13.9956 15.9647
R38kf 0.4531 0.2637 0.4424 0.4169 0.4475 0.2755 0.4000 0.4630
R38kr1 0.1352 0.1761 0.1456 0.1735 0.1645 0.1475 0.1413 0.1664
R38kr2 0.1258 0.1556 0.1359 0.1301 0.1505 0.1627 0.1605 0.1514
R39kf 0.1454 0.1725 0.1708 0.1152 0.1455 0.1540 0.1466 0.1426
R43kf 8.2445× 10−5 9.5862× 10−5 8.6038× 10−5 7.8719× 10−5 9.3335× 10−5 1.0149× 10−4 8.4183× 10−5 7.8718× 10−5
R43kr 1.0550 0.8424 1.2576 0.8389 0.9937 0.9620 1.1574 0.8464
R45k 1.3577× 105 1.3015× 105 1.5636× 105 1.6825× 105 1.4080× 105 1.6781× 105 1.4991× 105 1.4527× 105
R45kf2 1.1668 0.9146 0.7718 1.1837 0.9745 0.8427 0.8983 1.0755
R45kr 18.1402 19.6200 19.3012 22.7520 21.6210 18.7482 19.8129 21.5033
R46k2 2.9429× 105 5.3241× 105 2.9279× 105 3.6001× 105 2.9275× 105 5.2954× 105 2.9976× 105 2.9430× 105
R46k3 1.1027× 103 760.4746 949.5808 1.1330× 103 1.0088× 103 942.8491 1.0346× 103 975.2731
R46kf 1.2338× 104 2.1870× 104 1.1927× 104 1.0508× 104 1.0332× 104 1.8236× 104 9.0945× 103 1.0109× 104
R46kr1 1.2462× 10−4 1.1322× 10−4 8.6220× 10−5 9.1129× 10−5 9.7163× 10−5 1.0700× 10−4 9.9291× 10−5 1.0186× 10−4
R46kr2 0.9447 0.9201 0.9269 0.8874 0.9317 0.9655 1.0021 0.9856
R47kf 7.9018× 103 1.6282× 104 9.5162× 103 1.1757× 104 1.0049× 104 1.6222× 104 1.0673× 104 9.7016× 103
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AWMMPC+MBDOE (models with initial calibration and additional tuning via MBDOE)
AWMMPC (models with initial calibration only)
TargetBaseline
Fig. C.12.: AWMMPC strategy and experimental measurements for Treg-like ac-
tivation profile (scenario 1). Controller-designed input reagent dosing schedules
and adaptive model weights (left and right panels, respectively) for the two cases:
(A) AWMMPC based on initially calibrated models only (AWMMPC only) and
(B) AWMMPC with additional tuning through MBDOE (AWMMPC+MBDOE).
(C) In vitro measurements of intracellular calcium, AP-1, NFκB and FOXP3 at
60 minutes following application of the input schedules specified in (A) and (B).
Relative fluorescence measured using multi-channel flow cytometry (see Methods
for details). Resting: no stimulation; Baseline stimulation: 5 µg/mL αCD3 + 5
µg/mL αCD28; AWMMPC only: baseline stimulation + input schedule from (A);
AWMMPC+MBDOE: baseline stimulation + input schedule from (B). Black arrows
denote the means of the baseline responses and red arrows denote the target regions
for the controllers.
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AWMMPC+MBDOE (models with initial calibration and additional tuning via MBDOE)


















Fig. C.13.: AWMMPC strategy and experimental measurements for anergic T cell-
like activation profile (scenario 2). Controller-designed input reagent dosing sched-
ules and adaptive model weights (left and right panels, respectively) for the two
cases: (A) AWMMPC based on initially calibrated models only (AWMMPC only)
and (B) AWMMPC with additional tuning through MBDOE (AWMMPC+MBDOE).
(C) In vitro measurements of intracellular calcium, AP-1, NFκB and FOXP3 at
60 minutes following application of the input schedules specified in (A) and (B).
Relative fluorescence measured using multi-channel flow cytometry (see Methods
for details). Resting: no stimulation; Baseline stimulation: 5 µg/mL αCD3 + 5
µg/mL αCD28; AWMMPC only: baseline stimulation + input schedule from (A);
AWMMPC+MBDOE: baseline stimulation + input schedule from (B). Black arrows
denote the means of the baseline responses and red arrows denote the target regions
for the controllers.
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AWMMPC+MBDOE (models with initial calibration and additional tuning via MBDOE)


















Fig. C.14.: AWMMPC strategy and experimental measurements for Th-like activation
profile (scenario 3). Controller-designed input reagent dosing schedules and adaptive
model weights (left and right panels, respectively) for the two cases: (A) AWMMPC
based on initially calibrated models only (AWMMPC only) and (B) AWMMPC with
additional tuning through MBDOE (AWMMPC+MBDOE). (C) In vitro measure-
ments of intracellular calcium, AP-1, NFκB and FOXP3 at 60 minutes following
application of the input schedules specified in (A) and (B). Relative fluorescence
measured using multi-channel flow cytometry (see Methods for details). Resting: no
stimulation; Baseline stimulation: 5 µg/mL αCD3 + 5 µg/mL αCD28; AWMMPC
only: baseline stimulation + input schedule from (A); AWMMPC+MBDOE: baseline
stimulation + input schedule from (B). Black arrows denote the means of the baseline
responses and red arrows denote the target regions for the controllers.
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Table C.2.: AWMMPC target error values for the various conditions and targets.
Scenario 1 Scenario 2 Scenario 3
B A A+M B A A+M B A A+M
0.4567 0.3223 0.2432 0.5175 0.2357 0.1678 0.3559 0.2971 0.1941
Target 0.4496 0.3252 0.2401 0.5220 0.2304 0.1730 0.3278 0.3024 0.2027
0.4780 0.3282 0.2421 0.5349 0.2289 0.1730 0.3651 0.3469 0.1878
Error 0.4281 0.3209 0.2420 0.5569 0.2282 0.1684 0.3632 0.3514 0.1937
0.4456 0.3241 0.2379 0.5366 0.2402 0.1655 0.3610 0.3310 0.1956
Fraction 0 0.2943 0.4675 0 0.5445 0.6757 0 0.1652 0.4546
of 0 0.2767 0.4660 0 0.5586 0.6686 0 0.0775 0.3816
Relative 0 0.3134 0.4935 0 0.5721 0.6766 0 0.0498 0.4856
Target Error 0 0.2504 0.4347 0 0.5902 0.6976 0 0.0325 0.4667
Reduction 0 0.2727 0.4661 0 0.5524 0.6916 0 0.0831 0.4582
Mean 0 0.2815 0.4656 0 0.5636 0.6820 0 0.0816 0.4493
St. Dev. 0 0.0237 0.0208 0 0.0180 0.0121 0 0.0511 0.0397
Abbreviations: B (baseline); A (AWMMPC); A+M (AWMMPC+MBDOE).
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